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AIMS OF THE THESIS
1) To perform a qualitative and quantitative analysis of NF-kB in primary
CLL cells
2) To evaluate the relative sensitivity of CLL subsets to NF-kB inhibition
3) To investigate potential synergy between NF-kB inhibitors and
conventional chemotherapeutic drugs used for the treatment of CLL
4) To establish whether NF-kB is differentially expressed in subsets of
patients defined by cytogenetics and lgVH gene usage
5) To perform longitudinal analysis of NF-kB in serial patient samples to
determine whether constitutive NF-kB is altered over time or by 
therapeutic intervention
6) To investigate the hypothesis that NF-kB is a superior biomarker of
prognosis in chronic lymphocytic leukaemia
xv
ABSTRACT
In this study, I characterized basal NF-kB DNA binding in CLL samples and 
investigated the value of NF-kB as a prognostic marker and therapeutic target 
in CLL. In contrast to the previous studies, I demonstrated wide heterogeneity 
in basal NF-kB DNA binding among patients which was associated with in 
vitro survival (P = 0.01) with high white cell count (P = 0.01) and shorter 
lymphocyte doubling time (P = 0.01). Subunit analysis revealed that in primary 
CLL cells the principal components were p50, Rel A, and c-Rel. I next 
investigated the cytotoxicity of a putative NF-kB inhibitor, LC-1, and elucidated 
its mechanism of action in CLL patient samples. LC-1 induced apoptosis with 
a mean LD50 of 2.9pM after 24 hours; normal B and T-cells were significantly 
more resistant to its apoptotic effects (P <0.001). Apoptosis was associated 
with caspase-3 activation that was mediated via the upstream activation of 
both caspase-8 and caspsase-9. Apoptosis was preceded by a reduction of 
nuclear Rel A DNA binding and down regulation of the anti-apoptotic NF-kB 
target genes CFLAR, BIRC5 and BCL2. LC-1 was highly synergistic with 
fludarabine (mean combination index 0.26). Rel A DNA binding was strongly 
associated with advanced Binet stage (P<0.0001) but did not correlate with 
lgVH mutation status (P = 0.25), CD38 expression (P = 0.87) or ZAP-70 
expression (P = 0.55). In addition, it was predictive of time to first treatment (P 
= 0.02) and time to subsequent treatment (P = 0.0001). Indeed, Rel A was the 
most predictive marker of survival both from date of diagnosis (hazard ratio 
9.1, P = 0.01) and date of entry into the study (hazard ratio 3.9, P = 0.05). 
Taken together, the data suggests that NF-kB is a promising therapeutic 
target and prognostic marker in CLL. Prospective clinical trials designed to 
evaluate these conclusions are clearly now warranted.
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1.0 INTRODUCTION
1.1 Leukaemia
Leukaemogenesis is a clonal process derived from a single cell in the marrow 
or peripheral lymphoid tissue that has undergone genetic alteration (Pitot et 
al., 1991). Malignant cells arise due to a ‘multi-hit’ process requiring several 
genetic mutations (Vogelstein et al., 1993). In the process of haematopoietic 
cell proliferation, differentiation, maturation and cell survival errors may occur, 
resulting in aberrant expression of genes critical in cell development leading to 
uncontrolled proliferation, prolonged cell survival or blockage of differentiation 
pathways (Sawyers et al., 1991). These errors may lead to an imbalance 
between oncogenes and tumour suppressor genes resulting in uncontrolled 
growth of malignant cells (Hunter et al., 1997).
1.2 B-cell Chronic Lymphocytic Leukaemia (CLL)
Chronic lymphocytic leukaemia is a neoplasm of small monomorphic CD19+ 
B-lymphocytes in the peripheral blood, bone marrow, lymph nodes and spleen 
usually co-expressing CD5 and CD23 (Jaffe et al., 2001).
1.2.1 Epidemiology of CLL
CLL is 20-30 times more common in Europe, Australia and North America 
than India, China and Japan (Oscier et al., 2004). The highest incidence is in 
Australia, the USA, Ireland and Italy (Figure 1.1). The incidence rate in the UK 
is 3/100,000 per year (Oscier et al., 2004). It represents 30-40% of all
1
leukaemias and is the commonest leukaemia in the Western world (Cheson et 
al., 1996; Kali et al., 2000). The incidence of this disease increases 
dramatically with age (Redaelli et al., 2004) and therefore predominantly 
affects elderly individuals (Figure 1.2). The median age at diagnosis is 
between 65 and 70 years but 20-30% of the patients are less than 55 years of 
age at diagnosis (Oscier et al., 2004). The male:female ratio is approximately 
2:1 (Sgambati et al., 2001). The median survival time is approximately 10 
years but there is extraordinary heterogeneity in the natural history of CLL 
(Lee et al., 1987). The median survival of CLL is independent of whether 
patients present above or below 50-55 years, but younger patients are more 
likely to die of CLL-related causes while older patients more commonly die of 
unrelated causes including second primary malignancies (Oscier et al., 2004).
1.2.2 Aetiology of CLL
The cause of CLL is not known and debate about the origin of the leukaemic 
B-cell is long standing (Ghia et al., 2006). CLL was traditionally considered to 
be a homogenous disease of mature, immune-incompetent cells that 
accumulate because of defects in apoptosis (Kern et al., 2004). However, 
improved understanding of the immunobiology of CLL has led to substantial 
changes in the current view of this disease; CLL is now viewed as at least two 
related entities (Schoeder et al., 1994; Ghia et al., 2006). The presence of 
somatic mutations of lgVH gene indicates that at least a proportion of CLL 
cases have encountered an antigen during the natural history of the disease 
and have subsequently transitted the germinal centre (Walsh et al., 2005; 
Ghia et al., 2006). However, cases without lgVH mutation are distinct from
2
navie B-cells and are most similar to mutated CLL cases except for their lgVH 
status (Schroeder et al., 1994; Fais et al., 1998).
□ Male 
■ Female
Figure 1.1 Age-standardized world incidence of chronic lymphocytic 
leukaemia (adapted from Redaelli et al., 2004).
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Figure 1.2 Age-specific incidence of chronic lymphocytic leukaemia
(adapted from Redaelli et al., 2004)
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Furthermore, both CLL subtypes have a surface phenotype of activated 13- 
cells; expressing CD23, CD25, CD69, and CD79 and under expression of 
CD22 (Schroeder et al., 1994; Damle et al., 2002). In addition, gene 
expression profiling has revealed that both types are most similar to memory 
B-cells (Klein ef al., 2001; Rosenwald et al., 2001).
There are hereditary and genetic links proposed in CLL. Persons with close 
relatives who have CLL are more likely to develop the disease (Rawstron et 
al., 2002; Caporaso et al., 2004). No single environmental risk factor has been 
proven to be a causative factor in CLL but pesticides, radiation, an array of 
carcinogens, diet, hepatitis C and EBV have all been implicated in this 
disease (Linet et al., 2004a). Also some rheumatological conditions are 
associated with a higher risk of lymphoproliferative disorders including CLL 
(Mellemkjaer etal., 1996; Royer et al., 1997).
1.2.3 Microenvironment in normal haematopoiesis and in 
CLL
Bone marrow stroma consists of endothelial cells, fibroblasts, macrophages 
together with their extracellular matrix (Hoffbrand et al., 2005) and it is an 
important part of haematopoiesis (Roy et al., 1999). In addition, the germinal 
centres of secondary lymphoid organs provide microenvironmental support for 
developing B-cells (Ghia et al., 2002). Despite long life in vivo, CLL cells 
undergo spontaneous apoptosis in vitro under conditions that support the 
growth of normal B-cell lines (Lagneaux et al., 1998; Burger et al., 1999; 
Yamauchi et al., 2001). This suggests a specific requirement for in vivo
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signalling for the survival of CLL cells (Ghia et al., 2002; Ghia et al., 2005; 
Gorgun et al., 2005; Nishio et al., 2005).
Both cell contact and soluble factors are implicated in CLL cell survival. T-cells 
epithelial cells and Nurse like cells (NLC), differentiated from blood 
mononuclear cells (Nishio et al., 2005) are thought to play a major role in 
survival signalling in CLL (Tsukada et al., 2002; Nishio et al., 2005; Planelles 
et al., 2004; Endo et al., 2007). Also follicular dendtritic cells in the lymph 
nodes and bone marrow provide signals for malignant B-cell proliferation and 
survival through CD40 ligation and up regulation of BCL2 family proteins 
(Chilosi et al., 1985; Petrasch et al., 1994; Choe et al., 2000; Caligaris-Cappio 
et al., 2003). Interleukin 6 (IL-6), B-cell activating factor belonging to the TNF 
family (BAFF) and a proliferation-inducing ligand (APRIL) are among other 
soluble factors identified in B-cell survival. These factors are increased in CLL 
and are thought to play a major role in cell survival via activation of NF-kB and 
over expression of anti-apoptotic proteins including Mcl-1 (Tsukada et al., 
2002; Nishio et al., 2005).
1.2.4 Clinical manifestations of CLL
Most of the patients with CLL are asymptomatic hence more than 50% are 
diagnosed following a routine blood test. However, some patients present with 
fatigue, autoimmune haemolytic anaemia, infections, hepatomegaly, 
splenomegaly, lymphadenopathy or extra nodal infiltrates (Keating et al., 
1998; Hoffbrand et al., 2001; Hoffbrand et al., 2005). The term small 
lymphocytic lymphoma (SLL), consistent with CLL, is restricted to cases with
5
the tissue morphology and immunophenotype of CLL, but these cases do not 
have a frank leukaemia i.e. the disease is confined to the lymphoid organs.
1.2.5 Diagnosis of CLL
CLL is characterised by a morphologically normal B-lymphocytosis of £5xI09/L 
with confirmed clonality in the peripheral blood (Figure 1.4). In addition, CLL is 
invariably associated with bone marrow infiltration; the bone marrow infiltration 
pattern may be nodular, interstitial, diffuse or a combination of the three 
(Figure 1.5). Diagnosis is aided by the CLL immunophenotyping score which 
includes assessment of CD5 and CD23, FMC7, CD79b and surface 
immunoglobulin (Smlg) (Matutes et al., 1994) (Table 1.2 and Figure 1.6). 
Lymph nodes are affected in some cases by diffuse infiltration of small 
lymphocytes identical to low-grade SLL. Also there could be 
hypogammaglobulinemia and associated serum monoclonal protein (Oscier et 
al., 2004). The list of tests proposed by the National Cancer Institute Working 
Group (NCI-WG) for the diagnosis of CLL is summarised below (Hallek et al., 
2008).
1) Clonal B-lymphocytosis of £ 5x1091L.
Clonality of circulating lymphocytes is confirmed by flow cytometry.
2) Immunophenotype features
Co-expression CD5 and B-cell surface antigens CD19, CD20 and 
CD23. Low level expression of CD20, CD79b and surface 
immunoglobulin. Each clone of leukaemia cells is restricted to 
expression of kappa or lambda immunoglobulin light chains.
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3) Other tests
Molecular genetics, ZAP-70, CD38 and lgVH, Serum markers, Marrow 
examination
CD5 Positive
CD23 Positive
CD79b Weak
Smlg Weak
FMC-7 Negative
Table 1.2 CLL Score based on immunophenotyping (Matutes et a!., 1994) 
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Figure 1.4 Blood film appearance of CLL (X40)
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Figure 1.5 Bone marrow appearance showing nodular infiltration by CLL 
cells (X10) (adapted from Postgraduate Haematology; Hoffbrand et al., 2005)
CD19-ffC  K*ppa-FlTC
Figure 1.6 Flow cytometric analysis of CLL. Flow cytometric analysis of a 
CLL sample demonstrating CD5 and CD19 double positive CLL cells (red 
circle) expressing a lambda clone light chain restriction.
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1.2.6 Prognosis of CLL
CLL manifests a very heterogeneous clinical course with some patients having 
normal age-adjusted survival whereas the median survival for those patients 
with advanced stage disease is only 3 years (Lee et al., 1987). According to 
recent studies absolute 5 year survival in CLL is 50% - 60% (Catovsky et al., 
2007; Brenner et al., 2008). Clinical parameters as well as a wide array of 
laboratory tests are used to predict the tumour burden and natural course of 
the disease at diagnosis (Grever et al., 2007). An overview of these 
parameters is out lined below.
1.2.6.1 Clinical Stage
Clinical staging systems are the best available predictors of survival (Jaffe et 
al., 2001). Some patients have minimal signs and symptoms during their 
entire disease course while others experience rapidly deteriorating blood 
counts and organomegaly and suffer from symptoms at diagnosis or soon 
thereafter necessitating therapy. There are two widely accepted staging 
methods used in clinical practice; the Rai and Binet staging systems (Rai et 
al., 1975; Binet et al., 1981) (Table 1.3 and 1.4). The original Rai classification 
was subsequently modified to limit the number of prognostic groups (Rai et al., 
1987). These systems define early (Rai 0, Binet A), intermediate (Rai I/ll, 
Binet B) and advanced (Rai 11 I/I V, Binet C) stage disease with median 
estimated survival times of >10 years, 5-7 years, and 1-3 years respectively. 
Clinical staging solely relies on physical examination and standard laboratory 
tests and is simple, inexpensive and can be applied worldwide. These staging 
systems remain the cornerstone on which decisions regarding medical follow-
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up and treatment are built, but one of their major problems is their failure to 
predict progression of the disease particularly in early stages and hence there 
has been continual effort to identify other prognostic factors.
Low Risk (Former Rai 0)
Leukaemia cells in blood and/ bone 
marrow
Intermediate Risk (Former Rai I and
II)
Lymphocytosis, lymphadenopathy, 
splenomegally and/ or hepatomegally
High Risk ( Former Rai III and IV)
Haemoglobin <11g/dL or 
Platelets < 100 x109 /L
Table 1.3 Modified Rai Staging system
Stage A
£2 of involved lymph node areas*
Stage B
>2 of involved lymph node areas
Stage C Haemoglobin <10g/dL or 
Platelets <100 x109/  L
Table 1.4 Binet Staging system
‘Lymph node areas: head and neck, including Waldeyers ring, axillary, groin, 
including superficial femoral, palpable spleen, liver (clinically enlarged)
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1.2.6.2 Lymphocyte doubling time (LDT)
LDT, a clinical measure that addresses the kinetics of cell growth, is 
calculated by determining the number of months the absolute lymphocyte 
count (ALC) takes to double. Patients with an LDT of less than 12 months (6 
months in some studies) have been shown to have a shorter survival 
(Montserrat et al., 1986; Figure 1.7). Furthermore, LDT has been confirmed as 
an independent predictor of disease progression (Molica et al., 1987; Vinolas 
et al., 1987)
DOUBUNGTMIE >12 MONTHS
08
03- DOUBLfSlG TIME <12 MONTHS
0 2
MONTHS
Figure 1.7 LDT and survival in CLL (adapted from Montserrat et al., 1986)
1.2.6.3 Chromosomal aberrations
Fluorescence in-situ hybridization (FISH) can identify genomic aberrations in 
approximately 80% of CLL cases (Dohner et al., 2000; Zenz et al., 2007). The 
most frequent aberrations are deletions in 13q14, 11q or 17p and trisomy 12
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(Dohner et al., 2000; Krober et al., 2002, Mellstedt et al, 2005). The 17p and 
11q deletions occur almost exclusively in unmutated sub-groups and are 
associated with inferior prognosis in CLL patients. Apart from providing insight 
into the pathogenesis of the disease and defining prognostic subsets, 
genomic aberrations identify subgroups of patients with distinct clinical 
features for example 11q- is associated with lymphadenopathy. Deletions in 
11q and particularly 17p are associated with rapid disease progression and 
inferior survival (Grever et al., 2007) and there is increasing evidence that 
detection of certain chromosomal deletions denote resistance to standard 
chemotherapy. Patients with a deletion in 17p show resistance to standard 
chemotherapy regimens using alkylating drugs and purine analogues (Dohner 
et al., 1995; Grever et al., 2007). Therefore detection of these cytogenetic 
abnormalities has obvious prognostic value and may even influence 
therapeutic decisions.
1.2.6.4 Novel biological and molecular markers
Recent technological advancements have enabled investigators to examine a 
wider array of biological and molecular markers in an attempt to identify 
differences in disease biology that may predict those patients most likely to 
develop advanced-stage disease and who may benefit from alternative 
treatment strategies. Studies have shown that ZAP-70 expression, CD38 
expression, mutational status of lgVH genes and cytogenetic abnormalities 
can predict the prognosis in CLL.
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1.2.6.5 Somatic mutation in the immunoglobulin heavy
chain variable region (lgVH)
The mutational status of the immunoglobulin variable region genes (lgVH) has 
been shown to have a prognostic value in CLL (Damle et al., 1999; Hamblin et 
al., 1999). In addition, differential gene expression patterns characteristic for 
these genetically defined CLL subtypes have been reported (Haslinger et al., 
2004). Cases with somatically mutated lgVH genes have been consistently 
shown to have a better prognosis than those without mutations in lgVH genes 
(Krober et al., 2002; Oscier et al., 2002,). Initial reports indicated the median 
survival of mutated cases to be 293 months while those with unmutated genes 
was 117 months. However, cases that utilise segments VH 3-21 may confer a 
poor prognosis regardless of mutation status (Thorselius et al., 2006; Tobin et 
al., 2004b).
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Figure 1.8 Overall survival according to lgVH mutation status (adapted 
from Hamblin eta!., 1999)
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1.2.6.6 CD38 expression
The percentage expression of CD38 has been shown to be an independent 
prognostic marker and correlates with advanced stage of disease, poor 
responsiveness to chemotherapy, a shorter time to first treatment, progression 
rate following first-line therapy and a shorter survival time (Ibrahim et al., 
2001; Morabito et al., 2002; Ghia et al., 2003). It is considered to be a 
surrogate marker of lgVH mutation status although this is controversial 
(Hamblin et al., 2002) and is widely used for prognostication in its own right. 
However, there is an association between CD38 and soluble CD23, (52 
microblobulin (02M) and lymphocyte doubling time (LDT) (Heintel et al., 2001) 
and more recently a number of groups have shown an association between 
CD38 and proliferation markers (Damle et al., 2007; Lin et al., 2008). The best 
cut-off point for CD38 expression is still debatable. The most widely used cut­
off points in clinical studies are 7%, 20% and 30% (Thornton et al., 2004; 
Ibrahim et al., 2001; Damle et al., 1999). Also there some studies indicating 
predictive value of CD38 expression is enhanced by measurement of antigen 
density in terms of antibody binding capacity rather than as the percentage of 
cells expressing the antigen (Mainou-Fawler et al., 2004).
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Figure 1.9 Survival and CD38 status (adapted from Ibrahim et al., 2001)
1.2.6.7 ZAP-70 expression
ZAP-70 is part of signal transduction cascade in T-cells following T-cell 
receptor activation but is not usually expressed in normal B-cells (Qian et al., 
1997). Although its role in CLL is not yet clear, it has been shown to increase
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the effectiveness of B-cell signalling (Chen et al., 2002; 2005) but this would 
appear to be independent of its kinase activity (Chen et al., 2008). It also 
appears to enhance migratory and tumour survival responses and contribute 
to aggressive clinical behaviour (Richardson et al., 2006; Zanotti et al., 2007). 
Microarray analysis of CLL revealed that transcription of ZAP-70 was 
significantly higher in patients with unmutated lgVH genes compared to 
patients with mutated lgVH genes. It was therefore suggested that ZAP-70 
could be a surrogate marker for unmutated patients (Rosenwald et al., 2001). 
ZAP-70 was first described as a promising prognostic marker in CLL by 
Crespo et al., in 2003 and was shown to possess a strong correlation with 
mutational status (Crespo et al., 2003; Orchard et al., 2004).
ZAP-70 can be assessed by reverse transcriptase polymerase chain reaction, 
Western blotting, immunohistochemistry and flow cytometric methods (Crespo 
et al., 2003; Orchard et al., 2004; Rassenti et al., 2004). Although there are 
issues surrounding the optimal method for assessing ZAP-70 expression for 
clinical purposes, flow cytotometry-based methods are the most widely used 
(Letestu et al., 2006, Gachard et al., 2008). ZAP-70 expression by 
immunohistochemistry showed significant correlation with advance Binet 
stages B and C, diffuse bone marrow infiltration, (32M and LDT<12 (Zanotti et 
al., 2007). Currently ZAP-70 is not a routine test in clinical practice and further 
clinical trials are needed to standardise the method of assessment and 
determine whether it should affect the management of patients with CLL.
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Figure 1.10 Survival and ZAP-70 expression in CLL (adapted from Crespo 
etal., 2003)
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1.2.6.8 Other prognostic markers
The list of other prognostic markers under investigation in CLL is long. These 
markers should only be used in clinical trials until their validity is proven. 
Several studies have found serum markers CD23, thymidine kinase and (32M 
may predict progression-free survival but how these markers can be factored 
into the clinical management of CLL is yet to be established (Reinisch et al., 
1994; Hallek et al., 1999; Sarfati et al., 1996; Magnac et al., 2003; Wierda et 
al., 2007).
1.2.7 Treatment of CLL
1.2.7.1 Active disease (disease progression)
Recent reports indicate that approximately 50% of patients with early-stage 
CLL experience rapidly progressive disease and require therapy. Furthermore, 
these patients have a median survival period that is significantly shorter than 
that suggested by the original publications of the Rai and Binet staging 
systems. Most patients diagnosed as having CLL, including the majority of 
patients with early-stage disease, die of CLL or its complications, despite 
aggressive treatment. Disease progression is defined according to the criteria 
described by the National Cancer Institute Working Group (NCI-WG) in 2008 
(Hallek et al., 2008). Patients are considered to have an active disease if there 
is:
1) Evidence of progressive marrow failure
2) Massive or progressive splenomegally
3) Massive or symptomatic lymphadenopathy
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4) Progressive lymphocytosis with an increase of more than 50% over 
two month period or LDT <6 months
5) Autoimmune anaemia or thrombocytopenia poorly responsive to 
corticosteroids
6) Disease related symptoms like loss of weight
1.2.7.2 Indications for treatment in CLL
As there is no curative therapy for CLL and all drugs have side-effects, the 
decision to initiate therapy is an important consideration in the management of 
CLL. It has been shown that treatment of early stage disease does not 
prolong survival and about one third of patients do not progress and will never 
need any treatment (Shustik et al., 1988; Richardson et al., 2006). Well- 
established criteria have been developed by the NCI-WG for the treatment of 
patients with CLL and these include patients with Binet stage C disease as 
well as patients with stage A or B disease with features of disease progression 
(Hallek et al., 2008). Treatment decisions also need to include consideration 
of the patient’s own wishes, their age and performance status.
1.2.7.3 Treatment of CLL
Most patients do not receive treatment immediately after initial diagnosis 
unless they present with clear pathological symptoms. Indeed, it has been 
shown that treating CLL patients with indolent disease does not prolong 
survival (Shustic et al., 1988; Montserrat et al., 1991; Dighiero et al., 1998). 
Treatment of patients with CLL have been improved over the last few years 
due to advances in our understanding of the biology of the disease. Response
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rates to most conventional chemotherapeutic agents differ according to the 
clinical and biological characteristics of the disease. Furthermore, response 
rates to treatment and survival are better for women than men (Catovsky et 
al., 1989) although the precise reasons for this remain obscure. Recent data 
suggests that treatment should be tailored to the genetic features of each 
patient as these can predict the outcome of fludarabine-based regimens (Van 
Bockstaele et al., 2008). Pharmacological therapy may consist of 
chemotherapy or chemo-immunotherapy. Chemotherapy can be delivered as 
monotherapy or combination therapy involving glucocorticoids, alkylating 
agents and purine analogues. In addition, there are a large number of novel 
agents currently in clinical development that may be used on their own or in 
combination with conventional chemotherapy.
1.2.7.4 Single agent therapy
a) Alkylating agents
The alkylating agent chlorambucil has shown response rates between 47% 
and 71% and had been the mainstay of chemotherapy of CLL for many 
decades (Sawitsky et al., 1977; Montserrat et al., 1985; Hansen et al., 
1988; Catovsky et al., 2007). Chlorambucil can be administered as either a 
continuous or an intermittent single agent regimen or in combination with 
other alkylator agents. However, chlorambucil either alone or in 
combination has never demonstrated any difference in progression-free 
survival (PFS) or overall survival (OS) in clinical trials (Montserrat et al., 
1985; Hansen etal., 1988; Raphael, etal., 1991).
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b) Purine nucleoside analogues
Fludarabine, cladribine and pentostatin have been shown to be active in 
the treatment of CLL (Saven et al., 1995; Robak et al., 2000a; 2000b). 
Fludarabine treatment gives better overall responses (OR) and complete 
responses (CR) compared with chlorambucil though again no study has 
ever shown a survival benefit (Keating et al., 1991; Johnson et al., 1996; 
Byrd et al., 2000; Wierda et al., 2006; Catovski et al., 2007).
c) Monoclonal antibodies
Rituximab (anti-CD20) and alemtuzumab (anti-CD52) are the most 
commonly used monoclonal antibodies at the moment. Although only 
possessing limited activity as a single agent, Rituximab is used in many 
combination chemotherapeutic regimens with successful results (Byrd et 
al., 2001; Huhn et al., 2001; O’Brien et al., 2001a). Alemtuzumab is 
primarily used in relapsed / refractory patients with mainly bone marrow 
disease and patients with p53 deletions (Lundin et al., 2002; Robak et al., 
2008).
1.2.7.5 Combination therapy
The unique mode of action of fludarabine, which affects DNA synthesis 
including DNA repair, opened up the possibility of potentiating its effects in 
combination with other drugs. Fludarabine inhibits excision repair of DNA 
inter-stand cross links induced by cyclophosphamide (Yamauchi et al., 2001) 
and has been shown to synergise in laboratory experiments (Bellosillo et at., 
1999; Laurenti et al., 2008). A research team from the MD Anderson Cancer
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Centre in Houston, Texas (O’Brien et al., 2001b) showed in a clinical trial that 
the combination of fludarabine (F) with cyclophosphamide (C) was effective in 
previously untreated patients with CLL. This combination was also assessed 
in a large scale clinical trial in UK (Catovsky et al., 2007). According to this 
trial, there were better complete and overall response rates with fludarabine 
plus cyclophosphamide than fludarabine or chlorambucil alone but still there 
was no significant difference in overall survival.
Laboratory studies have shown fludarabine and rituximab can compliment 
each other. Rituximab sensitized leukaemic cells to fludarabine-induced 
apoptosis by down regulating the anti-apoptotic protein Bcl-2 (Alas et al., 
2001). In addition, fludarabine down-modulated the expression of complement 
resistance proteins CD46, CD55, CD59 on malignant B-cells and sensitized 
them to rituximab-induced complement dependent cytotoxicity (Di Gaetano et 
al., 2001). This was translated in to improved patient responses as shown in 
clinical trials; fludarabine, cyclophosphamide in combination with rituximab 
was highly effective for the treatment of CLL (Keating et al., 2005; Wierda et 
al., 2005; Tam et al., 2008). However, fludarabine plus cyclophosphamide 
(with or without Rituximab) cannot be recommended for poor-risk patients 
characterised by 17p (p53) deletion, since they are unlikely to respond well to 
this combination and show severe haematological toxicity (Kay et al., 2007).
Alemtuzumab has been shown to be effective in combination with other 
chemotherapeutic agents (Elter et al., 2005). It has been used as first line 
therapy in p53 deleted patients, for consolidation of fludarabine-based
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treatment or subsequent therapy in refractory disease in high risk patients 
(Lundin et al., 2002; Stilgenbauer et al., 2002; Lozanski et al., 2004).
1.2.7.6 Stem cell transplantation
Autologous or allogeneic stem cell transplantation is considered as another 
treatment option for patients with resistant / refractory disease (Paneesha et 
al., 2005; Dreger et al., 2007). In some instances, such as in young patients 
with progressive disease with 17p deletion /dysfunction, allogeneic 
transplantation may be considered upfront due to the lack of effective 
chemotherapeutic options. However, it is generally accepted that 
transplantation in CLL should be carried out in the context of a clinical trial. 
The consensus opinion is that allogeneic transplantation should be considered 
in younger patients with non-responsive or early relapse disease and patients 
with a p53 abnormality requiring treatment.
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1.3 Transcription factor Nuclear Factor kappa B 
(NF-kB)
1.3.1 Transcription factors
The term “transcription factor” describes a class of biological molecules that 
has the capacity to alter gene transcription. Typically, these proteins contain a 
domain capable of binding DNA and a domain involved in protein-protein 
interaction to allow the transcription factors to increase gene expression. The 
mechanisms for increasing gene expression can include the recruitment of the 
basal transcription machinery, thus increasing RNA synthesis, and the 
recruitment of other enzymes that allow better physical access to DNA, for 
example, those involved in chromatin remodelling (Brennan etal., 2008).
1.3.2 Nuclear Factor kappa B (NF-kB)
NF-kB is a collective name for a group of inducible homo- and heterodimeric 
transcription factors made up of members of the reticuloendotheliosis family 
(Rel family) of DNA binding proteins. In humans this family is comprised of Rel 
A (also known as p65), Rel B, c-Rel (also known as Rel), p50 (a processing 
product of p105, both of which are known as NF-kB1) and p52 (a processing 
product of p100, both of which are known as NF-kB2). All family members 
contain a highly conserved amino- terminal of approximately 300 amino acids, 
rel homology domain (RHD) which is important for DNA binding, dimerisation 
and nuclear localisation (known as nuclear localisation signal; NLS)(Perkins et 
a/., 1999). But only c-Rel, Rel A and Rel B contain a transactivation domain in 
their carboxy terminal which contains a sequence that is required for
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interaction with the transcriptional apparatus and for transcriptional activation 
(Perkins et al., 1999; Schmid et al., 2008). In their inactive state most 
transactivating NF-kB dimers are bound to inhibitory molecules (IkB family) 
(Ghosh et al., 1998; Karin et al., 2002). The IkB family consists of classical 
IkBs (IkBo, IkB|3, and IkBs), the NF-kB precursors (p100 and p105) and the 
unusual IkBs (BCL3, IkB£ and IkBNS) (Nolan et al., 1991; Hayden et al.,
2004). These inhibitory molecules possess ankyrin domains containing five to 
seven ankyrin repeat sequences which function by binding and inhibiting 
RHDs through masking NLSs and hence preventing their nuclear translocation 
(Ghosh et al., 1998). IkBo also blocks DNA binding and promotes nuclear 
export of DNA bound dimers (Tam et al., 2000; Lee et al., 2001; Schmid et al., 
2008).
Many genes are activated only by a subset of NF-kB proteins, while others are 
only expressed in certain cell types. In addition, NF-kB proteins interact with 
other DNA-binding proteins and associate with non DNA-binding coactivator 
proteins and components of the basal transcription complex. It is the 
differential expression of Rel proteins, their ability to heterodimerise with 
different family members and the interaction of these proteins with different 
components of the transcription apparatus that contribute to the diverse 
effects following activation of the NF-kB pathway (Perkins et al., 1999).
NF-kB is activated by signalling through many receptors involving classical 
(IKKp and IKKy dependent activation of NF-kB or canonical pathway) and 
alternate (IKKa and NF-kB inducing kinase, NIK dependent or non-canonical 
pathway) pathways (Hoffman et al., 2006a; 2006b). Also, there are other less
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well identified pathways releasing limited amounts of NF-kB (tyrosine 
phosphorylation-induced dissociation of I KBs and casein-kinase-2-induced 
increased turnover of IkBs) (Hoffman et al., 2006b). These receptors can be 
grouped in to two classes. The first, receptors that mainly activate the 
classical pathway which include the B-cell receptor (BCR), the T-cell receptor 
(TCR), tumour necrosis factor receptor (TNFR), interleukin-1 receptor (IL-1R) 
and members of toll-like receptor family (TLR). The second, receptors that 
activate both classical and alternate pathways which include lymphotoxin-(3 
receptor (LT-(3R), receptor activator of NF-kB (RANK), CD40 and B-cell 
activating factor receptor (BAFFR). After they have been released from their 
inhibitory partners, NF-kB dimers translocate to the nucleus, bind their DNA- 
binding sites and induce transcription of target genes (Ghosh et al., 1998; 
Karin et al., 2002). This in turn leads to the synthesis of proteins through 
alteration of the pattern of gene expression (Sen et al., 1986). Figure 1.11 
shows a simplified schematic diagram of the NF-kB activation pathway.
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Figure 1.11 Schematic representation of NF-kB activation.
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1.3.3 NF-kB and Cancer
Although the maintenance of appropriate levels of NF-kB activity is a critical 
factor in achieving normal cellular proliferation, constitutive NF-kB activation is 
likely involved in the enhanced growth properties seen in a variety of cancers 
(Karin et al., 2006a; 2006b). Tumourogenesis requires self sufficiency in 
growth signals, insensitivity to growth inhibition, evasion of apoptosis, 
sustained angiogenesis, tissue invasion and metastasis (Hanahan et al., 
2000). NF-kB proteins regulate genes controlling most of these processes 
particularly apoptosis (Beg et al., 1996), proliferation (Cao et al., 2001), 
angiogenesis (Koch et al., 1992) and metastasis (Wang et al., 1999).
The initial evidence for the association between Rel proteins and cancer came 
from v-Rel, an oncoprotein belonging to the NF-kB transcription factor family 
produced by avian reticuloendotheliosis virus T (REV-T), oncovirus causing 
rapidly fatal lymphomas and leukaemia in chickens and its ability to 
immortalise and transform a variety of avian cell types in vitro (Gilmore et al., 
1999). The mammalian equivalent of v-Rel, c-Rel mRNA has been shown to 
be elevated in mature B-cells (Tarte et al., 2003). Also the chromosomal 
region of c-Rel is linked to non-Hodgkin’s lymphoma, particularly to diffuse 
large B-cell lymphoma (Lu et al., 1991; Joos et al., 1996; Houldsworth et al., 
1996) and the chromosomal region of NF-kB2 is associated with CLL, Multiple 
myeloma, T-cell lymphoma and cutaneous B- and T- cell lymphomas (Neri et 
al., 1991; Neri et al., 1995). Furthermore, the human T-cell leukaemia virus, 
HTLV-1, has been shown to directly interact with IKK and activate the NF-kB 
signalling pathway (Xiao et al., 2001).
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1.3.4 NF-kB and CLL
CLL cells have been reported to exhibit high constitutive NF-kB activation 
compared to normal B-lymphocytes (Furman et al., 2000; Cuni et al., 2004; 
Tracey et al., 2005). Whilst the exact factors responsible for the constitutive 
expression of NF-kB are not fully resolved, many factors including Akt 
activation, BCR signalling, CD40 ligation, IL-4 and BAFF have been shown to 
increase NF-kB activity and enhance CLL cell survival with members of the 
Bcl-2 family being principal transcriptional targets (Dancescu et al., 1992; 
Barragan et al., 2002; Zaninoni et al., 2003; Kern et al., 2004). Furthermore, 
currently used chemotherapeutic agents can induce NF-kB activation as an 
unwanted side effect which confers apoptosis suppression and hence 
resistance to these drugs (Tergaonkar et al., 2002; Nakanishi et al., 2005).
1.3.5 Inhibition of NF-kB in haematological malignancies
Numerous inhibitors of NF-kB are under development, but because of the 
widespread importance of this factor to normal tissues it has been difficult to 
develop NF-kB inhibitors that act specifically on cancer cells (Yamamoto et al., 
2001; Braun et al., 2006). Therefore, a better understanding of NF-kB 
regulation is crucial for therapeutic approaches to specifically target cancer 
cells. Intrinsic NF-kB activation as well as its upstream and downstream 
regulator subunits and NF-kB target genes could be targeted in the process of 
developing inhibitors to dampen NF-kB expression (Braun etal., 2006).
A number of well established dietary chemo-preventative compounds have 
been shown to inhibit NF-kB (Yamamoto et al., 2001). The most common of
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these is red wine which has been shown to inhibit NF-kB activity and induce 
apoptosis in transformed cells (Holmes-McNary et al., 2000). Also, a variety of 
drugs commonly used in clinical medicine have been shown to possess NF-kB 
suppressive potential; glucocorticoids, non-steroidal anti-inflammatory drugs, 
Cyclosporine A, Tacrolimus, Rituximab, Thalidomide and Proteosome 
inhibitors are just a few from the long list (Braun et al., 2006).
There is a published list of NF-kB inhibitors from the literature divided in to 4 
main categories (http://people.bu.edu/ailmore/nf-kb/index.htmn (Gilmore et al., 
2006a; 2006b): anti-oxidants that have been shown to inhibit activation of NF- 
kB, proteasome and protease inhibitors that inhibit Rel/NF-KB, IkBa 
phosphorylation and/or degradation inhibitors and miscellaneous inhibitors of 
NF-kB. These distinct categories reflect diverse strategies and show the 
different research avenues available in the search for inhibitors of the NF-kB 
pathway.
Bortezomib (PS-341), Thalidomide and Rituximab are widely used for the 
treatment of haematological malignancies including CLL. PS-341, a 
proteosome inhibitor that can inhibit NF-kB activity, has shown consistent anti­
tumour activity against chemosensitive and chemoresistant (high NF-kB 
activity) multiple myeloma cells (Berenson et al., 2001) and promising results 
in clinical trials for the treatment of multiple myeloma, a disease characterised 
by constitutive NF-kB activation. In addition, PS-341 is cytotoxic to CLL cells 
In vitro and augments the cytotoxic effect of fludarabine (Duechler et al.,
2005). Thalidomide, which inhibits NF-kB activation via suppression of IKK 
activity, (Keifer et al., 2001; Mitsiades et al., 2002) has shown impressive
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results in clinical trials for the treatment of multiple myeloma. The monoclonal 
antibody rituximab, which targets the surface molecule CD20 was also shown 
to decrease the phosphorylation of NIK and IkBo, diminish IKK and NF-kB 
DNA binding activity in NHL cell lines and lead to the sensitisation of these 
cells to chemotherapeutic drug induced apoptosis (Jazirehi et al., 2005). 
However, these three molecules (Bortezomib, Thalidomide and Rituximab) 
exert other actions beyond NF-kB and highly specific inhibitors of NF-kB are 
still missing from clinical practice. There are potentially more specific NF-kB 
inhibitors under development which have been tested on cells in vitro and in 
animal models. These include PS-1145 (Lam et al., 2005), BAY 11-7082 
(Pickering et al., 2005), Curcumin (Everret et al., 2007), the sesquiterpene 
lactone parthenolide (Steele et al., 2006) and its analogue DMAPT (Guzman 
et al., 2007). PS-1145, an IKK inhibitor, has been shown to overcome the 
growth and survival advantage of B-cell malignancies like multiple myeloma 
cells (Hideshima et al., 2002; Hideshima et al., 2007) and was also found to 
be selectively toxic to subtypes of diffuse large B-cell lymphoma cells that are 
associated with NF-kB activation by down regulating NF-kB dependent genes 
(Lam et al., 2005). It remains an attractive agent to be tested in other B-cell 
malignancies like CLL. BAY 11-7082 is a well characterised inhibitor of IKK 
(Pierce et al., 1997) shown to induce apoptosis in CLL samples with relatively 
low toxicity to normal B-cells. Induction of apoptosis was associated with 
cytochrome c release from the mitochondria and caspase 9 activation 
(intrinsic pathway) suggesting a predominant role of NF-kB in preventing the 
activation of the intrinsic mitochondrial pathway in CLL (Pickering etal., 2007). 
In the study by Pickering et al., 2007, another NF-kB inhibitor, Kamebakaurin, 
a complex natural kaurane dierpene that directly inhibited DNA binding of p50
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(Lee et al., 2002) showed comparable results. Curcumin, a diferuloylmethane 
derived from turmeric, an inhibitor of IKK and NIK/IKK complex was shown to 
suppress the activation of NF-kB and expression of cyclin D1, Bcl-2 and Bcl- 
XL; all known NF-kB target genes (Everett et al., 2007). It causes apoptosis in 
human B-cell malignancies, Hodgkin’s lymphoma, multiple myeloma and 
activated B-cell neoplasms like DLBCL, CLL (Thomas et al., 2005; Everett et 
al., 2007) and mantle cell lymphoma cell lines (Shishodia et al, 2005a; 2005b). 
In addition, curcumin has been shown to augment the apoptotic effect of 
fludarabine, dexamethasone and vincristine (Everett etal., 2007).
The sesquiterpene lactone parthenolide (PTL) has been shown to be cytotoxic 
to cells isolated from patients with CLL with minimal cytotoxicity to normal T- 
lymphocytes or CD34 (+) haematopoietic progenitor cells (Steele et al., 2006). 
It was shown to decrease nuclear levels of NF-kB and diminish 
phosphorylation of its negative regulator IkB. The mechanism of cell killing 
appears to be via PTL-induced generation of reactive oxygen species, 
resulting in turn in a conformational change in the pro-apoptotic protein Bax, 
and the subsequent release of mitochondrial cytochrome c and caspase 
activation (Steele et al., 2006). Some of the patients used in this study were 
resistant to the conventional chemotherapeutic drug chlorambucil indicating 
the importance of identifying new targets in treating this incurable leukaemia. 
Dimethyl amino parthenolide (DMAPT) was shown to induce rapid death of 
primary human leukaemic cells from myeloid leukaemia via inhibition of NF- 
kB, induction of oxidative stress responses and activation of p53 (Guzman et 
al., 2007).
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In summary, NF-kB is an extremely attractive transcription factor to target for 
the treatment of leukaemia and lymphomas either alone or in combination with 
other drugs. The development of new agents acting upstream of NF-kB or 
perhaps agents that target the molecule itself using the strategies described 
above may offer valuable new anti-cancer drugs in the future.
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2.0 MATERIALS AND METHODS
2.1 Tissue culture
2.1.1 Sample collection
Peripheral blood samples and / or bone marrow samples from patients with 
CLL were obtained with the patients’ written informed consent (LREC # 
02/4806). CLL was defined by clinical criteria as well as cellular morphology 
and the co-expression of CD19 and CD5 in lymphocytes simultaneously 
displaying restriction of light-chain rearrangement. Clinical information 
including treatment histories was available for all patients and none of the 
previously treated patients had received chemotherapy within 3 months prior 
to sample collection.
2.1.2 Isolation of mononuclear cells
Reagents and instruments Used 
Histopaque 1077 (Sigma-Aldrich, Dorset, UK)
Phosphate-buffered saline (PBS) pH 7.2 (Sigma-Aldrich, Dorset, UK) 
Ammonium chloride 0.87M of (Sigma-Aldrich, Dorset, UK)
Vi-cell XR cell counter (Beckman-Coulter, High Wycombe,
Buckinghamshire)
Isolation of mononuclear cells
Peripheral blood was layered onto Histopaque 1077 and centrifuged at 300xg 
for 30 min. After centrifugation, the opaque interface containing mononuclear
33
cells was aspirated and transferred into a clean sterile centrifuge tube (Figure 
2.1). The mononuclear cells were then washed with PBS at 300xg for 5 min. 
After washing, the supernatant was aspirated and discarded. The pellet 
containing mononuclear cells were then washed with 0.87% (w/v) of 
ammonium chloride solution to lyse contaminating erythrocytes. Cells were 
then centrifuged at 300xg for 5 min. The supernatant was aspirated and 
discarded and the pellet was then washed twice with PBS followed by 
centrifugation at 300xg for 5 min after each washing step. After the final wash, 
the mononuclear cells were resuspended in PBS and counted using a Vi-cell 
XR counter. All mononuclear preparations contained at least 95% viable cells 
according to the Trypan Blue exclusion method.
Figure 2.1 Illustration of MNC separations on Histopaque centrifugation
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2.1.3 Separation of B- and T-lymphocytes
Reagents and instruments Used
Dynabeads CD19-labelled (Dynal, Invitrogen, Paisley, UK)
Magnetic particle concentrator (MPC, Invitrogen, Paisley, UK)
Separation of B and T-lymphocytes
A volume of 7.5 pi CD19-labelled Dynabeads was used for the isolation of 
1x10® target cells. The required volume of Dynabeads was added to a 1.5 ml 
microtube together with 1 ml of 2% foetal calf serum in PBS. The microtube 
was then placed in the magnetic particle concentrator (MPC) for 60 sec. After 
60 sec, the fluid was aspirated and the washed Dynabeads were resuspended 
again in 1ml of 2% foetal calf serum in PBS. The washed Dynabeads were 
then added to the isolated mononuclear cells and incubated for 30 min at 2- 
4°C with gentle tilting and rotation. After incubation, the rosetted cells were 
isolated by placing the microtube in the MPC for 2 min. The supernatant was 
then aspirated and the microtube was removed from the MPC. The 
supernatant contained non B-cells while the beads were bound to the B-cell 
fraction (Figure 2.2).
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Figure 2.2 Schematic representation of B-cell separation
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2.1.4 Tissue culture
2.1.4.1 Tissue culture media and reagents
Roswell Park Memorial Institute (RPMI-1640) culture medium (Gibco BRL, 
Paisley, UK)
Foetal calf serum (FCS) (Gibco BRL, Paisley, UK)
Penicillin/Streptomycin 5000U/ml and 5000|jg/ml (Gibco BRL, Paisley, UK) 
L-glutamine 200mM (Gibco BRL, Paisley, UK)
1x Phosphate Buffered Saline (PBS)
Dimethyl sulfoxide (DMSO) (Sigma, Dorset, UK)
2.1.4.2 Compounds used 
LC-1
The novel compound LC-1 is a dimethylamino derivative of the naturally- 
occurring small molecule parthenolide. LC-1 (also known as DMAPT) was 
prepared from the reaction of parthenolide with dimethylamine and the 
resulting dimethylamino analogue was then converted to its water-soluble 
fumarate salt. This was then reconstituted in sterile water and stored as 1mM 
solution at -20 C.
Fludarabine
Fludarabine was purchased from Bayer Pharmaceuticals and was stored as a 
100mM stock solution at -20° C.
IL-4 (Biosource, Paisley, UK)
CD154 (CD40 ligand) (Biosource, Paisley, UK)
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2.1.4.3 Preparation of 1x Phosphate Buffered Saline (PBS)
1 x PBS was made up by dissolving 50 PBS tablets (Sigma Aldrich) in 5 litres 
of distilled water. 500 ml aliquots were sterilised by autoclaving and stored at 
room temperature.
2.1.4.4 Preparation of media and cell culture
RPMI media was supplemented with L-glutamine (1%), FCS (10%), penicillin 
and streptomycin (2%) for all cell cultures. 1x106-5x106 mononuclear cells 
were cultured alone or with relevant compounds at 37°C in a 5% C 02 moist 
chamber for up to 48 hours. Cells were harvested by centrifugation and 
analysed by flow cytometry, processed for RNA extraction or sub-cellular 
fractionation.
2.2 Flow cytometry
Flow cytometry enables the discrimination of distinct cellular populations 
based on differential light scatter and fluorescence characteristics. The 
process of flow cytometry involves focusing cells into a unicellular stream of 
fluid and passing the stream through a laser beam. Specific antibodies against 
a particular antigen can be conjugated with fluorescent dye and then excited 
with a laser light. The subsequently emitted light differs in the wave length 
from the excitation light which enables separation using optical filters. This can 
be used for the quantification of antigens of interest.
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2.2.1 ZAP-70 and CD38 expression
2.2.1.1 Reagents and instruments used
Fix and Perm kit (Reagent A-fixative, Reagent B- permeabilisation) (CALTAG 
laboratories, Buckingham, UK)
ZAP-70-Alexafluor 488 (CALTAG laboratories, Buckingham, UK) 
CD19-Allophycocyanin (CD19-APC) (CALTAG laboratories, Buckingham, 
UK)
CD38-Phycoerythrin (CD38-PE) (CALTAG laboratories, Buckingham, UK) 
Summit 4.3 analysis software was used to analyse data generated from this 
machine (DAKO, Cambridgeshire, UK)
2.2.1.2 Determination of ZAP-70 and CD38 expression
Lymphocytes were aliquoted (1x106 cells) in duplicate; control and test 
samples. For test samples, the cells were stained with the following 
monoclonal antibodies: CD19-APC (4pl) and CD38-PE (4pl). For control 
samples, cells were labelled with a dual negative control (4pl) containing IgG^ 
FITC and IgGi /RPE (Dako) as well as CD19-APC. Both test and control 
samples were incubated in a dark place for 10min at room temperature. After 
incubation, samples were washed with 3-4 ml of PBS and centrifuged at 
300xg for 5 min. Then 50pl of Reagent A (fixative) was added and the cells 
were incubated for 10mins followed by a washing step in PBS and 
centrifugation at 300xg for 5 min. The supernatant was removed and 50pl of 
Reagent B (permeabilisation) and ZAP-70 Alexafluor 488 were added only to 
the test sample and both tubes were incubated for 10 min at room 
temperature in the dark. Then both samples were washed with PBS and
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centrifuged at 300xg for 5 min. The supernatant was discarded and the pellet 
was resuspended in 500pl of 1% paraformaldehyde. Stained cells were 
analysed on a FACS Calibur flow cytometer (Becton Dickinson, USA). Data 
were analysed using Summit 4.3 software (Dako, Ely, UK). The cut-off point 
for both CD38 positivity and ZAP-70 positivity was £20% (Figure 2.3 and 2.4).
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Figure 2.3A and Figure 2.3B illustration of ZAP-70 expression on CLL 
samples.
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2.2.2 Flow cytometric analysis of apoptosis
2.2.2.1 Reagents and Equipment
Propidium Iodide (PI) (CALTAG laboratories, Buckingham, UK)
Annexin V-FITC (Fluorescence isothiocyanate) (CALTAG laboratories, 
Buckingham, UK)
4 x binding buffer (CALTAG laboratories, Buckingham, UK)
CD3 PE (CALTAG laboratories, Buckingham, UK)
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CD19 APC (CALTAG laboratories, Buckingham, UK)
Becton Dickinson FACS Calibur Flow Cytometer (BD Pharmingen, Oxford, 
UK)
Summit 4.3 analysis software was used to analyse data
2.2.2.2 Viability analysis with propidium iodide and Annexin V
Apoptosis was assessed by dual-colour immunofluorescent flow cytometry as 
described previously (Vermes et a/., 1997, Pepper et a/., 2003). 1x106 cells 
were washed in ice-cold phosphate buffered saline and were incubated for 15 
min in the dark in 196 pi of binding buffer and 4 pi of Annexin V-FITC. 10pg/ml 
propidium iodide was added and cells were immediately analysed on a FACS 
Calibur flow cytometer. A minimum of 10,000 cells were counted in each 
sample for analysis. Differential apoptosis in B- and T-cells was analysed 
using CD3 and CD19 antibodies in conjunction with Annexin V. For B-cells, 
the proportion of Annexin V positive cells was derived from the total 
population of CD3/CD19* cells. For T-cells, the proportion of Annexin V 
positive cells was derived from the total population of CD3+/CD19‘ cells. A 
minimum of 10,000 events were acquired for each sample.
2.2.3 Flow cytometric analysis of caspase activation
2.2.3.1 Reagents and Equipment
PhiPhiLuxTM G1D2 substrate (Calbiochem, Nottingham, UK)
Caspase-8 inhibitor (ZIETD.fmk) (Calbiochem, Nottingham, UK)
Caspase-9 inhibitor (ZLEHD.fmk) (Calbiochem, Nottingham, UK)
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Pan-caspase inhibitor (ZVAD.fmk) (Calbiochem, Nottingham, UK)
2.2.Z.2 Analysis of caspase activation
CLL cells were incubated at 37°C in a humidified 5% carbon dioxide 
atmosphere in the presence of LC-1 (0.5 to 8pM) for up to 48h. Cells were 
then harvested by centrifugation and labelled with CD19-APC antibody. 
Subsequently the cells were incubated for 1h at 37°C in the presence of the 
PhiPhiLux™ Gi D2 substrate (Calbiochem, Nottingham, UK). The substrate 
contains two fluorophores separated by a quenching linker sequence that is 
cleaved by active caspase-3. Once cleaved, the resulting products fluoresce 
green and can be quantified using flow cytometry. The caspase activation 
cascade was further analyzed using a caspase-8 inhibitor (ZIETD.fmk, 50pM), 
a caspase-9 inhibitor (ZLEHD.fmk, 50 pM) and the pan-caspase inhibitor 
(ZVAD.fmk, 50pM).
2.3 Molecular biology
2.3.1 Preparation of cytosolic and nuclear extracts
2.3.1.1 Reagents and instruments used
Low salt detergent lysis buffer (10mM HEPES pH7.9, 1.5mM MgCI2 and 
10mM KCI)
High salt buffer (20mM HEPES pH7.9, 420mM NaCI, 1.5mM MgCI2, 0.2mM 
EDTA and 25% glycerol)
Storage buffer (10mM HEPES pH7.9, 25mM KCI, 0.1 mM EDTA and 10% 
glycerol)
Phosphatase Inhibitor Cocktails I and II (Sigma, Dorset, UK)
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Nonidet P40 (NP40)
Phenylmethosulfonylfluoride (PMSF)
2.3.1.2 Cytosolic and Nuclear extraction
Cytosolic and nuclear extracts were prepared using a method previously 
described (Brennan et a/., 1995). Cytosolic extracts were prepared by lysis of 
cells for 5 minutes on ice in 100 pi of low salt detergent lysis buffer 
supplemented with 1mM phenylmethylsulfonylfluoride (PMSF), 1:100 dilutions 
of Phosphatase Inhibitor Cocktails I and II (Sigma) and 0.1% NP40 detergent. 
These supplements were added immediately prior to use due to their short 
half-lives. Following centrifugation (Heraeus Biofuge) (16,600xg for 5 min at 
4°C), the supernatant was retrieved representing the cytosolic extract. Nuclear 
extracts were prepared by incubating the remaining pellet for 15 minutes in 50 
pi of high salt buffer supplemented with 1mM PMSF and 1:100 dilutions of 
Phosphatase inhibitor cocktails I and II immediately prior to use. Following 
centrifugation (16,600xg for 5 min at 4°C), the supernatant was collected 
representing the nuclear extract. For extracts prepared specifically for 
evaluation by EMSA, 50 pi storage buffer was added to the nuclear extract. All 
extracts were then stored at -80°C.
2.3.2 Quantification of protein concentration
2.3.2.1 Reagents and instruments used 
Bovine Serum Albumin (BSA) (Sigma, Dorset, UK)
Protein assay reagent (500-0006) (Bio-Rad Hemel Hempstead, UK)
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Microplate reader (170-6850) (Bio-Rad Hemel Hempstead, UK)
The NanoDrop® ND-1000 Spectrophotometer (Labtec international, 
Wilmington, USA)
2.3.2.2 Protein quantification using Bradford method
Protein concentration was determined using a method developed by Bradford 
(Bradford M, 1976). Protein concentration standards were generated using 
1 mg/ml BSA solution. Doubling dilutions of the 1 mg/ml BSA solution were 
prepared in a flat-bottomed 96 well plate. For the generation of a protein 
standard curve, duplicate 10 pi aliquots of each BSA dilution were used. Two 
wells containing 10 pi distilled H20  were included for the generation of the 
standard curve. A fixed volume (1 pi) of cytosolic or nuclear extract was 
pipetted into the 96 well plate. Protein assay reagent was diluted 1 in 5 with 
distilled H20  and 200 pi was added to each standard and extract. A microplate 
reader was used to read the absorbance of each well at 570nm. The protein 
concentration for each extract was first determined by plotting a standard 
curve (Figure 2.5) using the optical density at 570nm ( O D 57onm) of all the 
protein standards on a Microsoft Excel spreadsheet. The concentration of 
each sample extract was then calculated using the equation from the standard 
curve.
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Figure 2.5 Standard curve generated for Bradford assay
2.3.2.3 Protein quantification using NanoDrop® ND-1000
1|jl of each sample was pipetted onto the measurement pedestal of the 
apparatus (Figure 2.6).The protein concentration of sample was measured 
using absorbance at a wavelength of 280nm.
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Figure 2.6 NanoDrop® ND-1000
2.3.3 Electrophoretic Mobility Shift Assay (EMSA)
2.3.3.1 Reagents and instruments used 
Glycerol
Bovine Serum Albumin (BSA)
3M Whatman paper
Redivue adenosine 5'-[y-32P] triphosphate triethylammonium salt (Amersham 
(A0068) with relative radioactivity levels of 9.25MBq/250pCi)
10x T4 polynucleotide kinase buffer (Promega, Southampton, UK)
T4 polynucleotide kinase (100 units) (Promega, Southampton, UK)
Phenol: Chloroform: Isoamyl alcohol (25:24:1) (Sigma, Dorset, UK)
5x TBE (1L) containing 54g Tris HCI, 55g Boric acid and 7.4g EDTA and 
dH20
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Poly (dl dC) (100 A260 units, Amersham, Buckinghamshire, UK) was re­
suspended at 1 pg/pl I in 5 ml distilled H20
Loading dye containing 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene
cyanol, 30% (v/v) glycerol and 50mM EDTA and dH20
10x binding buffer containing 40% glycerol, 10mM EDTA, 50mM DTT,
100mM Tris pH7.5,1M NaCI, 1 mg/ml nuclease-free BSA and dH20  up to 
500pl
Acrylamide (40%) (BDH)
Ammonium persulphate (APS) (Sigma, Dorset, UK)
N N N’N’-Tetramethylethylenediamine (TEMED) (Sigma, Dorset, UK)
NF-kB binding oligonucleotide - sequence (5-CAA CGG CAG GGG AAT
CTC CCT CTC CTT-3') (Promega, Southampton, UK)
p50, p52, cRel, Rel B and Rel A antibodies (Kindly supplied by Nancy Rice,
USA)
2.3.3.2 End-labelling of double stranded oligonucleotides with [y-32P]- 
ATP
Prior to the addition of Redivue adenosine 5’-[y-32P] triphosphate 
triethylammonium salt, a labelling mix was first formed in a 1.5 ml eppendorf 
tube. This included 4 pi NF-kB binding oligonucleotide, 10 pi 10x T4 
polynucleotide kinase buffer, 2.5 pi T4 polynucleotide kinase (25 units) and
78.5 pi added to the mixture and incubated for 2.5 hours at 37°C in a Perspex 
container. Post-incubation, the Perspex box was returned to the controlled 
radiation area. 2.5 pi of 0.5M EDTA pH8 and 100 pi of phenol: chloroform was 
added to the mix. The mixture was briefly vortexed and centrifuged at 1390xg 
for 5 min in a microcentrifuge. The upper aqueous layer was removed to a
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fresh 1.5 ml eppendorf. 4 pi of 5M NaCI and 200 pi of absolute ethanol were 
then added to the aqueous layer. The mixture was incubated at -20°C for 60 
min in a lead container. The mixture was centrifuged at 1390xg for 10 min in a 
microcentrifuge and the supernatant was removed. The pellet was allowed to 
air-dry and dissolved in 50 pi TE buffer.
2.3.3.3 Preparation of native 4% polyacrylamide gels
Gels were prepared according to the following recipe: 35 ml distilled H20, 5x 
TBE, 5 ml 40% acrylamide, 0.1g ammonium persulphate and 20pl TEMED. 
Acrylamide gel mix was then poured into gel plates and a 12-well forming 
comb was inserted and gels were allowed to set for 40 min. The comb was 
then removed and wells were rinsed with distilled H20 and then filled with 0.5x 
TBE.
2.3.3.4 EMSA
Nuclear extracts were prepared as a reaction mix which included 1 pi 10x 
binding buffer, 2 pi poly (dl dC) and 2 pg nuclear extract and dH20  to make a 
final volume of 10pl. For supershift or cold competitor experiments, 2 pg of 
antibody or 100ng unlabelled NF-kB binding oligonucleotide respectively was 
pre-incubated for 30 min at 4°C. 1pl of 32P-labelled NF-kB binding 
oligonucleotide probe was added to the reaction mix and incubated at room 
temperature for 30 min. 1.2 pi of loading dye was then added to the mix. 
Samples were loaded under the 0.5x TBE in the wells using gel loading tips. 
The electrophoresis apparatus (Amersham) was assembled and 0.5x TBE 
was added to both the upper and lower reservoirs. The gels were then run at 
200V for 90 min using a Bio-Rad power pack. Following this, gels were placed
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on 3M Whatman paper was and dried under vacuum on a gel drier (Bio-Rad, 
model 583) set at 80°C for 120 min. Gels were then visualised by 
autoradiography. Atypical result is schematically represented in diagram 2.7.
2.3.3.5 Supershift EMSA
For the super-shift assay, the binding mixture was pre-incubated with the 
indicated antibodies for 30 min before adding the labelled probe. I used p50, 
p52, cRel, Rel B and Rel A antibodies for these experiments. Due to the 
change in size of the complexed molecules the mobility is altered which 
enables the visualization of different components.
NF-kB Probe
N iir lp a r  P Y trart toaqoq g c^ t tt  ccc ado c-31
C A I I d W  3'-TCAACT CCC CTC AAAGGG TCCG-5*
^  Binding motif
Free DMA im  w m D I I I I  IN 
Figure 2.7 Simplified schematic of an EMSA result.
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2.3.4 Enzyme Linked ImmunoSorbant Assay (ELISA)
(Trans AM™ NF-kB Rel A Transcription Factor Assay Kit, version E3)
2.3.4.1 Reagents and Equipment 
Microplate reader (Bio-Rad, 170-6850)
NFkB p65 antibody (Active Motif, Rixensart, Belgium)
Anti-rabbit HRP-conjugated IgG (Active Motif, Rixensart, Belgium)
Wild-type oligonucleotide (Active Motif, Rixensart, Belgium)
Mutated oligonucleotide (Active Motif, Rixensart, Belgium)
Positive control nuclear extract (Active Motif, Rixensart, Belgium) 
Dithiothreitol (DTT) (Active Motif, Rixensart, Belgium)
Protease Inhibitor Cocktail (Active Motif, Rixensart, Belgium)
Herring sperm DNA (Active Motif, Rixensart, Belgium)
Lysis Buffer AM2 (Active Motif, Rixensart, Belgium)
Binding Buffer AM3 (Active Motif, Rixensart, Belgium)
10X Wash Buffer AM2 (Active Motif, Rixensart, Belgium)
10X Antibody Binding Buffer AM2 (Active Motif, Rixensart, Belgium) 
Developing Solution (Active Motif, Rixensart, Belgium)
Stop Solution (Active Motif, Rixensart, Belgium)
Recombinant Rel A (Active Motif, Rixensart, Belgium)
2.3.4.2 Preparation of Complete Lysis Buffer
Complete Lysis Buffer was prepared by adding 5pl of 1 M DTT and 10pl of 
Protease Inhibitor Cocktail per ml of Lysis Buffer AM2 immediately before use.
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2.3.4.3 Preparation of Complete Binding Buffer
Complete Binding Buffer was prepared by adding 2pl of 1M DTT, and 10pl of 
1 pg/pl Herring sperm DNA per ml of Binding Buffer AM3 immediately before 
use.
2.3.4.4 Preparation of 1X Wash Buffer
Wash Buffer (1x) was prepared by diluting 1 to 10 dilution in distilled water 
and mixing it gently to avoid foaming. (10 ml 10x Wash Buffer AM2 with 90 ml 
distilled water).
2.3.4.5 Preparation of 1X Antibody Binding Buffer
10X Antibody Binding Buffer AM2 was warmed to room temperature and 
vortexed for 1 min prior to use. Antibody binding buffer (1x) was prepared by 
diluting 1 to 10 dilutions in distilled water and mixing gently to avoid foaming 
(Dilute 1 ml 10x antibody binding buffer AM2 with 9 ml distilled water). Both 
primary and secondary antibodies were diluted to 1:1000 with the Ixantibody 
binding buffer.
2.3.4.6 Preparation of standard curve
To quantify the amount of Rel A in the samples, I used recombinant Rel A 
protein to generate a standard curve. The following concentrations were used: 
0.5, 0.25, 0.125, 0.0625, 0.0312, 0.0156, 0.008 and 0 ng/pl for the standard 
curve.
52
2.3.4.7 ELISA
For each sample well 30pl of complete binding buffer was added followed by 
1pg of nuclear extracts diluted in 20pl of complete lysis buffer. For the positive 
control wells 30pl of complete binding buffer was added followed by 1 pi of 
Jurkat nuclear extract diluted in 20pl of complete lysis buffer. For the competi­
tive binding experiments 30pl of complete binding buffer containing 20pmol of 
wild-type or mutated consensus oligonucleotide was added followed by 
sample nuclear extracts diluted in 20pl complete lysis buffer. For the standard 
curve, 30pl of complete binding buffer followed by serial dilutions of 
recombinant Rel A diluted in 20pl of complete lysis buffer were used. Each 
plate was incubated for 1h at room temperature with mild agitation (100 rpm 
on a rocking platform). Each well was washed 3 times with 200pl 1x washing 
buffer followed by 100pl of pre-diluted Rel A antibody (1:1000 dilution in 1x 
antibody binding buffer) per well. After incubation for 1 h at room temperature 
without agitation the plate was washed 3 times with 200pl 1x washing buffer 
followed by 100pl of diluted HRP antibody (1:1000 dilution in 1x antibody 
binding buffer) per well. Each plate was then incubated for 1h at room 
temperature without agitation and then washed 4 times with 200pl 1x washing 
buffer. Subsequently, 100pl of developing solution was added to all the wells 
followed by incubation for 5 min at room temperature protected from direct 
light. Finally, 100pl of stop solution was added and the absorbance was read 
using a spectrophotometer within 5 min at 450nm with a reference wavelength 
of 655 nm (Benchmark, microplate reader, Bio-Rad). The processing steps for 
ELISA are represented schematically in Figure 2.8. An example of standard 
curve generated using recombinant Rel A proten is shown in Figure 2.9.
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Figure 2.9 Rel A was quantified in the patient samples by using a Rel A 
standard curve generated using recombinant proteins.
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Figure 2.8 Illustration
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2.3.5 Gene expression using real-time reverse
transcriptase polymerase chain reaction (RT-PCR)
RNA extraction
2.3.5.1 Reagents and Equipment
100% Ethanol (made up to 75% ethanol with deionized water prior to use and 
stored at room temperature) (Fisher Scientific)
Trizol (Invitrogen) stored at 4°C 
Chloroform (stored at 4°C) (Fisher Scientific)
Glycogen (5 mg/ml) (Applied Biosystems, stored at -20°C)
Isopropyl alcohol (Stored at room temperature) (Fisher Scientific)
RNase free water
2.3.5.2 RNA precipitation
Samples (mononuclear cells) were centrifuged at 8000xg for 5 min and the 
supernatant was discarded. 1ml of Trizol was mixed with the pellet and 
vortexed. This was then incubated for 5 min at room temperature followed by 
the addition of 200pl of chloroform. Samples were then centrifuged at 
12000xg for 15 min at 4°C. The aqueous phase was decanted into a fresh 
tube containing 2pl of glycogen (the aqueous phase containing RNA was 
colourless while the interface containing DNA was red). RNA was precipitated 
by adding 500pl of isopropyl alcohol followed by gentle mixing. This was 
incubated for 10 min at room temperature and centrifuged at 12000xg for 15 
min. The supernatant was removed and mixed with 1ml of 75% ethanol. Then 
it was centrifuged at 7500xg for 10 min at 4°C and the supernatant removed. 
This was then stored at -80°C after adding 1ml of 75% ethanol. Before use
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this was centrifuged at 7500xg for 5mins. The supernatant was then removed 
and the pellet was air dry before re-dissolving in 13pl of RNA free water. RNA 
was quantified using the NanoDrop® ND-1000 Spectrophotometer (Labtec 
international).
2.3.5.3 Reverse transcription reaction
Reagents and Equipment
MgCI2 (Applied Biosystems, Cheshire, UK)
10x PCR buffer II (Applied Biosystems, Cheshire, UK) 
dGTP (Applied Biosystems, Cheshire, UK) 
dATP (Applied Biosystems, Cheshire, UK) 
dTTP (Applied Biosystems, Cheshire, UK) 
dCTP (Applied Biosystems, Cheshire, UK)
RNAse inhibitor (Applied Biosystems, Cheshire, UK)
MuLV (Applied Biosystems, Cheshire, UK)
Random Hexamer primers (Applied Biosystems, Cheshire, UK)
For the master mix, 4pl of MgCI2 was added in addition to 2pl of 10x PCR 
buffer II, 1pl RNAse inhibitor and 2pl of each of dGTP, dATP, dTTP and 
dCTP. Subsequently, 1pl MuLV and 1pl Random hexamer primers were 
added and mixed thoroughly. To this 3 pi of RNA extract was added to make a 
20pl total reaction volume. Complementary cDNA was synthesized using a 
Thermal Cycler 480 (Applied Biosytems). The operating conditions were as 
follows: 10 min at 25°C followed by 30 min at 42°C followed by 5 min at 95°C. 
The resulting cDNA was stored at -20°C until use.
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2.3.5.4 Real-time quantitative polymerase chain reaction (qRT-PCR) 
(Light Cycler)
Reagents and Equipment
LightCycler System (Roche Diagnostics, Meylan, France)
Primers for target genes (Eurogentec S.A, Belgium)
CFLAR Forward 5-AGA-GTG-AGG-CGA-TTT-GAC-CTG-3'
Reverse 5-AAG-GTG-AGG-GTT-CCT-GAG-CA-3'
BIRC5 Forward 5'-T GTT GGG AAT CT GG AG AT G A-3
Reverse 5'-CGGATGAACTCCTGTCCTTT-3'
BCL2 Forward 5'-GGTCATGTGTGTGGAGAGCG-3'
Reverse 5'- GGTGCCGGTTCAGGTACTCA-3'
Primers for endogenous control
RPS14 Forward 5-GGCAGACCGAGAT GAACT CT -3'
Reverse 5-CCAGGTCCAGGGGTCTTGGT-3'
MgCI2 (25(jM stock)
Forward Primer (10pM stock)
Reverse Primer (10pM stock)
Syber Green (10x) 1A and 1B 
RNase free H20
2.3.5.5 Preparation of Syber green for use
Syber green was supplied by Roche in two separate tubes 1A and 1B. 
Immediately before use a mixture was prepared by adding 10pl of 1A to 1B 
and labelled as 1 (According to manufacturer’s instructions).
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2.3.5.6 Master mix for each study gene and endogenous control
The master mix for the PCR reaction was prepared by adding 1.6pl 5mM 
MgCI2, 0.5pl of 10pM forward primer, 0.5pl of 10pM reverse primer, 1pl of 10x 
Syber Green and 5.4pl of RNase free water (making a total master mix for 
each reaction of 9pl). Subsequently 1 pi of cDNA was added to each capillary 
to make a final volume of 10pl.
2.3.5.7 Real-time quantitative PCR
9pl of master was mixed with 1 pi of cDNA in a capillary tube. Capillary tubes 
were loaded onto the light cycler machine and the reaction was carried out 
under the following conditions:
Denaturation: 95°C for 10 min 
Amplification: 95°C for 3 sec 
Annealing Temp 63°C 5 sec 
Final extension: 72°C 10 min
The results of the real-time RT-PCR were expressed as normalized target 
gene values, e.g. the ratio between CFLAR and RPS14 transcripts calculated 
from the crossing points of each gene. All experiments were performed in 
duplicate.
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2.3.6 lgVH gene mutation analysis
2.3.6.1 Reagents and instruments used 
Qiagen RNeasy mini kit (Qiagen, Crawley, UK)
Reverse-iT kit (ABgene, Epsom, UK)
RNA was extracted from the patient samples using Qiagen RNeasy mini kits 
(Qiagen). Complementary DNA was synthesized using the Reverse-iT kit 
(ABgene). The lgVH gene mutation status of the CLL patients was analyzed 
according to the method previously described (Stankovic et al., 2002) and the 
resulting PCR products were sequenced using the BIG dye terminator 
sequencing kit version 3 (Applied Biosytsems). The sequences were 
subsequently analyzed using the following public databases: Immunoglobulin 
BLAST (http://www.ncbi.nlm.nih.gov/igblast/) and IMGT
(http://imat.cines.fr/IMGT vauest/vauest?livret=Q&Option=humanla). The 
sequences with a germ line homology of 98% or higher were regarded as 
unmutated and less than 98% as mutated.
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2.4 Clinical data collection
Comprehensive clinical information, including treatment histories, was 
available for all patients either through their case notes or direct interviews 
with the patients. The characteristics of the patients used for each experiment 
are given in the relevant experimental section.
Definitions of clinical characteristics gathered for the study
Date of diagnosis: The date the patient was
diagnosed with CLL
White blood cell count (WBC): Total white blood cell count at the
time of taking the sample for NF-
kB analysis
Lymphocyte count: Lymphocyte count at the time of
taking the sample for NF-kB
analysis
Lymphocyte doubling time (LDT): Time taken for the lymphocyte
count to double (in months)
Time to first treatment (TTFT): Time from diagnosis to the
treatment for the first time
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Time to subsequent treatment (TTST): Time from enrolment in the study
to the treatment.
Overall survival (OS): Time to death from date of
diagnosis
Overall survival from entry into study: Time to death from date of entry
into the study
2.5 Statistical analysis
Software packages used
Graphpad Prism 4.0 software (Graphpad Software Inc., CA, USA)
Calcusyn software (Biosoft, Cambridge, UK)
SAS statistical software (SAS Institute)
2.5.1 Assessment of dose of the drug required to kill 50% of the cells 
(LDso)
This was performed using Graphpad Prism 4.0 software (Graphpad Software 
Inc., San Diego, CA, USA). Drug sensitivity for each individual drug and drug 
combination was evaluated using non-linear regression and line of best fit 
dose-response curves.
2.5.2 Assessment of synergy
Data was analysed using the median effect method to determine the degree 
of synergy (Chou et a/., 1984) between the compounds tested. Combination
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Indices (Cl) and Dose reduction Indices (DRI) were calculated using Calcusyn 
software (Biosoft, Cambridge, UK).
2.5.3 Statistical analysis of prognostic parameters
The relationship between Rel A and known prognostic factors as well as time 
to first treatment and overall survival was explored through Wilcoxon rank sum 
tests for the categorical variables Binet stage, CD38, ZAP-70 and lgVH gene 
mutation status. Survival curves were constructed using the method of Kaplan 
and Meier and the Log-Rank test was used to assess any differences 
between patient and tumour characteristics. Cox regression analysis 
determined important independent prognostic factors for time to first treatment 
and overall survival. Statistical analysis was carried out using GraphPad Prism 
software 4.0 (Graphpad, CA) and SAS statistical software (SAS Institute).
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3.0 QUALITATIVE AND QUANTITATIVE
ASSESSMENT OF NF-kB IN CLL
3.1 Introduction
The factors that contribute to the pathogenesis and progression of CLL are 
poorly understood but decreased susceptibility to apoptosis (Kern et al., 2004; 
Romano et al., 2005; Greaney et al., 2006) and deregulated proliferation have 
been implicated (Messmer et al., 2005). NF-kB is known to contribute to the 
regulation of both apoptosis and proliferation and CLL cells have been 
reported to exhibit high constitutive NF-kB activation compared to normal B- 
lymphocytes (Furman et al., 2000; Cuni et al., 2004; Tracey et al., 2005). 
Therefore, I set out to investigate NF-kB activity in a cohort of primary CLL 
patient samples in order to determine its biological relevance in CLL and to 
evaluate its potential as a prognostic marker.
3.2 Measurement of NF-kB activity
In its inactive state NF-kB is bound to Inhibitor of kB (IkB) in the cytoplasm. 
Following cellular stimulation, IkB is phophorylated and degraded via 
proteosomal mechanisms allowing NF-kB proteins to be translocated in to the 
nucleus (Sun et al., 1994). NF-kB can be measured at the protein level and 
mRNA level or alternatively IkB levels can be quantified as an indirect method 
of NF-kB activity. An overview of most commonly used methods for the 
measurement of NF-kB is given below.
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3.2.1 Electrophoretic Mobility Shift Assay (EMSA)
EMSA (Schreck et al., 1990) is the most widely used method for measurement 
of NF-kB and is a direct measure of NF-kB DNA binding. In this method, 
nuclear extracts are incubated with radioactive double-stranded 
oligonucleotide containing a consensus sequence for NFkB binding. Active 
NF-kB in the nuclear extracts will bind to its consensus sequence and 
samples are then resolved by native polyacrylamide gel electrophoresis 
followed by autoradiography. A retarded band corresponding to the NF-kB 
DNA complex can be detected as well as a band that migrates much further in 
unit time corresponding to free DNA. When NF-kB is in its inactive form, 
bound to IkB, it is unable to bind to DNA. A further adaptation of this method 
involves the incubation of cellular extracts with antibodies against specific NF- 
kB subcomponents prior to mixing with the radioactive oligonucleotide. The 
resulting protein-oligonucleotide complex can show decreased mobility 
thereby distinguishing the individual NF-kB subunits (super-shift Assay). This 
gel retardation method is sensitive but is not suitable for high throughput 
screening of large numbers of patient samples.
3.2.2 Enzyme Linked ImmunoSorbant Assay (ELISA)
This DNA binding assay is based on the use of multi-well plates coated with 
an oligonucleotide containing the consensus binding site for NF- kB. This is 
different to a normal ELISA as the protein of interest is captured by a double­
stranded oligonucleotide containing the consensus binding sequence for NF- 
kB rather than an antibody. This technique only captures activated 
transcription factor which is then detected by primary antibody followed by a
64
secondary antibody conjugated to horseradish peroxidase. Finally, the 
reaction is quantified by a colourimetric or fluorometric reaction. This assay 
allows large scale screening than EMSA.
3.3 Programmed cell death
Programmed cell-death (PCD) is death of a cell in any form mediated by an 
intracellular programme and is often termed physiological cell death or 
apoptosis (Engelberg-Kulka et al., 2006). In contrast, necrosis is a form of cell 
death that results from acute tissue injury and provokes an inflammatory 
response (pathological cell death). There are different pathways consisting of 
many steps leading to the DNA fragmentation in apoptosis (Elsasser et al., 
2000). There are several completely unresolved issues in apoptosis. These 
include the time course of activation of the death signal to DNA fragmentation, 
point the apoptotic process is irreversible and the best way of quantification of 
apoptosis (Rodriguez et al., 2004). The first measurable phenomena are loss 
of mitochondrial transmembrane potential and activation of caspase 3. This is 
followed by transferred phosphatidyl serine (PS) to the outer cytoplasmic 
membrane. Chromatin condensation and DNA fragmentation are considered 
to be late features of apoptotic cell death. The reversibility of the apoptotic 
pathway may be cell type dependent. It has been shown that PS expression is 
reversible in some cell types while DNA single strand breaks are reversible in 
others (Chang etal., 2003; Lamarche etal., 2003).
Apoptosis is involved in several normal biological processes including foetal 
development, tissue renewal in the skin, gut and bone marrow and elimination 
of abnormal cells. The loss of effects as a controller may allow malignant cells
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to arise (Evan et al., 1997). In CLL, it has long been believed the 
accumulation of malignant cells is due to an inherent defect in apoptotic 
machinery. The diagram below illustrates the various pathways leading to 
apoptosis (Figure 3.1).
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Figure 3.1 Apoptotic pathways
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3.3.1 Apoptosis and CLL
CLL cell accumulation in peripheral blood and bone marrow is believed to 
result from failed apoptosis, alterations in cell cycle regulation and from cell 
proliferation (Kern et al., 2004; Messemer et al., 2005; Obermann et al, 2007). 
This leads to the progressive increase in malignant lymphocytes. Various 
studies have tried to identify the prognostic significance of both spontaneous 
and drug induced ex vivo apoptosis in CLL cells. However, results have not 
been conclusive with some authors describing a clear correlation between 
these parameters and the response to treatment and the clinical course of the 
disease while others attribute no such relationship (Jahrsdorfer et al., 2005; 
Sieklucka et al., 2008). However, ex vivo drug-induced cytotoxicity is more 
likely to predict the clinical response to treatment hence progression of the 
disease (Morabito et al., 1998). Also ex vivo drug induced apoptosis is shown 
to predict the in vivo response to chemotherapy (Byrd et al., 1988; Bosanquet 
etal., 1997; Morabito etal., 1998).
3.3.2 Measurement of apoptosis
Flow cytometric techniques can be used to track many of the changes that 
occur in cells during the process of apoptosis allowing the number of apoptotic 
cells in a sample to be accurately quantified (Ormerod et al., 2000). During 
apoptosis there is a loss of plasma membrane phospholipid asymmetry, with 
phosphatidyl serine residues flipping from the inside to the outside of the 
plasma membrane. Annexin V is a calcium-dependent phospholipid binding 
protein that has a high affinity for PS and can be used flow cytometrically with 
non-fixed cells as a sensitive probe for PS exposure (Koopman et al., 1994;
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Vermes et al., 1995). When using the Annexin V binding method to quantify 
apoptotic ceils, it is customary to add a cationic dye such as propidium iodide 
to distinguish between apoptotic cells with an intact plasma membrane and 
those cells that have lost membrane integrity and are undergoing secondary 
necrosis.
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3.4 Results
Patient characteristics used for this part of the study are described in Table 
3.1 and Table 3.2.
Table 3.1 Patient characteristics
Patient ID Gender Stage CD38 ZAP-70 lgVH status
1 M A 2 0 M
2 M A 14 0 M
3 F A 1 1 M
4 F C 2 1 M
5 M B 46 2 M
6 M A 79 3 M
7 F A 1 5 M
8 M A 3 8 M
9 M A 7 10 M
10 F B 34 10 M
11 F A 1 20 M
12 M A 46 20 M
13 F A 9 22 M
14 M C 2 28 M
15 F A 3 29 M
16 M C 18 31 M
17 M A 35 32 M
18 M A 23 36 M
19 F C 68 56 M
20 F A 100 61 M
21 M C 5 0 U
22 M A 35 1 U
23 M C 3 20 U
24 M A 54 24 U
25 F A 47 25 U
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Patient ID Gender Stage CD38 ZAP-70 lgVH status
26 M C 3 29 U
27 F A 70 33 U
28 M C 70 33 u
29 M B 39 37 u
30 M B 98 39 u
31 M B 42 40 u
32 M A 39 48 u
33 M B 81 1 ND
34 F A 3 1 ND
35 F A 4 2 ND
36 F A 87 4 ND
37 F A 29 22 ND
38 F A 47 33 ND
39 F C 87 88 ND
40 M A 16 ND ND
41 F A 21 ND ND
42 M A ND ND ND
43 F A ND ND ND
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Table 3.2 Patient characteristics
Patient ID Gender Stage CD38 ZAP-70 lgVH status
1 M A 8 11 M
2 F A 7 3 U
3 F A 9 13 M
4 M B 4 0.2 M
5 M A 5 70 M
6 M A 2 0.3 M
7 M A 13 24 M
8 F A 0.7 5.4 M
9 M A 10 0.2 M
10 M B 42 14 ND
11 F A 99 63 M
12 M A 9.8 10.4 M
13 M A 8 3 M
14 M A 84 13 M
15 M B 36 34 U
16 M A 99 90 ND
17 M B 99 40 U
18 M A 35 32 M
19 M A 26 7 M
20 F A 2.2 6.5 M
21 F A 3.2 0.8 M
22 M A 4.6 10.3 M
23 M A 10 4 M
24 M A ND ND ND
25 M A 0.4 0.6 M
26 M A 13 85 M
27 M A ND ND ND
28 M A 85 99 ND
29 M A 4.2 11 ND
30 F A 5 3 ND
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3.4.1 Total NF-kB binding is heterogenous in CLL patient 
samples
CLL cells have been shown to exhibit high levels of nuclear NF-kB when 
compared with non malignant B-cells (Furman et al., 2000; Endo et al., 2006). 
However, a detailed analysis of the variation in levels of NF-kB across multiple 
patients or a dissection of the constituent subunits in primary CLL cells has 
not been previously described. Therefore, in this study, the first objective was 
to determine the range of constitutive DNA binding of NF-kB within our patient 
cohort.
NF-kB DNA binding was investigated in 43 unselected CLL patient samples 
using electrophoretic mobility shift assay (EMSA). Two cell lines were chosen 
as reference for the assay: BL41, a Burkitt’s lymphoma line with relatively low 
NF-kB activity, and IARC-171, an EBV immortalised line derived from the 
same patient. EBV activates NF-kB during B-cell immortalization so IARC-171 
cells represent a positive control for a B-cell high in NF-kB. Figure 3.2 shows a 
representative sample of nuclear extracts derived from 12 patients 
demonstrating the differential expression of NF-kB DNA binding. DNA binding 
varied from almost undetectable (patients 2, 4, 7and 9) to levels comparable 
or higher than those found in the EBV immortalized cells (patients 3, 8 and 11) 
with other samples showing intermediate NF-kB DNA binding. The specificity 
of the NF-kB binding was confirmed by an EMSA cold competitor assay 
(Figure 3.3). A non-radioactively labelled NF-kB DNA oligonucleotide 
eliminated binding while an oligonucleotide for another transcription factor, 
AP1, left DNA binding unaffected.
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Figure 3.2 CLL patients show heterogeneity of NF-kB DNA binding. NF-
kB DNA binding activity in cell nuclear extracts was measured using 
electrophoretic mobility shift assays. An oligonucleotide corresponding to the 
consensus sequence to NF-kB was radiolabeled and incubated with 2 pg 
nuclear extract. The DNA-protein complex was restored by electrophoresis in 
a 4% native polyacrylamide gel in 0.5X TBE buffer. The gels were dried and 
protein binding was visualized by autoradiography.
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Figure 3.3 The specificity of the NF-kB binding was confirmed by an 
EMSA cold competitor assay. To 2 pg of nuclear extracts of CLL patient 11, 
a cold, non-radiolabeled NF-kB and a non-specific oligonucleotide, AP1 was 
added at 10X and 25X the concentration of radiolabeled NF-kB and incubated 
for 30 minutes, prior to addition of the radiolabeled NF-kB consensus 
oligonucleotide. The DNA-protein complex was resolved by electrophoresis in 
a 4% native polyacrylamide gel in 0.5X TBE buffer. The gels were dried and 
protein binding was visualized by autoradiography.
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3.4.2 Total NF-kB DNA binding and prognostic markers 
of CLL
A greater understanding of the clinical heterogeneity of CLL has emerged in 
the past few years from studies defining prognosis by molecular methods 
(Damle et al., 1999; Hamblin et al., 1999) and cytogenetic abnormalities 
detected by fluorescence in-situ hybridisation (Dohner et al., 2000). Specific 
molecular features of CLL, such as the absence of lgVH mutations or deletions 
in chromosomes 11 or 17, identify patients who are likely to progress and 
have a high probability of dying as a result of their disease (Dohner et al., 
2000; Crespo et al., 2003; Rassenti et al., 2004). Although major advances 
have been made in identifying subsets of patients with different prognoses, 
none of the currently available markers are able to predict the clinical course 
of every patient. Also there is a significant heterogeneity among availabe 
prognostic markers. I compared NF-kB DNA binding with other widely 
available prognostic markers in CLL. Due to variation in the radioactivity of the 
oligonucleotide probe and other experimental conditions, measurement of NF- 
kB DNA binding by EMSA is only semi-quantitative. Quantitation in this 
context utilised the IARC cell line as the positive control in each gel retardation 
experiment and the NF-kB DNA binding of each sample was standardised by 
generating the ratio between sample value and value for IARC. These values 
(relative NF-kB DNA binding) were then compared with other currently used 
prognostic markers in CLL. Relative NF-kB DNA binding was not significantly 
different in different prognostic subsets. P values as tested by non-parametric 
f-test for CD38+ £20% , ZAP-70+ £20% or lgVH status were 0.53, 0.15 and 
0.66 respectively (Figure 3.4 A, B and C). These findings illustrate that there
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was no corelation of total NF- kB DNA binding with ZAP-70, CD38 
expresssion or lgVH mutational status.
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Figure 3.4A Total NF-kB and other prognostic markers. There was no 
significant difference in NF-kB DNA binding between CD38 positive and CD38 
negative samples.
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Figure 3.4B Total NF-kB and other prognostic markers. There was no 
significant difference in NF-kB DNA binding between ZAP-70 positive and 
negative samples.
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Figure 3.4C Total NF-kB and other prognostic markers. There was no 
significant difference in NF-kB DNA binding between lgVH unmutated and 
mutated samples.
3.4.3 Qualitative analysis of NF-kB subunits
Specific NF-kB subunits have different capacities to activate gene expression. 
For instance, Rel A functions as the critical transactivating component of the 
NF-kB signalling pathway (Sun et al., 1994; Takada et al., 2004). The next 
step in this study was to characterise the NF-kB subunits present in leukaemic 
B-cells. For this, super-shift EMSA was performed using antibodies against 
specific NF-kB proteins (Rel A, p50, p52, c-Rel and Rel-B). A rabbit serum 
control was used in each case. Figure 3.5 shows a representative supershift 
EMSA derived from primary CLL cell nuclear extracts. Rel A, p50 and c-Rel 
subunits were detected in all the samples tested, as evidenced by shifts in 
their respective bands following antibody binding. However, there was marked 
variation in the amounts of each in the different patient samples.
Mutated Unmutated
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Figure 3.5 Rel A, p50 and c-Rel are the predominant NF-kB subunits in 
CLL patient samples. For qualitative analysis of NF-kB subunits, supershift 
analysis was performed on NF-kB using p50, Rel A, p52, Rel B, c-Rel 
antibodies and normal rabbit sera. 2 pg nuclear extracts from CLL nuclear 
extracts were used for these experiments. The different lanes marked, none, 
p50, Rel A, p52, Rel B, c-Rel and Rab ser (Rabbit sera), represent incubation 
with different antibodies. They were then incubated with a radiolabelled 
oligonucleotide corresponding to the consensus sequence of NF-kB for 30 
minutes. Ab: represents the different antibodies used. “None” indicates that no 
antibody was incubated. White arrows indicate the antibody-protein-DNA 
complexes, while the black arrows indicate the protein-DNA complexes.
3.4.4 Quantitative analysis of NF-kB
NF-kB subunits Rel A, Rel B and c-Rel are shown to have transactivation 
domains (Schmid et al., 2008) and this analysis shows that, of the three, Rel A 
is the most abundant subunit therein CLL cells. Furthermore constitutively 
activated Rel A has been shown to have oncogenic potential in cell lines 
(Beauparlant et al., 1994). Quantification of Rel A was the next step of this 
study. In order to accurately quantify NF-kB in the CLL samples a 
colourimetric enzyme linked immunosorbant assay (ELISA) technique was
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employed. A standard curve was generated from recombinant Rel A protein 
for the quantification of Rel A DNA binding. As shown in Figure 3.6, there was 
a very good correlation with recombinant Rel A and optical density at 450nm 
(r2 = 0.99). In addition, samples from the same patients were tested on 
different plates on different days. As shown in Figure 3.7 there was less than 
10% variability between each experiment performed on different days. This 
indicates that this method can be used reliably to screen large number of 
patient samples and suggests that results derived from different centres could 
be directly compared with one another. Rel A DNA binding measured using 
ELISA and total NF-kB DNA binding as measured by EMSA was compared. 
There was a correlation between these two values (r2 = 0.2) (Figure 3.8).
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Figure 3.6 Standard curve was generated using recombinant Rel A 
proteins. ELISA was performed using various concentrations of (doubling 
dilutions) recombinant Rel A. There was a linear relationship with the 
concentration of recombinant protein and optical density.
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Figure 3.7 Inter assay variability of Rel A DNA binding was less than 
10%. To assess the inter assay variability, Rel A DNA binding was measured 
from the same samples on two different ELISA plates. There was a strong 
correlation between two results generated on different days (r2 = 0.92).
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Figure 3.8 Rel A DNA binding correlates with total NF-kB DNA binding.
NF-kB DNA binding was measured by EMSA and were compared with Rel A 
DNA binding measured by ELISA. There was a correlation between total NF- 
kB and its subunit Rel A measured by DNA binding methods (r2 = 0.20)
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After initial experiments to assess the reliability of quantifying Rel A using 
DNA binding ELISA, this technique was used for subsequent experiments. 
Figure 3.9 demonstrates Rel A DNA binding in B-cells, T-cells and monocytes 
from a normal donor. Samples derived from normal B- and T-lymphocytes had 
levels of Rel A below the threshold of detection. As shown in this figure there 
was a higher Rel A DNA binding among CLL samples when compared with 
normal B- and T-cells. Furthermore, CLL cells show wide variation in Rel A 
DNA binding. In the next stage of the study Rel A DNA binding was quantified 
in 30 CLL patient samples (Figure 3.10). There was considerable variability in 
Rel A: from undetectable levels up to 1.909 ng/pg of nuclear extract.
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Figure 3.9 Rel A DNA binding was variable among CLL B-cells but higher 
than normal B- and T-cells. Subunit-specific Rel A ELISA (Active Motif) 
assays were performed using 2pg of nuclear extracts from B-cells, T-cells and 
macrophages from normal donors and 19 CLL samples. Absorbance was 
measured at 450nm.
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Figure 3.10 Quantitative analysis of Rel A DNA binding in CLL B-cells.
Subunit-specific Rel A ELISA (Active Motif) assays were performed using 2\xg 
of nuclear extracts from 30 CLL samples. Absorbance was measured at 
450nm. Results were compared to a standard curve generated using 
recombinant protein which allowed the calculation of the amount of Rel A 
present in CLL cells expressed relative to total nuclear protein from CLL 
patient samples.
3.4.5 CLL samples show marked variability in apoptosis
which correlates with Rel A DNA binding
In parallel experiments, samples from each of these 30 patients were also 
analysed for in vitro apoptosis after 48 hours in cell culture using Annexin V 
and propidium iodide labelling (Figure 3.11). Samples showed a wide variation 
ranging from 9% to 80% (Figure 3.12). This variation in spontaneous 
apoptosis was then correlated with the ex vivo Rel A DNA binding activity of 
each sample. Figure 3.13 shows that there was a significant inverse
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correlation between CLL cell in vitro apoptosis and Rel A DNA binding activity 
(r* = 0.21, P = 0.01).
# • •
.♦
•
• •
*.!.*• •
• ■«, . « • *
p .. ,* ^  »■ 
m'*_______
’  •  *  •
- • • . ■
V - 1 ’
v  -  ^ r .
•  . * »  *  > > < ;  
_ _ _ _ _  • * ,  _
> Annexin V
Figure 3.11 Apoptosis was assessed using Annexin V and PI staining.
CLL cells were cultured for up to 48h and apoptosis was asseessed using 
Annexin V and PI staining.
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Figure 3.12 CLL samples show marked variability in spontaneous 
apoptosis. The in vitro spontaneous apoptosis of CLL cells was measured 
using Annexin V and Propodium Iodide (PI) staining (Top Panel). Percentage 
apoptosis was defined as the total Annexin V+ cells (PI+ and PI-) after 48 
hours in culture derived from the same 30 CLL patients (Bottom Panel).
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Figure 3.13 Correlation between Rel A DNA binding and apoptosis in 
CLL cells. Rel A DNA binding was measured using subunit specific ELISA 
and was correlated with spontaneous apoptosis measured by Annexin V and 
PI staining. The level of apoptosis showed a significant negative correlation 
with Rel A expression in the nucleus of CLL cells.
3.4.6 Rel A DNA binding is a marker of disease
progression and tumour bulk in CLL
Having implicated NF-kB subunit Rel A as being important for in vitro CLL cell 
survival, the next step was to investigate Rel A in relation to clinical markers of 
tumour burden and disease progression in CLL. Clinical laboratory parameters 
such as lymphocyte count or total white cell count, bone marrow infiltration 
pattern and lymphocyte doubling time (LDT) reflect the tumour burden and/or 
disease activity in CLL (Montillo et a/., 2005). Rel A DNA binding, using the 
subunit-specific ELISA was compared with lymphocyte doubling time (LDT) 
and total white cell count on the date of sample collection. Rel A was
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significantly higher in patients with an LDT less than 12 months (P=0.01; 
Figure 3.14). There was also a significant correlation (^=0.2, P=0.01) between 
Rel A DNA binding and total white cell count (Figure 3.15). Taken together 
these data suggest that Rel A contributes to tumour burden and disease 
activity in CLL.
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Figure 3.14 Rel A DNA binding is higher in samples from patients with 
shorter lymphocyte doubling time. Rel A levels were measured by DNA 
binding ELISA (Active Motif) and were compared in patients with a lymphocyte 
doubling time above or below 12 months. Patients with lymphocyte doubling 
times of less than 12 months showed significantly higher levels of Rel A 
(P=0.01).
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Figure 3.15 Correlation between Rel A DNA binding and total white cell 
count. Rel A levels were measured by DNA binding ELISA (Active Motif) and 
were compared in patients with WBC. There was a significant positive 
correlation between Rel A DNA binding activity in cells from patients and their 
total white cell count (^=0.2, p= 0.01).
3.5 Discussion
One of the key achievements of this part of the study was to move beyond the 
relatively simplistic concept that NF-kB is elevated in CLL patient samples 
towards a more detailed qualitative and quantitative study of this important 
family of transcription factors. CLL cells show wide variation in total NF-kB 
expression but typically express p50, Rel A and c-Rel but in varying amounts. 
In agreement with previous reports (Furman et al., 2000; Cuni et al., 2004), 
even the CLL samples that had low NF-kB expression had higher levels than 
primary B-cells in which no NF-kB could be detected by ELISA.
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This present study used more than one method to assess NF-kB activity in 
CLL samples. EMSA is regarded as the “gold standard” of measuring NF-kB 
and ELISA is a new development within the last few years as a mean of 
quantifying NF-kB subunits. A comparison of total NF-kB and Rel A 
measurement in CLL patient samples showed that the correlation between Rel 
A DNA binding and total NF-kB DNA binding was only 20%. This further 
highlights the results of the supershift EMSA experiments that showed that 
p50 was the commonest subunit in CLL cells.
NF-kB has been implicated in tumourogenesis and survival of a growing list of 
leukaemias and lymphomas, including Hodgkin lymphoma, diffuse large B-cell 
lymphoma, multiple myeloma, acute lymphoblastic leukaemia and chronic 
myeloid leukaemia (Karin et al., 2002). However, no previous study has 
quantified NF-kB subunits in primary patient samples. Furthermore, this is the 
first study to relate this quantification to in vitro cell survival, tumour burden 
and disease activity (LDT) thus demonstrating that an individual component of 
the NF-kB complex can contribute to the regulation of a human disease.
This study builds directly on others that have shown NF-kB provides pro­
survival signals to a number of different cell types. Both primary cancer 
tissues and cell culture models of these cancers exhibit constitutive activated 
NF-kB and inhibition of this activity by over expression of IkB or 
pharmacological agents induces in vitro apoptosis (Romano et al., 2000; 
Habens et al., 2005; Pickering et al., 2006). Our data correlating Rel A with 
spontaneous in vitro apoptosis revealed that the variation in Rel A can explain 
21% (r2 = 0.21) of the variation in apoptosis of CLL cells.
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Surprisingly, there was no significant correlation between Rel A and lgVH gene 
mutation status, CD38 expression or ZAP-70 expression. In contrast, there 
was a clear association between elevated Rel A, short LDT and high WBC. 
LDT and WBC are markers of disease progression and tumour burden and 
have been shown to correlate with overall survival in a number of studies and 
reinforce the importance of this transcription factor in CLL (Montserrat et al., 
1986; Vinolas et al., 1987; Wierda et al., 2007). I hypothesize that the lack of 
correlation between basal Rel A DNA binding and lgVH gene status, CD38 and 
ZAP-70 is because these factors contribute to the ability of CLL cells to induce 
NF-kB following stimulation rather than constitutive expression. This notion is 
currently being tested experimentally in our laboratory.
In summary, in this part of the study I analysed both total and NF-kB subunit 
Rel A in relation to other prognostic parameters. The data highlight the 
importance of NF-kB subunit Rel A in relation to in vitro survival and possibly 
proliferation of CLL cells. Importantly, this work suggests that NF-kB has the 
potential to be a target for therapy in CLL and the potential to be a valuable 
biomarker for disease. These two issues will be addressed in the next two 
chapters of this thesis.
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4.0 NF-kB INHIBITION IN CLL
4.1 INTRODUCTION
Chemotherapeutic drugs, such as fludarabine, chlorambucil, prednisolone and 
certain monoclonal antibodies induce CLL cell apoptosis in vivo, although 
complete remission is difficult to attain and most patients eventually relapse 
(Schriever et al., 2003). The results of the UK CLL4 clinical trial clearly 
showed improved responses to fludarabine plus cyclophosphamide (FC) when 
compared to fludarabine or chlorambucil monotherapies. Therefore FC has 
now become the standard chemotherapy in the UK. However, this increase in 
response rates is at the expense of elevated off-target toxicities e.g. in the FC 
arm 56% of the patients developed neutropenia and 38% needed hospital 
admission (Catovsky etal., 2007).
Most side effects are due to the non-selectivity of drugs toward target 
malignant cells. Development of new treatment options based on the biology 
of CLL cells is needed to improve prognosis, limit side effects and induce 
cures. Treatment strategies to target molecules that support the maintenance 
and growth of the tumour cells have been pursued (Griffin et al., 2001); these 
approaches have the ability to alter the nature of clinical cancer treatment 
because they can distinguish cancer cells from their normal counter-parts 
(Kurzrock et al., 2007). Agents like Imatinib mesylate, a Bcr-Abl and Kit kinase 
inhibitor in chronic myeloid leukaemia, and all-trans retinoid acid (ATRA) in 
acute promyelocytic leukaemia have revolutionised the treatment of these 
tumours by inducing remarkable responses with minimal host toxicities.
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Several survival signalling mechanisms are implicated in vivo and ex vivo 
survival of CLL cells (Cuni et al., 2004; Hajdu et al., 2005; Perez-Chacon et 
al., 2007; Natani et al., 2007; Pablo et al., 2007). It is now believed the relative 
resistance to apoptosis in CLL cells is caused by a combination of micro­
environmental signals and inherent defects in cell cycle and apoptosis 
regulatory machinery in these cells (Endo et al., 2006). The contribution of the 
micro-environment is believed to be mediated by humoral factors and cell to 
cell interactions (Ghia et al., 2005). Bone marrow stromal cells and nurse like 
cells are prime candidates for cells ‘feeding’ survival signals to CLL cells (Ghia 
et al., 2005; Endo et al., 2006). IL-4 and IL-1p are among the humoral factors 
known to contribute to CLL cell survival. Also it has been shown that CLL cells 
can regulate their survival by secreting growth factors in an autocrine manner 
(Kern et al., 2004; Novonty et al., 2008). BCL-2 family proteins (Bcl-2, Bcl-XL, 
and Mcl-1) and IAP family proteins (IAP1, IAP2, XIAP, Survivin) are major 
candidate pro-survival proteins considered to be important in CLL (Pepper et 
al., 2003; Schliep et al., 2004; Grzybowska-lzydorczyk et al., 2008; de Graaf 
et al., 2008). Several cell signalling pathways, including the NF-kB pathway, 
are involved in regulation of these anti-apoptotic proteins; implicating a role of 
NF-kB in modulation of these anti-apoptotic factors and hence in the 
regulation of CLL cell survival (Munzert et al, 2002).
4.2 NF-kB inhibition in CLL
The NF-kB cell signalling pathway is an attractive therapeutic target as NF-kB 
proteins are implicated in the regulation of genes that control apoptosis, 
proliferation, angiogenesis and metastasis (Koch et al., 1992; Beg et al., 1996; 
Wang et al., 1999; Cao et al., 2001) in various cancers. Furthermore, CLL
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cells have been reported to exhibit high constitutive NF-kB activation 
compared to normal B-lymphocytes (Furman et al., 2000; Cuni et al., 2004; 
Tracey et al., 2005; see Chapter 3) and numerous NF-kB inhibitors have been 
shown to have in vitro efficacy in CLL cells (Escobar-Diaz et al., 2005; Horie et 
al., 2006; Steele et al., 2006; Everett et al., 2007; Geeraerts et al., 2007; 
Pickering et al,. 2007). The sesquiterpene lactone parthenolide (PTL) and its 
analogue, dimethylamino-parthenlide (DMAPT), are probably the most widely 
studied NF-kB inhibitors to date. PTL has been shown to be cytotoxic to cells 
isolated from patients with CLL with minimal cytotoxicity to normal T- 
lymphocytes or CD34 (+) haematopoietic progenitor cells (Steele et al., 2006).
4.3 Cytotoxicity (apoptosis) assessment
A number of different techniques can be used to quantify the cytotoxic effect 
of drugs on leukaemia cells. These include,
1) Trypan blue exclusion method.
2) 3H-thymidine incorporation assay.
3) Colourimetric proliferation assays using compounds such as MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) or MTS 
(3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4- 
sulphophenyl] -2H- tetrazolium salt)
4) Apoptosis assays such as the Annexin V binding assay or the 
detection of poly (ADP)-ribose polymerase (PARP) cleavage.
5) Activation of various members of caspase cascade can be used as 
a measure of cell death.
(Martin et al., 2001; Muppidi et al., 2004; Rodriguez et al., 2005)
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4.4 Drug combination studies
Confusion surrounds the use of the terms synergism to describe the effects of 
drug combinations. Also terms like augmentation, potentiation, super- 
additivism and additivism are used in place of synergism in the literature of 
pharmacological studies (Berenbaum et al., 1977). Several different terms are 
used to describe the same phenomenon and the same term means different 
things to different authors (Goldin et al., 1957). The introduction of the 
combination index method by Chou & Talalay has achieved a greater degree 
of scientific consensus over fractional product method by Webb (Webb et al., 
1961; Chou et al., 1984). The Chou & Talalay method is based on the median 
effect principle; which is a single generalised method that can be applied to 
analyse dose-effect relationships in enzymatic, cellular and whole animal 
systems. It is derived from the law of mass-action: the basic law in nature that 
forms the basis of chemical equilibrium dynamics, biological receptor theory 
and enzyme kinetics. The Chou & Talalay method is distincts from all other 
methods by the fact that it not only takes in to account the ‘potency’ but also 
the ‘shape’ of dose-effect curves of each drug and their combinations. The 
median effect equation correlates the ‘dose’ and ‘effect’ according to the 
relationship:
f A  = ( D / D  m)m 
Where: D is the drug dose
Dm is the ‘median-effect dose’ -  equivalent to the IC50 
fa js the fraction affected by the dose 
fu is the fraction unaffected (fu=1-fa)
m is a coefficient signifying the sigmoidicity of the dose effect 
curve
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The median effect plot is a plot of log (D) on the x-axis against log (fa/fu) on the 
y-axis. This plot has the form of a straight line, with the x-intercept equating to 
Dm: the median effect dose, and the slope of the line equating to m: the 
coefficient signifying the sigmoidicity of the dose-effect curve. The Chou and 
Talalay method designates a combination index (Cl) for each drug 
combination studied. The combination index equation is derived from the 
median effect equation and describes the interaction between the two drugs. 
Cl<1 indicate synergism, Cl=1 indicate an additive effect while Cl>1 indicate 
antagonism. In addition to calculating Cl, newer computer software 
programmes also gives the dose reduction index (DRI). This determines how 
many fold of dose reduction is allowed for each drug in synergistic 
combinations. Reduction of dose (Dose reduction in combination drug 
experiments) leads to reduce toxicity while mainatining the desired efficacy.
In the current study, the software package Calcusyn (Biosoft) was used to 
construct median effect plots and calculate combination indices for each 
individual patient for each drug combination. Also we used this software to 
calculate the DRI for fludarabine in combination with LC-1. Non-mutual 
exclusivity was assumed for combinations of LC-1 with fludarabine. These 
assumptions were generally borne out in the layouts of the resulting median- 
effect plots. Combination indices differ according to the level of effect. If a drug 
is meant to stay in the body as an active agent for a long duration of time 
(drugs used for chronic disorders) it is important to demonstrate synergism at 
a low affect level. But some other drugs are meant to exert their effect more 
quickly and be inactivated or metabolised. In these circumstances it is more
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important to be synergistic at a higher effect level. We used Cl at 50% cell 
killing for interpretation of data.
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4.5 RESULTS
Table 4.1 Patient characteristics
Patient ID Gender Stage CD38 ZAP-70 lgVH Status
1 M A 32 12 M
2 M A 20 7 M
3 F A 16 22 M
4 M B 45 75 U
5 M A 2 6 M
6 M A 5 2 M
7 M A 37 9 U
8 M A 3 36 M
9 F A 62 78 M
10 F A 56 34 U
11 F A 97 79 U
12 M A 8 18 M
13 M B 62 27 U
14 M A 3 9 M
15 M C 3 29 U
16 M A 7 3 M
17 F B 4 3 M
18 M A 4 4 M
19 M A 36 87 M
20 F C 99 100 M
21 F A 47 76 U
22 M A 24 37 M
23 M A 31 23 U
24 M A 3 0 M
25 F A 4 ND M
26 M A 1 0 M
27 F A 5 6 U
28 M A 3 6 M
29 M A 5 7 M
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Patient ID Gender Stage CD38 ZAP-70 lgVH Status
30 M A 0 6 M
31 M A 100 63 M
32 M A 32 8 M
33 M C 68 17 U
34 M B 34 1 U
35 M A 0 38 M
36 M A 85 94 U
37 M A 18 22 U
38 F A 70 33 U
39 F A 2 14 M
40 M C 4 43 U
41 F A 79 3 M
42 F A 2 1 M
43 M A 73 1 U
44 F A 0 10 M
45 M A 5 12 M
46 M A 100 8 M
47 M C 65 68 U
48 F A 7 23 M
49 F B 41 51 U
50 M A 31 39 U
51 F A 5 ND U
52 M B 2 67 U
53 M A 94 7 U
54 F B 6 64 U
55 F A 97 43 ND
56 F C 7.4 3 U
57 F A 0.6 0.7 M
58 M C 4.6 0.2 M
59 M B 2.4 2 M
60 M A 35 10.6 M
61 M A 84 1 U
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Patient ID Gender Stage CD38 ZAP-70 lgVH Status
62 M A 0.6 17 ND
63 M A 2 1.3 M
64 F A 0.7 5.4 M
65 M A 6.6 10 M
66 M A 35 0.7 U
67 M A 3.7 10 M
68 M A 8.9 4.6 ND
69 M A ND ND ND
70 M A 50.4 15.4 ND
71 F A 6 3.6 ND
72 M A 4.6 10.3 M
73 M A 81 85 ND
74 M C 38 65 ND
75 M A 100 87 ND
76 F A 5.4 3 ND
77 F A 0.6 0.2 ND
78 M A 2.3 2 ND
79 M A 1 6.5 M
80 M A 1.3 1.1 M
81 M A 93.5 8.9 M
82 M A 1.5 0.1 M
83 M A 9.8 10.4 M
84 M A 46 1.7 M
85 F A 16 12.7 M
86 F A 100 66 ND
87 F A 100 94.5 M
88 F A 0.6 1 ND
89 M A 2 4.3 ND
90 M A 0.34 6 M
91 F A 1.1 20.4 M
92 F A 12 20 ND
93 M A 47 98 U
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Patient ID Gender Stage CD 38 ZAP-70 lgVH Status
94 M A 85 99 ND
95 F A 5 27 ND
96 M A 0.4 3.9 M
4.5.1 LC-1 induces apoptosis of CLL cells
The in vitro effects of the NF-kB inhibitor, LC-1 were investigated in freshly 
isolated CLL patient samples. LC-1 is a derivative of the sesquiterpene 
lactone parthenolide which has been shown to selectively kill CLL cells in vitro 
(Steele et al., 2006) and targets the transcription factor NF-kB. Parthenolide 
has poor solubility and unfavorable pharmacokinetics (Sweeney et al., 2005). 
In contrast, LC-1 has superior pharmacokinetic properties and over 1000-fold 
greater solubility than the parent compound and therefore represents an 
excellent candidate drug. CLL cells were incubated with a range of 
concentrations of LC-1 (0.5-8 pM) for up to 48h and apoptosis was quantified 
using Annexin V and propidium iodide labelling. LC-1 induced time- and dose- 
dependent apoptosis in primary CLL cells (Figure 4.1). The drug concentration 
necessary to cause 50% cell death (LD50 values) were calculated for each 
patient sample using GraphPad prism software. An example from a 
representative patient sample is shown in Figure 4.2. The mean LD50 value 
(±SD) for LC-1 in the 96 CLL patient samples tested was 2.9 pM (± 1.4 pM) at 
24h and 1.8pM ± 1.0 at 48h (Figure 4.3).
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Figure 4.1 LC-1 induced time and concentration-dependent apoptosis in 
primary CLL cells. CLL cells were treated with LC-1 (0-8|jM) for 24h and 48h 
and were then labelled with Annexin V and propidium iodide. The percentage 
of apoptotic cells was calculated as the sum of Annexin V+ / propidium 
iodide+ and Annexin V+ / propidium iodide-. A concentration-dependent and 
time-dependent increase in Annexin V positive cells was observed.
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Figure 4.2 Representative example of a sigmoid dose-response curve 
generated from CLL cells cultured with LC-1 for 24h.
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Figure 4.3 Mean LD50 values (± SD) for LC-1 were 2.9pM (± 1.4 pM) at 24h 
and 1.8pM (±1.0 pM) at 48h. CLL cells incubated with LC-1 (0-8|jM) and 
apoptosis assayed using Annexin V and PI staining. LD50 values were 
calculated using Graphpad Prism software using best fit sigmoid curves.
4.5.2 LC-1 is preferentially cytotoxic to CLL cells
The relative cytotoxicity of LC-1 in CLL cells and normal B- and T- 
lymphocytes was next assessed. For this, B- and T-lymphocytes from 10 age- 
matched non-leukaemic controls were assessed for their sensitivity to LC-1- 
induced apoptosis. In addition, the T-lymphocytes from 6 CLL patients from 
the untreated patient group were also analysed in order to determine whether 
LC-1 had differential cytotoxic effects on the various lymphocyte sub­
populations. The T-cells from the CLL samples showed consistently higher 
LD50 values than their corresponding malignant B-cell clones (P<0.0001; 
paired Mest). In addition, the normal age-matched control B-lymphocytes and 
T-lymphocytes demonstrated higher LD50 values than the CLL cells 
(P<0.0001). The relative sensitivities of the various lymphocyte populations to
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LC-1 are illustrated in Figure 4.4. The conclusion from these experiments is 
that LC-1 is preferentially cytotoxic to leukaemic B-cells. The fact that LC-1 is 
less cytotoxic to T-lymphocytes in CLL samples is particularly interesting as T- 
cell depletion is a major cause of morbidity and mortality associated with 
treatment with conventional chemotherapeutic agents like fludarabine 
(Blijlevens et al., 2005).
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Figure 4.4 LC-1 is preferentially cytotoxic to leukaemic B-cells. B-cells 
and T-cells from non-leukaemic, age-matched, donors and T-cells from 
CLL patients were incubated with LC-1. Apoptosis was assessed using 
Annexin V and propidium iodide. The percentage of apoptotic cells was 
calculated as the sum of Annexin V+ / propidium iodide+ and Annexin V+ / 
propidium iodide-. LD50 Values calculated using Graphpad Prism software. 
Normal B-lymphocytes were more than 2-fold less sensitive to the apoptotic 
effects of LC-1 than CLL cells (P0.0001).
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4.5.3 LC-1 induces both the intrinsic and extrinsic 
apoptotic pathways
As the next step, the kinetics of LC-1-induced cell killing and the specific 
mechanism(s) of apoptosis induction in CLL patient samples were studied. 
CLL cells were incubated with a range of concentrations of LC-1 (0.5-8pM) for 
up to 48h and apoptosis and caspase-3 activation was quantified using 
Annexin V/propidium iodide labelling and Caspase substrate PhiPhiLuxTM 
G1D2 respectively. LC-1-induced apoptosis was associated with caspase-3 
activation (Figure 4.5) and this could be inhibited by the pan-caspase inhibitor 
(z.VAD.fmk), a caspase-9 inhibitor (z.LEDH.fmk) and a caspase-8 inhibitor 
(z.lETD.fmk) (Figure 4.6). These data indicate that LC-1 induces apoptosis 
through the induction of both the intrinsic and extrinsic apoptotic pathways.
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Figure 4.5 LC-1 induced apoptosis was associated with caspase-3 
activation. (A) CLL cells were treated with LC-1 (0-8|jM) for 24h and 48h and 
were then labelled with Annexin V and propidium iodide. A concentration- 
dependent increase in Annexin V positive cells was observed. (B) Under the 
same conditions, caspase-3 activity was determined by using a fluorogenic 
substrate molecule that once cleaved by active caspase-3, fluoresced green 
and was detected by flow cytometry. The increase in caspase-3 activation was 
concentration dependent and was correlated with an increase in apoptotic cell 
death.
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Figure 4.6 LC-1 induces both the intrinsic and extrinsic apoptotic 
pathways. CLL cells were cultured with a caspase-8 inhibitor (50 pM), a 
caspase-9 inhibitor (50 pM) or a pan caspase inhibitor (50 pM) with or without 
LC-1. Apoptosis was measured using Annexin V and PI staining. LC-1 
induced apoptosis was partially abrogated by all three caspase inhibitors.
4.5.4 LC-1 inhibits Rel A DNA binding
To investigate the relationship between LC-1-induced apoptosis and inhibition 
of NF-kB DNA binding in CLL cells the following experiments were performed. 
CLL cells were incubated with LC-1 (0-8pM) for 4 hours before harvesting 
cells for apoptosis assessment or for protein extraction. Protein extracts were 
used for Rel A DNA binding assay by ELISA. Figure 4.7A demonstrates that 
LC-1 inhibits Rel A DNA binding in a dose-dependent manner. Also, CLL cells 
were incubated with 2pM of LC-1, and apoptosis was assessed and protein 
extracted hourly for up to 6h. Figure 4.7B demonstrates that LC-1 induced a 
time-dependent decrease in Rel A DNA binding. The inhibition is detectable at
103
4 hours and precedes any loss of cell viability and hence the effect is not 
merely a consequence of cell death induction (Figures 4.8A and 4.8B).
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Figure 4.7 LC-1 causes a dose-dependent reduction in Rel-A DNA 
binding that precedes apoptosis induction in CLL samples. (A) CLL cells 
were treated with 2pM of LC-1 for 1 h, 2h, 4h and 6h prior to apoptosis assay 
and nuclear protein extraction. ELISA analysis revealed a time-dependent 
decrease in Rel A DNA binding (B) Paired samples were analysed for 
apoptosis over the same time course with little evidence of elevated cell 
death.
104
AO.8-1
0.0
0 1 2 3 4 5 6 7
Time (hours)
i
T---------1---------1--------1---------1-------1----------1
1 2 3 4 5 6 7
Time (hours)
Figure 4.8 LC-1 induced a time-dependent reduction in Rel A DNA 
binding. (A) CLL cells were treated with 2^M of LC-1 for 1h, 2h, 4h and 6h 
prior to apoptosis assay and nuclear protein extraction. ELISA analysis 
revealed a time-dependent decrease in Rel A DNA binding. (B) Up to the 6h 
time point there was little evidence of apoptosis induction as measured by flow 
cytometry using the Annexin V / propidium iodide assay.
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4.5.5 LC-1-induced suppression of NF-kB target gene 
transcription
In the next part of this study, I examined whether LC-1-mediated inhibition of 
Rel A had an effect on downstream gene transcription using real time RT- 
PCR. Three NF-xB-regulated genes (CFLAR, BIRC5 and BCL2) were 
selected for evaluation due to their known importance in CLL cell survival 
(Granziero et al., 2002; Aron et al., 2003; Tracey et al., 2005). Gene 
transcription was compared in paired samples from individual patients (n = 6) 
with and without the addition of 2pM LC-1 for 4h. Figure 4.9 demonstrates 
significant reductions in the transcription of all 3 NF-xB-regulated genes 
following exposure to LC-1 (CFLAR by 2.7 fold, BIRC5 by 5.3 fold and BCL2 
by 3 fold).
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Figure 4.9 LC-1-induced suppression of NF-kB target gene transcription
5x106 CLL cells incubated with LC-1 (2pM) for 4h prior to RNA extraction. 
The expression of CFLAR, BIRC5 and BCL2 were quantified using real-time 
PCR. For each case, experiments were carried out in duplicate.
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4.5.6 LC-1 overcomes the cytoprotective effects of CD40 
ligand and lnterleukin-4
There is growing evidence that micro-environmental factors play a major role 
in in vivo survival of CLL cells (Ghia et al., 2000; Caligaris-Cappio et al., 2000; 
Ghia et al., 2005). A number of these factors, including CD40 ligand (CD154) 
and interleukin-4 (IL-4), cause their pro-survival effects, at least in part, via the 
induction of NF-kB (Furman et al., 2000; Barragan et al., 2002; Zaninoni et al.,
2003). As these signals appear crucial to CLL cells in vivo, it was important to 
assess the cytotoxic effects of LC-1 in the presence of these survival signals 
in vitro. Recombinant CD154 (1pM) or recombinant IL-4 (5nM) was added to 
the in vitro cytotxocity assays. As expected, the addition of CD154 and IL-4 
significantly reduced spontaneous apoptosis in the untreated control cultures 
(P = 0.0006 and P = 0.004 respectively). However, in the presence of LC-1 
the pro-survival effect of both CD154 and IL-4 was abrogated (P = 0.49, 
Figure 4.10 and P = 0.33, Figure 4.11 respectively) suggesting that LC-1 has 
the potential to overcome in vivo survival signalling.
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Figure 4.10 LC-1 over comes the cytoprotective effect induced by CD40 
ligation. (A) CLL cells from 7 patient samples were cultured with or without 
CD154 (1pM) for up to 48h. (B) There was a significant cytoprotective effect 
by CD154 when compared with control cultures (P = 0.0006). Addition of LC-1 
(2pM), overcome the pro-survival effect of CD154 (P = 0.49).
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Figure 4.11 LC-1 over comes the cytoprotective effect induced by IL-4.
(A) Mononuclear cells from 5 patient samples were cultured with or without IL- 
4 (5nM) for 24h. (B) There was a significant cytoprotective effect by IL-4 when 
compared with control cultures (P = 0.004). Addition of LC-1 (2pM), overcome 
the pro-survival effect of IL-4 (P = 0.33).
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4.5.7 LC-1 is equipotent in poor prognostic subsets of 
CLL
Pleiotropic drug resistance is a significant obstacle to the successful clinical 
management of CLL whereby treatment with one agent causes resistance to 
others (Pepper et al., 1999). In order to evaluate whether LC-1 was subject to 
conventional drug resistance mechanisms, the in vitro effects of fludarabine 
and LC-1 in samples derived from previously treated and untreated CLL 
patients were compared. Previously treated patients were relatively more 
resistant to fludarabine than their untreated counter-parts (P<0.0001). In 
contrast, both treated and untreated groups show equal sensitivity to LC-1 (P 
= 0.53, Figure 4.12). The next step was to compare the LC-1 LD50 values 
within prognostic subsets to assess their relative sensitivity to LC-1. As shown 
in Figure 4.13, there was no significant difference in LC-1 LD50 values between 
prognostic subsets define by lgVH gene mutation status (P = 0.21) and in vitro 
response to fludarabine (P = 0.21). Prognostic groups defined by CD38 
expression (P = 0.06) and ZAP-70 expression (P = 0.05) showed a trend 
towards increased sensitivity to LC-1 in the poor prognostic subsets. In 
addition, patients with 17p and 11q abnormalities also showed similar 
sensitivity to the apoptotic induction by LC-1. Taken together, these data show 
the potential value of inhibiting NF-kB as a therapeutic strategy in CLL 
particularly in resistant and relapsed disease.
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Figure 4.12 LC-1 is effective in patients who were treated previously.
Fludarabine LD50 and LC-1 LD50 values were compared between treated and 
untreated patient groups. Previously treated patients showed significant ex 
vivo resistance to fludarabine (P<0.0001) but treated and untreated patient 
groups were equally sensitive to LC-1 (P=0.53).
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Figure 4.13 LC-1 is equipotent in poor prognostic subsets of CLL. LC-1 
LD50 values were compared between prognostic subsets of patients. CLL cells 
derived from patients with CD38 expression >20% (n = 40) and <20% (n = 
50), ZAP-70 expression >20% (n = 37) and <20% (n = 53), unmutated lgVH 
genes (n = 23) and mutated lgVH genes (n = 50), and ex vivo fludarabine 
resistance (n = 16) and fludarabine sensitive (n = 44) showed no significant 
difference in sensitivity to LC-1 (P = 0.06 , P = 0.05, P = 0.21 and P = 0.21 
respectively).
4.5.8 LC-1 shows strong synergy with fludarabine in
primary CLL cells
Having demonstrated the cytotoxic profile of LC-1 in poor prognostic subsets 
of CLL and its ability to overcome in vitro resistance to fludarabine, the next 
was to investigate potential synergy between LC-1 with fludarabine. The 
optimal molar ratio (2:1, LC-1: fludarabine) for the combination of the two 
drugs was experimentally determined by comparing the combination indices
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derived from different molar combinations. Subsequently, a cytotoxic effect of 
each drug and their combination was measured over a 24h culture period. 
Figure 4.14A shows a representative dose-response curve for CLL cells 
derived from one patient treated with each drug and their combination. The 
combination of the two drugs was significantly more cytotoxic than either 
single agent as shown by the median effect plots (Figure 4.14B). Furthermore, 
the combination index (Cl) plot (Figure 4.15A) showed synergism across a 
wide range of cell killing (fractional effect). The Cl values revealed strong 
synergistic effects in the LC-1 /fludarabine combination with a mean Cl of 0.26 
(Figure 4.15B). In addition, the undiminished synergy in samples from poor 
prognosis subsets was demonstrated (Figure 4.16). This finding that the LC- 
1/fludarabine combination exerts synergistic cytotoxicity in fludarabine 
resistant cells raises the possibility that the combination of NF-kB inhibitors 
and conventional chemotherapy may be clinically useful in poor prognosis 
groups of CLL.
113
A1.0 ^
0 8 _
x  co m b  +  L C -1  o flu d ara0.2 _
B
6.0 _
x  c o m b  +  L C -1  o  flu d a ra
4.0 _
&
45
O)o
-2 0 2 0-4 0
- 2.0 _
Log (D )
Figure 4.14 Synergistic effect of LC-1 with fludarabine in primary CLL 
cells. CLL cells were treated for up to 48h with LC-1 (0.5 to 8pM) and / or 
fludarabine (0.25 to 4pM) at a fixed molar ratio of 2:1. Cytotoxicity was 
quantified using an Annexin V/ propidium iodide assay. The median-effect plot 
was constructed using Calcusyn software where Fa = fraction affected and Fu 
= fraction unaffected. (A) Dose-response curve for CLL cells treated with LC-1 
and/or with fludarabine. (B) Median-effect plot for CLL cells treated with LC-1 
and/or with fludarabine.
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Figure 4.15 Synergistic effect of LC-1 with fludarabine in primary CLL 
cells. (A) The combination Index (Cl) plot was constructed by computer 
analysis of the data. (B) Distribution of Cl among 24 patients tested with mean 
value of 0.26 ± 0.20.
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Figure 4.16 Undiminished synergy between LC-1 and fludarabine in poor 
prognostic subsets of CLL. Analysis of samples from prognostic subsets 
revealed that there was no significant difference in synergy in samples derived 
from patients who had previously received treatment, those who show ex vivo 
resistance to fludarabine, those with >20% CD38 expression, those with 
>20% ZAP-70 expression or those with unmutated lgVH genes (P = 0.79, P = 
0.49, P = 0.18, P = 0.79, P = 0.84 respectively).
4.5.9 Combination of LC-1 with fludarabine would
facilitate a significant dose reduction of fludarabine
One of the major benefits of using combinations of drugs that have synergistic 
effects is that doses of individual drugs can be reduced to limit dose- 
dependent side effects, whilst maintaining efficacy. In this study the dose 
reduction index (DRI) for fludarabine in each patient sample tested was 
calculated (n = 24). Figure 4.17 shows a representative DRI for fludarabine
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(DRI/ fractional effect curve) in CLL cells derived from one patient treated with 
the combination of LC-1 and fludarabine. The DRI was highly favourable in all 
the samples tested with a mean DRI for fludarabine when combined with LC-1 
of >1000. This means that there could be a theoretical 3 log reduction in the 
dose of fludarabine.
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Figure 4.17 Combination of LC-1 with fludarabine would facilitate a 
significant dose reduction of fludarabine. CLL cells were treated for 48 h 
with LC-1 (0.5 to 8pM) and / or fludarabine (0.25 to 4pM) at a fixed molar ratio 
of 2:1.The cytotoxicity was quantified using an Annexin V/ propidium iodide 
assay. Dose reduction index- Fraction affected plots were calculated using 
CalcuSyn software. DRI values of more than 1 for fludarabine were observed 
over a wide range of inhibition levels when combined with LC-1.
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4.6 DISCUSSION
In the previous chapter, I demonstrated that the NF-kB subunit Rel A is a 
biomarker of disease progression in CLL. This part of the study shows that 
inhibition of NF-kB by the novel parthenolide analogue LC-1 resulted in 
effective and preferential CLL cell killing. All of the samples tested were 
sensitive to LC-1 with a mean LD50 at 24h of 2.9pM. In addition, there was no 
significant difference in sensitivity to LC-1 within prognostic subsets. Indeed, 
LC-1 showed a trend towards increased efficacy in poor prognostic groups 
even in cells that showed marked in vitro resistance to fludarabine. This raises 
the possibility of using this agent as salvage treatment in poor prognostic 
subsets of CLL.
In addition, I investigated the specific mechanism(s) of LC-1-induced cell 
killing. It was previously shown that parthenolide-induced cell killing is 
mediated via intrinsic pathways of apoptosis pathway (Steele et al., 2007). 
Unusually, LC-1-mediated apoptosis resulted in the activation of both the 
intrinsic and extrinsic pathways and this provides one possible explanation for 
the efficacy of this agent in samples with drug resistance to conventional 
therapy.
Importantly, I showed that LC-1 specifically inhibited the DNA binding of Rel A 
in a dose- and time-dependent manner. This inhibition preceded the induction 
of apoptosis indicating that it may be a critical regulator of LC-1-mediated cell 
killing. I then explored the downstream consequences of Rel A inhibition by 
quantifying the transcription of three NF-xB-regulated genes CFLAR, BCL2
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and BIRC5 which have been implicated in CLL cell survival and resistance to 
chemotherapy (Pepper et al., 1997; Munzert et al., 2002; Morales et al., 2005; 
Willimott et al., 2007). Transcription of all three genes was significantly 
suppressed by LC-1 suggesting that NF-kB plays a role in preventing the 
activation of both the intrinsic and extrinsic apoptotic pathways in CLL. This is 
substantiated by the fact that CFLAR is involved in the inhibition of the 
extrinsic pathway and BCL2 inhibits the intrinsic pathway (Kroemer et al., 
2005)
Despite their prolonged survival in vivo, most CLL cells undergo spontaneous 
apoptosis when cultured in vitro (Collins et al., 1989) suggesting that humoral 
factors and cellular interactions provide critical survival signals in vivo. There 
is growing evidence that the lymphoid organs are the sites of delivery of many 
of these pro-survival signals as it is here where CLL cells come into direct 
contact with stromal cells, T-cells and follicular dendritic cells (Jurlander et al., 
1998; Lagneaux et al., 1998; Burger et al., 1999). Two of the key survival 
stimuli appear to be derived from CD40 ligation and IL-4 and both of these 
interactions have the ability to induce NF-kB in CLL cells (Romano et al., 
1998; Dancescu et al., 1992). I therefore included recombinant CD40 ligand 
and IL-4 into the drug sensitivity assay to determine whether LC-1 could 
overcome their cytoprotective effects. In accordance with previously published 
data CD40 ligation and IL-4 prevented CLL cells from apoptosis but the 
addition of LC-1 abrogated this pro-survival effect. Taken together, these data 
clearly show that NF-kB inhibition can overcome the survival signals induced 
by micro-environmental factors and this may be crucial in ensuring the clinical 
efficacy of these agents.
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The ability to induce apoptosis is an essential property of most
chemotherapeutic drugs (Thompson et al., 1995). Perversely this may result in 
the activation of survival pathways, including the NF-kB pathway, as an 
unwanted side effect (Beg et al., 1996; Wang et al., 1996; Webster et al., 
1999; Nakanishi et al., 2005). In keeping with this notion, samples from 
previously treated patients showed relative resistance to fludarabine in our 
study together with elevated Rel A DNA binding. However, I have
demonstrated the equal potency of LC-1 in all samples tested irrespective of 
their previous treatment or other prognostic parameters. This highlights the 
potential value of NF-kB inhibitors for the treatment of CLL particularly in the 
context of resistant and relapsed disease.
One of the major benefits of using combinations of drugs that have synergistic 
effects is that doses of individual drugs can be reduced to limit dose- 
dependent side effects, whilst maintaining efficacy. The concept of the dose
reduction index (DRI) was proposed by Chou (Chou et al., 1994). DRI is a
measure of how the dose of an individual drug in a synergistic combination 
can be reduced whilst retaining the same cytotoxic effect. A DRI >1 is 
beneficial and the greater the DRI value the greater the dose reduction for a 
given therapeutic effect. Remarkably, the mean DRI for fludarabine was 
>1000 indicating that the dose of fludarabine could theoretically be reduced by 
more than 3 logs thereby significantly reducing its immunosuppressive side 
effects while retaining the cytotoxic effects on CLL cells.
This part of the work provides a number of important new insights. It 
elucidated the mechanism of action of the novel NF-kB inhibitor LC-1 and also
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demonstrates the efficacy of LC-1 in poor prognostic subsets of CLL including 
samples with fludarabine resistance. This data also provide a compelling 
argument for the use of LC-1 in combination with fludarabine in the clinical 
setting.
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5.0 Rel A IS AN INDEPENDENT
PROGNOSTIC MARKER OF 
CLINICAL OUTCOME IN CLL
5.1 INTRODUCTION
The clinical course of individual patients is highly variable and reliable 
predictors of prognosis are lacking in the clinical workup of this condition. This 
has stimulated the search for prognostic markers that can predict patient 
outcome in CLL. The need for these biomarkers is particularly important 
because of the introduction of more effective therapies that might be optimally 
employed in the early phase of the disease before the problems associated 
with high tumour burden and drug resistance are encountered. Clinical studies 
have consistently shown that unmutated lgVH genes, high ZAP-70 expression, 
high CD38 expression and cytogenetic abnormalities (especially deletions of 
11 q and 17p) are all associated with inferior outcome (Damle et al., 1999; 
Hamblin et al., 1999; Dohner et al., 2000; Ibrahim et al., 2001; Rassenti et al.,
2004). However, none of these markers are able to accurately predict the 
clinical course of individual patients or their likely response to therapy. This 
limits their use in clinical management particularly in deciding if and when to 
treat. Therefore, the search for better markers is both timely and relevant.
The association of NF-kB subunit Rel A with in vitro survival and clinical 
disease progression in CLL was shown in chapter 3. I therefore hypothesized 
that Rel A could be a prognostic marker in this disease. In order to test this
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hypothesis, Rel A DNA binding was analysed in 131 patients and the results 
were correlated with the established markers of prognosis and clinical 
outcome.
5.2 Results
5.2.1 The patient characteristics of the CLL cohort used 
for this part of the study are described in Table 5.1.
Patient ID Gender Stage % CD38 % ZAP-70 lgVH Status
1 F B 6 4 ND
2 M A 96 80 98%
3 M B 11 5 ND
4 M A 73 48 100%
5 M A 3 2 87%
6 F A 5 3 87%
7 F A 88 82 94%
8 F A 1 19 ND
9 M A 3 0 ND
10 M A 40 48 100%
11 M A 22 2 92%
12 F A 100 62 96%
13 M C 2 29 95%
14 F A 3 30 93%
15 F A 100 92 82%
16 M A 1 31 91%
17 M A 100 14 89%
18 M A 62 78 83%
19 M A 10 13 93%
20 M C 22 11 90%
21 F C 47 86 98%
22 F A 2 7 92%
23 M A 13 24 94%
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Patient ID Gender Stage % CD38 % ZAP-70 lgVH Status
24 M A 84 1 100%
25 F A 4 13 95%
26 M B 47 2 96%
27 M A 30 9 ND
28 M A 0 4 93%
29 M A 1 1 91%
30 M A 42 14 75%
31 M A 3 8 85%
32 M A 35 11 94%
33 F A 7 2 94%
34 F A 13 11 96%
35 M A 5 53 ND
36 M A 35 32 96%
37 M A 0 70 ND
38 F C 5 14 98%
39 M A 14 20 97%
40 M A 1 17 ND
41 M A 2 0 83%
42 M B 99 39 100%
43 F A 1 1 ND
44 M A 0 1 90%
45 F A 1 5 95%
46 M C 6 4 ND
47 M C 18 31 96%
48 F A 87 4 ND
49 M C 3 29 99%
50 F A 46 31 95%
51 F A 39 18 ND
52 M A 6 37 ND
53 M A 9 5 96%
54 M A 5 8 90%
55 M B 99 99 93%
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Patient ID Gender Stage % CD38 % ZAP-70 lgVH Status
56 M A 72 3 ND
57 M B 43 40 100%
58 M A 11 27 94%
59 F B 4 3 85%
60 M A 50 5 92%
61 F A 6 34 ND
62 M A 6 2 91%
63 F A 16 13 83%
64 M A 16 81 100%
65 M A 3 81 ND
66 M A 16 1 91%
67 F C 7 3 100%
68 M A 4 10 96%
69 F C 69 57 91%
70 F C 99 100 96%
71 M A 80 1 100%
72 F A 5 3 ND
73 M A 8 23 93%
74 M A 4 2 ND
75 F A 23 2 90%
76 F A 47 26 98%
77 M A 36 1 100%
78 M A 3 1 ND
79 M A 9 3 ND
80 M A 24 37 92%
81 M A 27 25 92%
82 M A 30 11 83%
83 M A 50 0 96%
84 F A 1 0 ND
85 M A 1 10 ND
86 M A 8 11 95%
87 F A 3 54 ND
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Patient ID Gender Stage % CD38 % ZAP-70 lgVH Status
88 M A 98 47 99%
89 M A 1 63 89%
90 M A 5 10 94%
91 M A 85 99 98%
92 M A 34 1 100%
93 M B 5 0 96%
94 M A 2 2 ND
95 M B 40 37 99%
96 F A 70 33 99%
97 M A 13 85 89%
98 M A 7 10 91%
99 F A 13 7 91%
100 M C 47 21 97%
101 M B 2 20 91%
102 M C 4 43 100%
103 F A 79 3 89%
104 M A 73 1 100%
105 F A 4 32 88%
106 M C 3 21 100%
107 F A 10 1 97%
108 M A 2 4 ND
109 F A 1 5 94%
110 M A 10 4 93%
111 F A 2 2 90%
112 M A 26 7 94%
113 M A 9 9 90%
114 F A 100 7 91%
115 F A 100 95 93%
116 M A 3 7 97%
117 F A 7 23 96%
118 F A 3 22 94%
119 M A 2 0 86%
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Patient ID Gender Stage % CD38 % ZAP-70 lgVH Status
120 M A 100 87 88%
121 M A 8 58 92%
122 M A 0 1 89%
123 M B 3 18 90%
124 M A 8 3 93%
125 M A 47 10 94%
126 M A 85 13 92%
127 M A 0 6 91%
128 F A 4 121 ND
129 M A 36 34 98%
130 F C 2 1 89%
131 F A 7 20 92%
5.2.2 Measurement of Rel A DNA binding in CLL patient 
samples
Rel A was measured in nuclear extracts derived from 131 CLL patient 
samples using the quantitative DNA binding ELISA-based method described 
in chapter 3. Data from all 131 patients is shown in Figure 5.1; Rel A DNA 
binding ranged from undetectable to 2.44 ng/pg of nuclear extract with a 
median value of 0.44ng/pg (95% Cl 0.48-0.66).
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Figure 5.1 Variation in Rel A. Samples from all 131 patients were analysed 
for Rel A DNA binding using an ELISA-based assay.
5.2.3 Rel A DNA binding and prognostic markers of CLL
The correlation between Rel A and other prognostic markers was analysed in 
this part of the study. Rel A was markedly elevated in patients with advanced 
disease (P<0.0001, Figure 5.2) and those who required treatment (P<0.0001, 
Figure 5.3) but was not associated with CD38 expression (P = 0.87, Figure 
5.4), lgVH mutation status (P = 0.25, Figure 5.5) or ZAP-70 expression (P = 
0.55, Figure 5.6).
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Figure 5.2 Comparison of Rel A DNA binding in Binet subsets. Rel A DNA
binding was compared in different subsets of CLL patients categorised 
according to Binet stage. Elevated Rel A was strongly associated with 
advanced Binet stage (P<0.0001).
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Figure 5.3 Comparison of Rel A DNA binding in treated and untreated 
groups. Rel A DNA binding was compared in samples derived from untreated 
patients and those who had previously recieved treatment. Elevated Rel A 
was strongly associated with the need for prior treatment (P<0.0001). No 
samples were analysed within 3 months of therapy.
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Figure 5.4 Comparision of Rel A DNA binding in CD38 subsets. Rel A
DNA binding was compared in different subsets of CLL patients categorised 
according to CD38 expression. Elevated Rel A was not associated with CD38 
expression (P=0.87).
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Figure 5.5 Comparison of Rel A DNA binding in lgVH subsets. Rel A DNA
binding was compared in different subsets of CLL patients categorised 
according to lgVH mutational status. Elevated Rel A was not associated with 
the lgVH status (P=0.25).
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Figure 5.6 Rel A DNA binding in ZAP-70 subgroups Rel A DNA binding 
was compared in different subsets of CLL patients categorised according to 
ZAP-70 expression. Elevated Rel A was not associated with ZAP-70 
expression (P=0.55).
5.2.4 Association between Rel A DNA binding and time to 
initial therapy
Time to first treatment is defined as the time from diagnosis to the first 
treatment intervention (TTFT). It is considered to be an important clinical end­
point in assessing disease progression and is less subjective than an 
assessment of progression-free survival. Patients in this cohort were treated 
according to accepted guidelines (Cheasonet at al., 1996; Hallek et al., 2008); 
therefore the need for treatment denotes progressive disease or patients 
becoming symptomatic due to effects of their leukaemia. Rel A levels were 
analysed in relation to TTFT in 131 patient samples. 19 (14.5%) had 
previously received treatment and a further 33 (25.2%) required therapy
131
during the course of the study. Patients were categorised according to their 
Rel A DNA binding (above and below median values). The median TTFT in 
the low Rel A subset was 13.6 years versus 6.8 years in the high Rel A subset 
(P = 0.01, Figure 5.7). Since Rel A DNA binding was independent of CD38, 
lgVH mutation status and ZAP-70, I examined the ability of these established 
prognostic parameters to define TTFT in our cohort (Figure 5.8, 5.9 and 5.10 
respectively). In keeping with previous reports, unmutated igVH genes, £20% 
CD38 expression and £20% ZAP-70 expression were all associated with 
significantly shorter TTFT (P = 0.0005, P = 0.04 and P = 0.05 respectively) 
indicating that this study was carried out on a representative CLL cohort.
In multivariate analysis, the inclusion of Rel A in the model showed 
independent prognostic significance for TTFT (P = 0.01) and its inclusion 
diminished the prognostic value of CD38 (P = 0.25), lgVH gene mutation status 
(P = 0.05) and ZAP-70 (P = 0.28).
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Figure 5.7 Time to first treatment according to Rel A DNA bindingTime to 
first treatment was assessed from the date of diagnosis. Rel A DNA binding 
above the median value was able to define a population at increased risk of 
requiring treatment in unit time (P = 0.01).
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Figure 5.8 Time to first treatment according to CD38 expression Time to 
first treatment was assessed from the date of diagnosis. CD38 expression 
was able to define a population at increased risk of requiring treatment in unit 
time (P = 0.04).
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Figure 5.9 Time to first treatment according to lgVH status Time to first 
treatment was assessed from the date of diagnosis. igVH mutational status 
was able to define a population at increased risk of requiring treatment in unit 
time (P = 0.0005).
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Figure 5.10 Time to first treatment according to ZAP-70 expression Time 
to first treatment was assessed from the date of diagnosis. ZAP-70 expression 
was able to define a population at increased risk of requiring treatment in unit 
time (P = 0.05).
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5.2.5 Rel A is a predictor of time to subsequent treatment
Not all of the samples analysed for Rel A were taken at diagnosis. Some 
patients have had treatment before their inclusion in the study. As a next step 
of the study prognostic value of Rel A was more accurately assessed by 
controlling for previous treatment effect by analysing the predictive value for 
treatment after entering in to the study. The time to subsequent treatment 
(TTST) was defined as the date of entry into the study to the date requiring 
treatment. Rel A values were analysed in relation to TTST. Figure 5.11 shows 
the predictive value of Rel A in this CLL patient cohort. Patients with high Rel 
A DNA binding showed a median TTST of 22 months. In contrast, the median 
TTST of the low Rel A subset was not reached as only 5/68 patients with low 
Rel A DNA binding required treatment during the 24 month follow-up period (P 
= 0.0001). The ability of lgVH mutation, CD38 and ZAP-70 to predict TTST 
during the study period was also evaluated (5.12, 5.13 and 5.14 respectively). 
Only lgVH mutation status had prognostic value in this context (P = 0.04); 
CD38 (P = 0.17) and ZAP-70 (P = 0.13) were not predictive.
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Figure 5.11 Time to subsequent treatment according to Rel A DNA 
binding Time to subsequent treatment was measured from the date of entry 
into the study to the treatment intervention. Rel A DNA binding above the 
median value was able to define a population at greater risk of requiring 
treatment during the 24 month follow-up period (P = 0.0001).
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Figure 5.12 Time to subsequent treatment according to CD38 expression
Time to subsequent treatment was measured from the date of entry into the 
study to the treatment intervention. CD38 expression could not differentiate 
the population needing treatment during the 24 month follow-up period (P = 
0.17).
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Figure 5.13 Time to subsequent treatment according to lgVH status. Time 
to subsequent treatment was measured from the date of entry into the study to 
the treatment intervention. VH mutational status could differentiate the 
population needing treatment during the 24 month follow-up period (P = 0.04).
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Figure 5.14 Time to subsequent treatment according to ZAP-70 
expression. Time to subsequent treatment was measured from the date of 
entry into the study to the treatment intervention. ZAP-70 expression could not 
differentiate the population needing treatment during the 24 month follow-up 
period (P = 0.13).
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5.2.6 Rel A is a predictor of overall survival
Overall survival is defined as time to death from date of diagnosis (OS). This 
is used as a clinical end-point in assessing treatment modalities and 
prognostic markers. The ability of Rel A to predict patient OS was assessed 
as the next step of this study. Rel A DNA binding was predictive of survival 
from date of diagnosis (P = 0.01, Figure 5.15). Similarly, lgVH mutation status, 
CD38 and ZAP-70 were all predictive of survival from date of diagnosis 
(Figure 5.16, 5.17 and 5.18). In multivariate analysis, the inclusion of Rel A in 
the model showed independent prognostic significance for overall survival (P 
= 0.04) and its inclusion removed the prognostic value of CD38 (P = 0.38), 
lgVHgene mutation status (P = 0.22) and ZAP-70 (P = 0.14).
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Figure 5.15 Rel A DNA binding and overall survival. Comparison of Kaplan 
Meier curves for survival demonstrated that Rel A was prognostic for survival 
from date of diagnosis (P = 0.01).
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Figure 5.16 CD38 expression and overall survival. Comparison of Kaplan 
Meier curves for survival demonstrated that CD38 was prognostic for survival 
from date of diagnosis (P = 0.05).
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Figure 5.17 lgVH status and overall survival. Comparison of Kaplan Meier 
curves for survival demonstrated that lgVH mutational status was prognostic 
for survival from date of diagnosis (P=0.01).
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Figure 5.18 ZAP-70 expression and overall survival. Comparison of Kaplan 
Meier curves for survival demonstrated that ZAP-70 expression was 
prognostic for survival from date of diagnosis (P = 0.05).
5.2.7 Rel A is a predictor of survival during the period of
I also assessed the ability of Rel A to predict survival during the study period. 
The survival during the study was defined as the date of entry into the study to 
the date of death. Patients with high Rel A DNA binding showed a significantly 
shorter survival even over the relatively short study period (P= 0.05, Figure 
5.19). In contrast CD38 expression (P=0.66), lgVH mutational status (P=0.71) 
or ZAP-70 (P=0.39) expression could not predict survival during this short 24 
months follow-up.
study
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Figure 5.19 Rel A DNA binding and survival from date of entry into the 
study. Comparison of Kaplan Meier curves for survival demonstrated that Rel 
A was prognostic for survival from date of entry into the study (P = 0.05).
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Figure 5.20 CD38 expression and survival from date of entry into the 
study. Comparison of Kaplan Meier curves for survival demonstrated that 
CD38 expression was not prognostic for survival from date of entry into the 
study (P = 0.66).
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Figure 5.21 lgVH status and survival from date of entry into the study.
Comparison of Kaplan Meier curves for survival demonstrated that lgVH 
mutational status was not prognostic for survival from date of entry into the 
study (P = 0.71).
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Figure 5.22 ZAP-70 expression and survival from date of entry into the 
study. Comparison of Kaplan Meier curves for survival demonstrated that 
ZAP-70 expression was not prognostic for survival from date of entry into the 
study (P = 0.39).
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5.2.8 Rel A is constitutively higher in patients who 
require treatment
In order for Rel A to be considered a useful marker of TTFT in CLL it seemed 
important to demonstrate that Rel A was constitutively higher in untreated 
patients who went on to require therapy. I therefore compared Rel A DNA 
binding in samples derived from patients who never required therapy (n = 79) 
with those who went on to receive their first treatment after I had measured 
their Rel A DNA binding (n = 33). Figure 5.23 shows that patients who require 
therapy have significantly higher Rel A DNA binding than those patients who 
do not (P<0.0001).
P<0.0001
Xoqoo 
<>0-0
Never recieved treatment (n = 79)
•  Rel A measured before treatment (n = 33)
Figure 5.23 Rel A DNA binding in patients needing treatment. Rel A DNA
binding was significantly higher in samples derived from previously treated 
patients (P<0.0001).
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5.2.9 Is Rel A modulated by therapy?
Studies in other diseases have shown that Rel A DNA binding can increase in 
response to chemotherapeutic drugs (Denlinger et al., 2004; Rundall et al., 
2004; Artl et al., 2001). I therefore set out to determine if this was also true in 
CLL. This question was examined in two ways. Firstly, Rel A DNA binding was 
compared in samples derived from patients who received therapy after I had 
measured their Rel A with those who received therapy before I measured their 
Rel A (Figure 5.24). Although there was no statistical difference in Rel A DNA 
binding between these two groups (P = 0.41) the median Rel A DNA binding 
was higher in the previously treated subset (median Rel A 0.81ng/pg versus 
0.49ng/pg). Secondly, intra-patient Rel A DNA binding was evaluated in a 
longitudinal manner in patients before and after treatment and in selected 
patients that did not require therapy. Figure 5.25 shows a clear increase in Rel 
A DNA binding following treatment (P=0.04). In contrast serial samples from 
patients not requiring therapy showed no significant change in Rel A DNA 
binding (P=0.89). None of the samples tested were derived from patients 
within 3 months of completion of a cycle of therapy in order to avoid the 
possibility of a transient modulation in Rel A DNA binding induced by 
chemotherapeutic drugs. The median interval between measurements was 
similar for the treated and untreated patient groups (15 months vs 13 months 
respectively).
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Figure 5.24 Modulation of Rel A DNA binding with treatment. There was 
no statistical difference in Rel A DNA binding in samples analysed before 
treatment and those in whom Rel A was measured after treatment (P = 0.41).
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Figure 5.25 Rel A DNA binding in individual samples before and after 
treatment Serial intra-patient analysis of Rel A in samples derived from 
patients who received treatment during the course of the study and those who 
did not revealed that there was a significant increase in Rel A DNA binding 
following therapy (P = 0.04). In contrast, samples from patients who did not 
require treatment remained stable (P = 0.89).
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5.3 DISCUSSION
A number of previous studies have shown that NF-kB is constitutively 
activated in CLL patients (Furman et al., 2000; Cuni et al., 2004). In chapter 3 
of this thesis, I demonstrated that NF-kB subunit Rel A DNA binding was 
highly variable in CLL samples (n = 30) and it is higher compared with normal 
B-cells. Here I have confirmed the heterogeneity of Rel A DNA binding in 131 
unselected CLL patients. High Rel A DNA binding was strongly associated 
with advanced stage of disease but remarkably, was not associated with lgVH 
gene mutation status, CD38 expression or ZAP-70 expression; indicating that 
Rel A could contribute independent prognostic information in CLL. This is 
compatible with our initial findings that total NF-kB DNA binding was not 
associated with lgVH gene mutation status, CD38 expression or ZAP-70 
expression (Hewamana et al., 2008 and Chapter 3).
Furthermore, I went on to assess the ability of Rel A to predict for time to first 
treatment (TTFT), time to subsequent treatment (TTST) and overall survival in 
our patient cohort. Elevated Rel A DNA binding was predictive of significantly 
shorter TTFT (P = 0.01, hazard ratio 1.9). As NF-kB has been implicated in 
the development of drug resistance in other tumour settings (Artl et al., 2002; 
Artl et al., 2003), I assessed whether Rel A could predict for the relative 
effectiveness of therapy in CLL patients. In order to do this TTST was used 
from the date of entry into the study as a measure of the depth of remission / 
stable disease. Rel A was more predictive of TTST than any of the other 
prognostic markers assessed (P = 0.0001, hazard ratio 5.2) indicating that it is 
an excellent biomarker of response as well as a predictor of needing treatment 
in the CLL patients studied.
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Most strikingly, Rel A was the best predictor of overall survival from date of 
diagnosis in this study (P = 0.01, hazard ratio 9.1) adding to our hypothesis 
that Rel A is a key regulator of CLL survival both in vitro and in vivo. In 
keeping with this notion, Rel A was the only parameter tested that showed a 
significant difference in survival over the 24 month follow-up period of this 
study (P = 0.05, hazard ratio 3.9). Furthermore, the inclusion of Rel A in multi­
variate modelling showed the independent importance of Rel A in determining 
overall survival in our cohort (P = 0.05, hazard ratio 8.0); CD38 expression, 
lgVH mutation status and ZAP-70 expression all failed to influence survival in 
the presence of Rel A.
NF-kB can be activated in response to chemotherapy and can promote drug 
resistance through the induction of anti-apoptotic proteins like Bcl-2, survivin 
and c-FLIP as well as the activation of the AKT survival pathway (Ozes et al., 
1999; Granziero et al., 2001; Aron et al., 2003; Schimmer et al., 2003a; 
2003b). In this cohort, Rel A DNA binding was significantly higher in samples 
derived from previously treated patients (P<0.0001) and clearly increased in 
serial samples tested pre- and post-therapy. However, constitutive Rel A was 
significantly higher in patients who went on to require treatment when 
compared to those who did not. Furthermore, high Rel A was also associated 
with a shorter TTST in this cohort. Taken together, this data indicates that Rel 
A is constitutively elevated in patients with more aggressive disease but is 
also induced by conventional chemotherapy which in turn appears to 
contribute to the depth of response to subsequent treatment cycles.
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One of the biggest drawbacks of this study was of the variability of treatment 
modalities used and the inability of assessing the response to treatment. 
Therefore it is important to prospectively assessing Rel A in a randomised 
clinical trial in order to address this issue in the future.
In conclusion, Rel A is a superior prognostic marker for survival in CLL and is 
the only prognostic marker currently available that appears to have the 
capacity to predict the duration of response to therapy (Grever et al., 2007). In 
addition, this finding strongly supports the search for more accessible 
surrogate markers of NF-kB activation in this disease. Vascular endothelial 
growth factor (VEGF) and interleukin 6 (IL-6) are probable candidates for this 
purposes. The fact that Rel A DNA binding is independent of lgVH mutation 
status, CD38 expression and ZAP-70 expression offers the possibility that the 
prognostic information derived from some or all of these factors could be 
combined to provide even more accurate prediction of clinical outcome for 
CLL patients in the future.
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CONCLUSIONS AND FINAL 
DISCUSSION
SUMMARY OF FINDINGS
Total NF-kB activity, measured by EMSA, is heterogeneous in CLL 
patient samples.
Total NF-kB activity does not correlate with known prognostic markers 
like lgVH mutational status, ZAP-70 expression and CD38 expression. 
Rel A, p50 and c Rel are the main NF-kB subunits in CLL.
Rel A ELISA is a reliable method for assessment of NF-kB activity with 
good inter-assay variability.
NF-kB subunit Rel A activity measured by ELISA correlates with total 
NF-kB measured by EMSA.
NF-kB subunit Rel A activity measured by ELISA correlates with in 
vitro CLL cell survival, tumour bulk and disease progression and 
provides prognostic information that is independent of lgVH mutational 
status, ZAP-70 expression and CD38 expression.
LC-1 is a potent NF-kB inhibitor and effective in all prognostic subsets 
of CLL samples.
LC-1 activates intrinsic and extrinsic apoptotic pathways.
LC-1 induced cell killing is preceded by time and dose- dependent 
reduction of Rel A and down regulation of NF-kB dependent anti- 
apoptotic genes.
10. LC-1 has the ability to overcome pro-survival signalling by CD40 
ligation and IL-4.
11. LC-1 synergises with fludarabine and synergy is maintained in poor 
prognostic subsets of CLL. This combination allows fludarabine to be 
used at lower concentrations than clinically used today.
12. Rel A is a promising new clinical prognostic factor with ability to predict 
TTFT, TTST and OS.
6.2 FINAL DISCUSSION
In this study, I identified and validated NF-kB signalling as a key pathway in 
CLL and set out to conduct a detailed analysis of NF-kB activity, its biological 
relevance and its clinical implications. In addition, I also investigated the 
potential for using NF-kB inhibitors in the treatment of CLL.
One of the key achievements was to move beyond the simple concept that 
NF-kB is constitutively elevated in CLL. This study showed considerable 
variation in total NF-kB and the specific subunits of NF-kB, using more than 
one technique. We associated this variability with the biology of CLL cells. 
According to these results, only 20% of the variability of spontaneous 
apoptosis can be explained by Rel A DNA binding. It would be interesting to 
know what is controlling the rest of in vitro cell survival in these leukaemia 
cells. As NF-kB is a transcription factor, it may have a broader role in the CLL 
cells by altering the expression of genes under its control. Therefore, a logical 
next step would be to assess the differential expression of genes that are 
transcriptionally regulated by NF-kB.
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Data from our research group clearly demonstrates that there is an 
association between the change in NF-kB DNA binding post stimulation with 
anti-IgM and in vitro cell survival. In this context, some cells showed increased 
and others showed decreased total NF-kB DNA binding. This suggests a 
functional importance of change of (inducible) NF-kB DNA binding in CLL cells 
and is supported by other published work. According to Mockridge et at (2007) 
cases responding to slgM ligation usually expressed higher levels of CD38 
and ZAP-70 and had unmutated lgVH genes. This data implies downstream 
pathways are intact in CLL and it is interesting to investigate this further and 
identify the clinical differences between responders and non-responders. 
Again this would be an interesting part of a next step in our research.
Although it has long been known that NF-kB can be constitutively activated in 
CLL, the mechanism(s) involved in this are poorly understood. Signalling via 
BAFF and APRIL is thought to play a major role in NF-kB activation and 
survival of CLL (Nishio et al., 2005; Tomoyuki E, 2006; Shinners et al., 2007; 
Endo et al., 2007). In addition, certain micro-environmental factors are thought 
to modulate NF-kB (Burger et al., 2000; Tsukada et al., 2002). In this study, I 
showed that NF-kB is not uniformly elevated in CLL but is very heterogeneous 
across the patient population studied. The question is what causes the 
differential signalling? Is it due to variability in micro-environmental factors or 
due to the inherent signalling capacity of CLL cells? In addition, there is some 
evidence to suggest that genetic mutations of the NF-kB signalling pathway 
change the expression of downstream molecules in haematological 
malignancies (Keats et al., 2007). A reasonable next step in this line of
151
research would be to study the impact of micro-environmental factors on the 
regulation of NF-kB expression in CLL patients.
I have shown that Rel A DNA binding has the ability to predict a number of 
relevant clinical end-points in CLL including TTFT, TTST and OS. 
Furthermore, in agreement with the published data in other tumour settings 
(Nikanishi et al., 2005), NF-kB increased post treatment in some of the 
patients studied. Also Rel A DNA binding was shown to influence the depth of 
remission as evidenced by shorter TTST in patients with high Rel A DNA 
binding. This finding has wider clinical implications in relation to the role that 
Rel A plays in drug resistance in CLL. However, the next challenge will be to 
test these findings in prospective clinical trials. One of the key factors in this 
regard will be the standardisation of the Rel A assessment process. We 
assessed Rel A in 131 patients with excellent inter-assay variability. However, 
there are a number of significant problems associated with this assay. Firstly, 
there may be batch to batch differences in antibody affinity (both primary and 
secondary). Secondly, there may also be variation in the concentration / 
strength of recombinant Rel A used to quantify Rel A DNA binding. In addition, 
the quality and absolute amount of nuclear extract can significantly vary 
between patients and so characterisation of these parameters is also 
essential. We managed to overcome a number of these issues by performing 
Rel A DNA binding using the same batch of ELISA kit and recombinant 
proteins. However if Rel A is to be used as a prognostic parameter in the 
clinical setting more stringent quality control measures are required. This 
could be done by developing locally or internationally accepted median levels 
and controls for antigen affinity and recombinant protein concentrations.
152
NF-kB is often differentially expressed in cancer cells and this can enhance 
the expression of MDR-1, whose product, P-glycoprotein, a plasma 
membrane transporter, mediates chemoresistance by inducing the efflux of 
chemotherapeutic molecules (Bentires-Ali et al., 2003). In addition, p53 
stabilization is decreased upon NF-kB activation (Tergaonka et al., 2002). 
Taken together this makes NF-kB a promising drug target in cancer (Braun et 
al., 2006). There is a wide array of small molecules targeting NF-kB under 
development. Some examples are sulphasalazine analogues, BAY-117082, 
Deguelin, Curcumin, DHMEQ and AT514 (Habens et al., 2005; Escobar-Diaz 
et al., 2005; Everett et al., 2006; Horie et al., 2006; Pickering et al., 2007; 
Greeraerts et al., 2007). In this study I demonstrated that the novel 
parthenolide analogue LC-1 is capable of induction of CLL cell killing 
irrespective of prognostic markers or in vitro resistance to conventional 
chemotherapeutics.
This highlights the potential for using drugs like LC-1 as a salvage treatment 
particularly in poor prognostic subsets of CLL. Unusually, LC-1 induced cell 
killing by activating both the intrinsic and extrinsic apoptotic pathways. In 
contrast, the purine nucleotide analogue fludarabine has been shown to 
induce apoptosis through the intrinsic apoptosis pathway only (Klopfer et al., 
2004). This observation led to my hypothesis that LC-1 and fludarabine may 
synergise in apoptosis induction. This was tested in 26 CLL patient samples 
and strong synergy was observed between these two agents. In addition, the 
synergy was undiminished in poor prognostic subsets of CLL, further 
supporting the use of LC-1, and NF-kB inhibitors in general in this subset of 
CLL patients.
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The Bcl-2 family and IAP family proteins are implicated in apoptosis regulation 
and drug resistance in CLL and at least some of these proteins are regulated 
by NF-kB. In this study I examined the gene expression using RT-PCR of a 
limited number of proteins from these families (Bcl-2, BIRC5 and C-FLIP) and 
showed that LC-1 induced a significant reduction in gene transcription. Also 
this supports the results seen in apoptosis induction by LC-1 via both the 
extrinsic (CFLAR being an inhibitor of the extrinsic apoptotic pathway) and the 
intrinsic (BCL-2 being inhibitor of intrinsic apoptotic pathway) pathways.
In conclusion, the results derived from this study implicate a role for NF-kB in 
disease progression and resistance to treatment in CLL. Furthermore, NF-kB 
was shown to be a valid target for the treatment of this incurable disease and 
the pre-clinical agent LC-1 showed promising in vitro synergy with 
conventional chemotheraputic agents. Further work is clearly now warranted 
to validate these findings and to more fully understand how NF-kB is regulated 
in CLL cells.
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The N F -kB  subunit Rel A  is associated w ith in vitro survival and clinical disease 
progression in chronic lymphocytic leukemia and represents a promising 
therapeutic target
Saman Hewamana,1,2 Suhair Alghazal,1 Thet Thet Lin,1 Matthew Clement,2 Chris Jenkins,1 Monica L. Guzman,3 
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Paul Brennan,2 and Chris Pepper1
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In this study, we characterized nuclear 
factor kB (NF-kB) subunit DNA binding in 
chronic lymphocytic leukemia (CLL) 
samples and demonstrated heterogene­
ity in basal and inducible NF-kB. How­
ever, all cases showed higher basal NF-kB 
than normal B cells. Subunit analysis 
revealed DNA binding of p50, Rel A, and 
c-Rel in primary CLL cells, and Rel A DNA 
binding was associated with in vitro sur­
vival (P -  .01) with high white cell count 
(P =  .01) and shorter lymphocyte dou­
bling time (P = .01). NF-kB induction after
Introduction _____________
in vitro stimulation with anti-IgM was as­
sociated with increased in vitro survival 
(P <  .001) and expression of the signal­
ing molecule ZAP-70 (P = .003). Prompted 
by these data, we evaluated the novel 
parthenolide analog, LC-1, in 54 CLL pa­
tient samples. LC-1 induced apoptosis in 
all the samples tested with a mean LD50 of 
2.8 11.M after 24 hours; normal B and 
T cells were significantly more resistant 
to its apoptotic effects (P < .001). Apopto­
sis was preceded by a marked loss of 
NF-kB DNA binding and sensitivity to
LC-1 correlated with basal Rel A DNA 
binding (P = .03, r2 = 0.15). Furthermore, 
Rel A DNA binding was inversely corre­
lated with sensitivity to fludarabine 
(P =  .001, r2 = 0.3), implicating Rel A in 
fludarabine resistance. Taken together, 
these data indicate that Rel A represents 
an excellent therapeutic target for this 
incurable disease. (Blood. 2008;111: 
4681-4689)
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B-cell chronic lymphocytic leukemia (CLL) is a malignancy 
characterized by the accumulation of CD5, CD 19, and CD23 
positive lymphocytes. Diagnosis is aided by the CLL immuno- 
phenotyping score which includes assessment of CD5 and 
CD23, FMC7, CD79b, and surface IgM .1 Although CLL is the 
commonest leukemia in the Western world, it manifests a very 
heterogeneous clinical course, with some patients having nor­
mal age-adjusted survival, whereas the median survival for 
those patients with advanced stage disease is only 3 years.2 The 
factors that contribute to the pathogenesis and progression of 
this disease are poorly understood, but decreased susceptibility 
to apoptosis3 and dysregulated proliferation have been im pli­
cated.4 Clinical studies have shown that high ZAP-70 expres­
sion, high CD38 expression, unmutated V H genes, and cytoge­
netic abnormalities (especially deletions of llq  and 17p) are all 
associated with a poor prognosis.5'9
Nuclear factor kB (NF-kB) is a collective name for a group 
of inducible homodimeric and heterodimeric transcription fac­
tors made up of members of the Rel family of DNA-binding 
proteins. In humans, this family is composed of c-Rel, Rel B, 
p50, p52, and Rel A (p65) which, when bound in the cytoplasm 
to inhibitor of NF-kB (IkB ) proteins, are inactive.10,11 Various 
factors, including ligation of CD40 or the B-cell receptor
(BCR), result in proteosomal degradation of IkB releasing 
NF-kB, which then translocates to the nucleus.10,11 Once in the 
nucleus, NF-kB can enhance survival by inducing apoptosis 
inhibitory proteins, including inhibitor of apoptosis proteins 
(IAPs), Fas-associated death domain (FADD)-like interleukin 
(IL)-ip-converting enzyme (FLICE), and FADD-like IL-113- 
converting enzyme-inhibitory protein (FLIP ) .12-14 CLL cells 
have been reported to exhibit high constitutive NF-kB activation 
compared with normal B lymphocytes.15'17 Although the exact 
factors responsible for the constitutive expression of NF-kB are 
not fully resolved, many factors, including Akt activation, BCR 
signaling, CD40 ligation, IL-4, and B-cell activating factor 
(BAFF), have been shown to increase NF-kB activity and 
enhance CLL cell survival, with members of the Bcl-2 family 
being principal transcriptional targets.18 22 Several recent studies 
have demonstrated the proof of concept of the effectiveness of 
targeting NF-kB in hematologic malignancies, including CLL23,24 
and acute myeloid leukemia.25,26
In this study, we first set out to determine the range of 
constitutive DNA binding of NF-kB within our patient cohort and 
to characterize the specific subunits of NF-kB in these primary 
CLL cells. We then went on to investigate the ability of freshly 
isolated CLL cells to induce NF-kB expression in response to BCR
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stimulation with anti-IgM and correlated our findings with proxi­
mal and distal signaling events, as defined by tyrosine phosphoryla­
tion, and changes in in vitro apoptosis. Basal and induced NF-kB 
was subsequently correlated with other known clinical prognostic 
markers. Finally, we investigated the effects of a novel NF-kB 
inhibitor LC-1 in primary CLL cells to identify potential biologic 
response markers to be used in an imminent clinical trial.
Methods
This study was approved by the South East Wales local research ethics 
committee (LREC #02/4806).
Patients
Peripheral blood samples from CLL patients were obtained with their 
written informed consent in accordance with the Declaration of Helsinki. 
CLL was defined by clinical criteria as well as cellular morphology and the 
coexpression of CD19 and CD5 in lymphocytes simultaneously displaying 
restriction of light-chain rearrangement. Comprehensive clinical informa­
tion, including treatment histories, was available for all patients, and none 
of the previously treated patients had received chemotherapy within 
3 months before sample collection. Staging was based on the Binet 
classification system.27 The novel agent under investigation in these studies, 
LC-1, is a dimethylamino analog of parthenolide generated from the 
reaction of parthenolide with dimethylamine and was formulated as a 
water-soluble fumarate salt (by S.N. and P.A.C.). Details of the synthesis 
and structural identity of LC-1 are currently being prepared for publication. 
LC-1 was recently shown to selectively eradicate acute myelogenous 
leukemia stem cells in vitro via the induction of stress responses and the 
inhibition of NF-kB.25
ZAP-70 and CD38 expression
Cytoplasmic ZAP-70 expression was determined by using a modification of 
a previously published flow cytometry method.28 Cells were fixed and 
permeabilized using the Fix and Perm kit (Caltag, Botolph Claydon, United 
Kingdom) according to the manufacturer’s instructions. Permeabilized cells 
were labeled with the following antibodies: ZAP-70-Alexa fluor 488 
(Caltag), CD3-phycoerythrin (PE), CD56-PE (BD Biosciences, Cowley, 
United Kingdom), and CD19-Allophycocyanin (APC) (Caltag). After 
appropriate lymphocyte gating, cytoplasmic ZAP-70 expression was deter­
mined in CD19+ CLL cells by gating on the CD3+ cells. Patients were 
considered to be ZAP-70 positive when more than or equal to 20% of the 
CD19+ CLL cells had equal or greater expression of ZAP-70 than the gated 
CD3+ cells. Cell surface expression of CD38 was examined by flow 
cytometry using a standard 3-color flow cytometry approach using CD5- 
fluorescein isothiocyanate (FTl'C; Dako UK, Ely, United Kingdom), 
CD38-PE (Caltag), and CD 19-APC (Caltag). The cutoff point for CD38 
positivity in CLL cells was more than or equal to 30%.
Intracellular expression of tyrosine phosphorylated proteins
CLL lymphocytes were analyzed by 3-color immunofluorescent staining 
using CD5 and CD 19 surface antigenic markers in conjunction with a 
FITC-labeled phosphorylated-tyrosine antibody. The cells were analyzed 
on a FACS Calibur flow cytometer (BD Biosciences, San Jose, CA) and at 
least 10 000 events were acquired from each sample. The mean fluorescent 
intensity for phosphorylated tyrosine was calculated using WinMDI 
software (J. Trotter, Scripps Research Institute, La Jolla, CA).
VH gene mutation analysis
V h gene mutational status was determined for all patients using the method 
described previously.29 The resulting polymerase chain reaction products 
were sequenced and were considered unmutated if they showed 98% or 
greater homology with the closest germ line sequence.
Cell culture
Peripheral blood lymphocytes from 54 CLL patients and 10 age-matched 
normal control patients were isolated from freshly collected blood samples 
by density centrifugation. B cells were subsequently positively isolated 
using CD19+ Dynabeads (Invitrogen, Paisley, United Kingdom), and the 
beads were then detached using DETACHaBEAD CD19 reagent (Invitro­
gen). The purity of the CD5+/CD19+ CLL cells was more than 96% and 
normal B cells (CD19+) more than 90% as assessed by flow cytometry. 
CD19+ lymphocytes were then cultured in RPMI 1640 medium supple­
mented with 10% heat-inactivated fetal calf serum (Invitrogen), 100 U/mL 
penicillin, and 100 pg/mL streptomycin in the presence of parthenolide or 
LC-1 (10—7 to 10-5 M) for up to 48 hours. Parallel experiments using 
fludarabine (10—7 to 10-5 M) were also performed to assess the comparative 
intrasample and intersample in vitro cytotoxicity. Control cultures were also 
carried out to which no drug was added to normal and leukemic 
lymphocytes. Cells were subsequently harvested by centrifugation and 
were analyzed by flow cytometry. Experiments were performed in either 
duplicate or triplicate.
Measurement of apoptosis by annexin V/propidium iodide 
dual labeling
Apoptosis was assessed by dual-color immunofluorescent flow cytometry 
as described previously. Briefly, 106 cells were washed in ice-cold 
phosphate buffered saline and were incubated for 15 minutes in the dark in 
200 pL of binding buffer contain 4 pL annexin V-FITC and 10 pg/mL 
propidium iodide (PI; Caltag). Cells were analyzed on a FACS Calibur flow 
cytometer (BD Biosciences, San Jose, CA).
Caspase-3 activation assay
CLL cells were incubated at 37°C in a humidified 5% carbon dioxide 
atmosphere in the presence of LC-1 (10—7 to 10-5 M) for 24 hours. Cells were 
then harvested by centrifugation and labeled with CD 19-APC antibody. Subse­
quently, the cells were incubated for 1 hour at 37°C in the presence of the 
PhiPhiLux G1D2 substrate (Calbiochem, Nottingham, United Kingdom). The 
substrate contains 2 fluorophores separated by a quenching linker sequence that is 
cleaved by active caspase-3. Once cleaved, the resulting products fluoresce green 
and can be quantified using flow cytometry.
NF-kB detection by electrophoretic mobility shift assay
Nuclear extracts were generated from CLL cells ( >  90% CD5+/CD19+ 
lymphocytes as assessed by flow cytometry) using a modification of a 
previously described protocol.30 The protein from nuclear extracts was 
quantified by the Bradford method. Equivalent quantities of nuclear 
protein (1-4 pg) were incubated with 32P radiolabeled probes, generated 
by T4 polynucleotide kinase labeling. The probes used corresponded to 
a consensus NF-kB binding site (Promega, Southampton, United 
Kingdom). The binding reaction was performed in binding buffer (4% 
glycerol, 1 mM ethylenediaminetetraacetic acid, 10 mM Tris, pH 7.5, 
100 mM NaCl, 0.1 mg/mL nuclease-free bovine serum albumin, 50 mM 
dithiothreitol) with the addition of 2 ng of poly dldC (GE Healthcare, 
Little Chalfont, United Kingdom) for 30 minutes at room temperature 
before separation of protein DNA complexes using a 4% native 
acrylamide gel. NF-kB DNA binding was quantified by scanning 
densitometry. NF-kB inhibition studies were also carried out in CLL 
cells exposed to LC-1 for 2,4, 8, 16, and 24 hours.
Rel A NF-kB DNA binding detection by enzyme-linked 
immunosorbent assay
Nuclear extracts from CLL patients and B and T lymphocytes derived 
from age-matched controls were assayed for Rel A activity with a 
TransAM NF-kB transcripton factor assay kit according to the manufac­
turer’s instructions (Active Motif, Carlsbad, CA). The principle behind 
the assay involves the capture of NF-kB by an oligonucleotide 
containing an NF-kB consensus site, which is immobilized in each well 
of a 96-well plate. The Rel A subunit was subsequently detected using a
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Rel A-specific antibody. The normal lymphocytes were cell sorted 
(purity >  95% for each lymphocyte population), and these samples 
were compared with the C LL  samples. The optical density reading at 
450 nm (OD450) was read on a microtiter plate reader (Bio-Rad, Hemel 
Hempstead, United Kingdom). OD 4 5 0  values were converted into 
nanograms per microgram of nuclear extract for each sample tested from 
a standard curve constructed using known quantities o f recombinant Rel 
A NF-kB.
BL41 I ARC
Patient ID
* ■
Statistical analysis
All of the datasets derived in this study were tested for normality using the 
Kolmogorov-Smimov test. Where the data were deemed to be Gaussian or 
approximately Gaussian, the datasets were compared using parametric 
assays (equal variance or paired Student t test); in all other cases, a 
Mann-Whitney test was used. Correlation coefficients were calculated from 
least squares linear regression plots, and LD 50 values were calculated from 
line of best-fit analysis of the sigmoidal dose response curves. A ll statistical 
analyses were performed using Graphpad Prism 3.0 software (GraphPad 
Software, San Diego, CA).
Results
NF-k B is heterogeneous in CLL patient sam ples
CLL cells have been shown to exhibit high levels of nuclear NF-kB 
compared with nonmalignant B cells.I6'31 However, a detailed 
analysis of the variation in levels of NF-kB across multiple patients 
or a dissection of the constituent subunits in primary CLL cells has 
not been previously described. We investigated NF-kB DNA 
binding in 30 unselected CLL patients using electrophoretic 
mobility shift assay (EMSA). All of the isolated mononuclear 
samples tested had more than 90% CD5+/CD19+ lymphocytes as 
assessed by flow cytometry. We chose 2 cell lines as reference for 
the assay: BL41, a Burkitt lymphoma line with relatively low 
NF-kB activity, and IARC-171, an Epstein-Barr virus (EBV) 
immortalized line derived from the same patient. EBV activates 
NF-kB during B-cell immortalization, so IARC-171 cells represent 
a positive control for a B-cell high in NF-kB.
Figure 1A shows a representative sample of nuclear extracts 
derived from 12 patients demonstrating the differential expression 
of NF-kB DNA binding. DNA binding varied from almost 
undetectable (patients b, d, g, and i) to levels comparable to or 
higher than those found in the EBV-immortalized cells (patients c, 
h, and k) with other samples showing intermediate NF-kB DNA 
binding. The specificity of the NF-kB binding was confirmed by an 
EMSA cold competitor assay (Figure IB). A nonradioactively 
labeled NF-kB DNA oligonucleotide eliminated binding, whereas 
an oligonucleotide for another transcription factor, API, left DNA 
binding unaffected.
Specific NF-kB subunits have different abilities to activate gene 
expression. For this reason, the next step of our study was a 
qualitative analysis of individual NF-kB subunits in leukemic CLL 
B cells. For this we performed super-shift EMSA using antibodies 
against specific NF-kB proteins (Rel A, p50, p52, c-Rel, and Rel-B) 
with nuclear extracts prepared from CLL cells (Figure 1C). A rabbit 
serum control was used in each case. Rel A, p50, and c-Rel subunits 
were detected in all the samples tested, as evidenced by shifts in 
their respective bands following antibody binding, but with marked 
variation in the amounts of each in the different patient samples.
NF-k B is a key link betw een BCR signals and cell apoptosis
We next investigated the ability of CLL cells to induce NF-kB as 
a downstream consequence of BCR ligation. Proximal signaling
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Figure 1. CLL patients show heterogeneity of NF-kB DNA binding. (A) NF-kB 
DNA binding activity in cell nuclear extracts was measured using electrophoretic 
mobility shift assays. An oligonucleotide corresponding to the consensus sequence 
to NF-kB was radiolabeled and incubated with 2 »xg nuclear extract. The DNA- 
polynucleotide complex was restored by electrophoresis in a 4% native polyacryl­
amide gel in 0.5X Tris-borate/EDTA buffer. The gels were dried, and protein binding 
was visualized by autoradiography. To demonstrate specificity, a cold competitor 
assay was performed on 2 p.g nuclear extracts of CLL patient k (B). Cold, 
nonradiolabeled NF-kB and a nonspecific oligonucleotide, AP1, was added at 10x 
and 25 x the concentration of radiolabeled NF-kB and incubated for 30 minutes, 
before radiolabeled NF-kB incubation. (C) For qualitative analysis of NF-kB subunits, 
super-shift analysis was performed on NF-kB using p50, Rel A, p52, Rel B, and c-Rel 
antibodies and normal rabbit sera; 2 p.g nuclear extracts from CLL nuclear extracts 
were used for these experiments. The different lanes marked, none, p50, Rel A, p52, 
Rel B, c-Rel, and Rab ser (pre-immune rabbit sera) represent incubation with different 
antibodies. They were then incubated with a radiolabeled oligonucleotide correspond­
ing to the consensus sequence of NF-kB for 30 minutes. Ab indicates the different 
antibodies used; None, no antibody was incubated. White arrows indicate the 
antibody-protein-DNA complexes; black arrows, the protein-DNA complexes. Free 
DNA has been omitted. (D) Nuclear extracts from sample a through sample e were 
Western blotted for p-actin to assess the relative integrity of the nuclear protein 
extracts between samples and to confirm equal loading of nuclear proteins in the 
experiments.
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Figure 2. Analysis of proximal and distal signaling 
events in CLL cells derived from CLL patients.
(A) CLL cells were left untreated (black histogram) or 
treated with anti-IgM (gray histogram) for 15 minutes. 
They were then fixed and stained with an FITC- 
conjugated antiphosphotyrosine antibody (PY20), and 
fluorescence was measured by flow cytometry. (B) CLL 
cells were left untreated or treated with anti-IgM as 
indicated for 1 hour. Nuclear extracts were prepared 
and NF-kB activity was evaluated by electrophoretic 
mobility shift assay; only the shifted bands are shown. 
(C) The percentage change in protein tyrosine phos­
phorylation and NF-kB activity (before and after ligation 
with anti-IgM) was calculated. The percentage change 
in NF-kB correlated with percentage change in protein 
tyrosine phosphorylation (r2 = 0.2, P = .03). (D) Cell 
apoptosis was measured after 24 hours using annexin 
V binding and PI exclusion in untreated CLL cells and 
cells treated with anti-IgM. The percentages shown in 
the upper right quadrant of each dot plot denote the 
total percentage of apoptotic cells in the upper and 
lower right quadrants. (E) The relationship between the 
percentage change in NF-kB and the percentage 
change in apoptosis was investigated, and a significant 
inverse correlation was detected (r2 = 0.67, P <  .001). 
(F) ZAP-70 expression was associated with NF-kB 
activation after exposure to anti-IgM (P =  .003).
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was assessed by quantifying protein tyrosine phosphorylation 
before and after cross-linking of the BCR. Subsequently, NF-kB 
induction and cellular apoptosis were measured in paired CLL 
samples. Freshly isolated CLL cells from 24 patients were 
stimulated with anti-IgM for 15 minutes, and protein tyrosine 
phosphorylation was analyzed by flow cytometry. Figure 2A 
shows a typical example of an overlaid histogram plot of 
tyrosine phosphorylation in CLL cells derived from an indi­
vidual patient before and after stimulation with anti-IgM. Using 
the same experimental paradigm, NF-kB was analyzed by 
electrophoretic mobility shift in samples with and without BCR 
stimulation. Figure 2B shows representative data from 4 differ­
ent patient samples. To analyze the effects of BCR stimulation 
on NF-kB nuclear expression and because of the inherent 
variation from experiment to experiment when using EMSA, we 
internally controlled the experiments by expressing the data as 
percentage change in NF-kB after BCR stimulation (stimu­
lated -  control/control X 100). We identified a correlation 
(r2 = 0.2, P <  .05) between the percentage change in protein 
tyrosine phosphorylation and the percentage change in NF-kB 
(Figure 2C). We observed that anti-IgM treatment of CLL cells 
caused an increase in apoptosis in some samples and a decrease 
in apoptosis in others (Figure 2D). Importantly, this was 
reflected by a change in NF-kB; and when data from 24 patients
were analyzed, a striking inverse correlation (r2 = 0.67, 
P <  .001) was detected in which an increase in NF-kB corre­
lated with a reduction in cellular apoptosis (Figure 2E). 
Therefore, the data suggest that NF-kB is a key regulator of in 
vitro CLL cell survival. Furthermore, the ability of CLL cells to 
induce NF-kB DNA binding was closely associated with the 
expression of ZAP-70 (Figure 2F). These data support a 
previous report finding that forced overexpression of ZAP-70 in 
CLL cells enhanced BCR signaling.32
The Rel A NF-k B subunit DNA binding shows marked 
variability, which correlates with CLL cell survival
The variation in basal NF-kB prompted us to quantify the Rel A 
component of the complex. This component was of particular 
interest because it contains a transactivation domain absent in 
the p50 component of NF-kB.33 Using a DNA binding ELISA- 
based method, we analyzed Rel A in nuclear extracts derived 
from freshly isolated CLL cells. We generated a standard curve 
(data not shown) using recombinant Rel A, which showed 
excellent linearity (r2 = 0.98), and this allowed us to express the 
values for Rel A as nanograms per microgram of nuclear extract. 
Data from 30 patients are shown in Figure 3A, which shows the 
variability in Rel A from undetectable levels up to 1.909 ng/p.g 
of nuclear extract. Samples derived from normal B and
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Figure 3. Quantitative analysis of rel A DNA binding In CLL B cells and Its 
relationship to apoptosis. (A) Subunit-specific Rel A ELISA (Active Motif) assays 
were performed using 2 fig of nuclear extracts derived from 30 freshly isolated ex vivo 
CLL samples. Absorbance was measured at 450 nm. Results were compared with a 
standard curve generated using recombinant protein that allowed the calculation of 
the amount of p65 present in CLL cells expressed relative to total nuclear protein from 
CLL patient samples. (B) Parallel experiments were performed in which aliquots of 
CLL B cells derived from the same 30 CLL patients were set up in in vitro culture for 
48 hours, and spontaneous apoptosis was then measured using annexin V and PI 
staining. FACS plots were analyzed using Summit 4.3 software (Dako). Percentage 
apoptosis was defined as the total annexin V+ cells (Pl+ and PI- ) after 48 hours in 
culture. (C) The level of apoptosis showed a significant negative correlation with 
nuclear Rel A DNA binding activity in the nucleus of freshly isolated CLL cells.
T lymphocytes had levels of Rel A below the threshold of 
detection (data not shown). In parallel experiments, samples 
from each of these 30 patients were also analyzed for in vitro 
apoptosis after 48 hours in cell culture using annexin V  and PI 
labeling (Figure 3B); again, the samples showed a wide 
variation ranging from 9% to 80%. We then compared the ex 
vivo Rel A DNA binding activity of each sample with their 
propensity to undergo in vitro apoptosis after 48 hours in 
culture. Figure 3C shows that there was a significant inverse 
correlation between CLL cell in vitro apoptosis and Rel A DNA  
binding activity (r2 =  0.21, P =  .01).
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Figure 4. Rel A DNA binding Is higher in samples from patients with shorter 
lymphocyte doubling time and positively correlates with total white cell count.
(A) Rel A levels were measured by DNA binding ELISA (Active Motif) and were 
compared in patients with a lymphocyte doubling time above or below 12 months. 
Patients with lymphocyte doubling time of less than 12 months show a significantly 
higher level of Rel A (P <  .01). (B) There was a significant positive correlation 
between Rel A DNA binding activity in cells from patients and their total white ceil 
count (r2 = 0.2, P  = .01).
Basal Rel A DNA binding is higher in patients with shorter 
lymphocyte doubling times and positively correlates with total 
white cell count
Having implicated NF-kB subunit Rel A as important for in vitro 
CLL cell survival, we next investigated Rel A in relation to clinical 
markers of tumor burden and disease activity in CLL. Clinical 
laboratory parameters, such as lymphocyte count or total white cell 
count, bone marrow infiltration pattern, and lymphocyte doubling 
time (LDT), reflect the tumor burden and/or disease activity in 
CLL.34 Rel A DNA binding was measured using subunit-specific 
ELISA in 30 freshly isolated patient samples and results were 
compared with LDT, calculated from patient records, and total 
white cell count on the date of sample collection. Rel A was 
significantly higher in patients with an LDT less than 12 months 
(P <  .01; Figure 4A). There was also a significant correlation (r2 = 0.2, 
P =  .01) between Rel A DNA binding and total white cell count (Figure 
4B). Taken together, these data suggest that Rel A contributes to tumor 
burden and disease activity in CLL. It is of interest that basal Rel A 
expression did not correlate with VH gene mutation status, CD38 
expression, or ZAP-70 expression in this cohort.
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Figure 5. LC-1 and parthenolide induce time- and concentration-dependent apoptosis in primary CLL cells and follow the reduction of NF-kB. (A) CD19+ CLL ceils 
were treated with LC-1 (0-10 p.M) for 24 and 48 hours and were then labeled with annexin V and PI. The percentage of apoptotic cells was calculated as the sum of the upper 
and lower right quadrants (ie, annexin V+/PI+ and annexin V+/PI~). A concentration-dependent increase in annexin V+ cells was observed. (B) Normal CD19+ B lymphocytes 
derived from nonleukemic, age-matched, donors were more than 2-fold less sensitive to the apoptotic effects of LC-1 than CD19+ CLL cells (P <  .001). (C) CLL cells were 
treated with LC-1 (0-5 pM) for 4 hours before harvesting and nuclear protein extraction. EMSA analysis (top panel) and quantification by densitometry (middle panel) revealed a 
dose-dependent decrease in NF-kB activity in the absence of detectable apoptosis (bottom panel) measured by annexin V and PI.
LC-1 inhibits N F-k B and induces ap op tos is  of C LL cells
We next investigated the in vitro effects of a putative NF-kB 
inhibitor, LC-1, in 54 freshly isolated CLL patient samples. LC-1 is 
a derivative of the sesquiterpene lactone parthenolide, which has 
been shown to selectively kill CLL cells in vitro23 and targets the 
transcription factor NF-kB. This has been shown to be mediated 
through the inhibition of IkB kinase in HeLa cells,35 but this has not 
been definitively shown in primary CLL cells. Parthenolide has poor 
solubility and unfavorable pharmacokinetics; in contrast, LC-1 has 
superior pharmacokinetic properties and more than 1000-fold greater 
solubility than the parent compound and therefore represents an 
excellent candidate drug. As part of our evaluation of the molecule, 
we wanted to establish whether Rel A DNA binding could predict 
for in vitro sensitivity to LC-1 and fludarabine.
CLL cells were incubated with a range of concentrations of 
LC-1 or parthenolide (0.1-10 |xM) for up to 48 hours, and 
apoptosis was quantified using annexin V and PI labeling. Both 
LC-1 (Figure 5A) and parthenolide (data not shown) induced 
apoptosis was dose- and time-dependent. The 24-hour mean 
LD50 value ( ± SD) for LC-1 in the 54 CLL patient samples 
tested was 2.8 |xM ( ± 1.0 p-M). LC-1-induced apoptosis was
associated with a concomitant increase in the activation of 
caspase-3 (not shown). LC-1 and parthenolide showed a time- 
and concentration-dependent increase in apoptosis with equimo- 
lar concentrations of LC-1 significantly more cytotoxic than 
parthenolide at both 24 hours (P = .02) and 48 hours (P =  .03). 
Importantly, the mean LC-1 LD50 value was significantly lower 
for CLL cells than that derived from normal B and T cells and 
the T-cell derived from CLL patients (Figure 5B). This suggests 
a specificity of this inhibitor for leukemic cells. Figure 5C 
demonstrates that LC-1 inhibits NF-kB DNA binding in a 
dose-dependent manner. The inhibition is detectable at 4 hours 
and precedes any loss of cell viability; hence, the effect is not 
merely a consequence of cell death induction.
C orrelation between Rel A DNA binding and in vitro drug  
sensitivity
We next examined the relationship between Rel A DNA binding 
and sensitivity to LC-1 and the purine nucleoside analog, fludara­
bine. Basal nuclear Rel A DNA binding was inversely correlated 
with LC-1 LD50 values (Figure 6A), suggesting that CLL cells that 
relatively overexpress Rel A are more dependent on NF-kB signaling to
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Figure 6. Rel A DNA binding correlates with sensitivity to LC-1 and resistance to 
fludarabine. (A) Sensitivity to LC-1 was inversely correlated with nuclear Rel A 
NF-kB DNA binding. (B) In contrast, in vitro resistance to fludarabine was positively 
correlated with nuclear Rel A NF-kB DNA binding.
maintain in vitro cell viability. In contrast, fludarabine LD50 values 
positively correlated with nuclear Rel A expression (Figure 6B), 
suggesting that drug resistance to fludarabine may be mediated, at least 
in part, through the transcriptional effects of Rel A
Discussion
One of the key achievements of this study was to move beyond the 
relatively simplistic concept that NF-kB is elevated in CLL patient 
samples toward a more detailed qualitative and quantitative study 
of this important group of transcription factors. We have shown that 
CLL cells typically express p50, Rel A, and c-Rel but in various 
amounts. In agreement with previous reports,15,16 even the CLL 
samples that had low NF-kB expression had higher levels than 
primary B cells in which no NF-kB could be detected by EMSA or 
Rel A-specific ELISA. NF-kB has been implicated in tumorigen- 
esis and survival of a growing list of leukemias and lymphomas, 
including Hodgkin lymphoma, diffuse large B-cell lymphoma, 
multiple myeloma, acute lymphoblastic leukemia, and chronic 
myeloid leukemia.10 However, no previous study has quantified 
NF-kB subunits in primary patient samples. Furthermore, this is 
the first study to relate this quantification to in vitro cell survival, 
tumor burden, and disease activity (LDT), thus demonstrating that 
an individual component of the NF-kB complex can contribute to 
the regulation of human disease.
This study builds directly on others that have shown NF-kB 
provides prosurvival signals to several different cell types. Both
primary cancer tissues and cell culture models of these cancers 
exhibit constitutive activated NF-kB and inhibition of this activity 
by overexpression of IkB or pharmacologic agents induces in vitro 
apoptosis.24,36,37 Our data, correlating Rel A with spontaneous in 
vitro apoptosis, show that the variation in Rel A can explain 21% 
(r2 =  0.21) of the variation in apoptosis of CLL B cells. This raises 
2 important questions: (1) what genes are regulated by Rel A to 
promote increased CLL cell survival? and (2) what molecules are 
regulating the other 79% of CLL cell survival? Both of these 
questions are currently under investigation.
Previous work has suggested that the majority of CLL cells with 
unmutated VH genes respond to BCR stimulation, whereas the 
majority of mutated cases do not. Furthermore, ZAP-70 expression 
appears to enhance this proximal signaling process.32,38 However, 
the downstream targets of BCR signaling in CLL cells have not 
been fully elucidated. Given that a downstream target of BCR 
signaling in normal B lymphocytes is NF-kB,20,39 we assessed the 
ability of CLL cells to induce NF-kB after stimulation with 
anti-IgM. We found an association between ZAP-70 expression 
and the ability of CLL cells to activate NF-kB. Furthermore, the 
magnitude of the change in NF-kB after stimulation with anti-IgM 
was associated with the suppression of in vitro apoptosis. Taken 
together, these data suggest that the ability to induce NF-kB may be 
a critical factor in the pathology of CLL and present a rationale for 
the poor prognosis associated with ZAP-70 expression.
We went on to evaluate the relationship between basal Rel A 
DNA binding and prognostic markers. Surprisingly, we found no 
significant correlation between Rel A and VH gene mutation status, 
CD38 expression, or ZAP-70 expression. In contrast, we did find a 
clear association between elevated Rel A, short LDT, and high 
white cell count. These markers of disease activity and tumor 
burden have been shown to correlate with overall survival in 
several studies and reinforce the importance of this transcription 
factor in CLL.40-42 We hypothesize that the lack of correlation 
between basal Rel A DNA binding and VH gene status, CD38, and 
ZAP-70 is because these factors contribute to the ability of CLL 
cells to induce NF-kB after stimulation rather than constitutive 
expression. In support of this, the data presented in this manuscript 
clearly show an association between ZAP-70 expression and the 
ability of CLL cells to activate NF-kB after stimulation with 
anti-IgM. Given the association between basal Rel A and high 
white cell count and LDT and the striking association between 
ZAP-70 and the ability to induce NF-kB, it seems that both basal 
and inducible NF-kB is important in the pathology of CLL.
Finally, this report represents the first preclinical evaluation of 
LC-1, a novel dimethylamino analog of parthenolide, in primary 
human CLL cells. LC-1 was more than 2-fold more potent in vitro 
than molar equivalents of parthenolide and has greater solubility 
and superior pharmacokinetics than the parent compound. Interest­
ingly, LC-1 uniformly inhibited nuclear NF-kB activity in all the 
CLL samples tested, but strikingly cells derived from patients with 
the highest nuclear NF-kB activity were most sensitive to LC-1- 
induced apoptosis, suggesting some aspect of preferential NF-kB 
“oncogene addiction.” Given the heterogeneity of NF-kB in the 
CLL patient cohort and our observation that Rel A is elevated in 
patients with a shorter lymphocyte doubling time, this study 
indicates that targeting NF-kB could be most valuable for patients 
with a poor prognosis. In this context, it is noteworthy that several 
other NF-kB inhibitors have also shown promise in preclinical 
evaluation in primary CLL cells.23,24,43-46
The development of drug resistance is a major clinical problem in 
CLL 47-51 Therefore, it is important to note that sensitivity to LC-1 was
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undiminished in patients who had received prior chemotherapy. Further­
more, 7 patients included in this study had marked clinical resistance to 
fludarabine but retained in vitro sensitivity to LC-1. In addition, a patient 
with a known p53 deletion showed similar sensitivity to LC-1 but, in 
contrast, showed marked in vitro resistance to fludarabine. At present, 
only 3 agents, alemtuzumab, flavopiridol, and corticosteroids, appear to 
retain clinical activity in patients with p53 deletions/mutations so new 
effective agents are urgently required for the treatment of these clinically 
problematic subsets.52-60 LC-1, with its unique cytotoxic profile, could 
be considered for clinical trials for the treatment of poor prognosis CLL 
patients, including those with clinical resistance to fludarabine.
In conclusion, the data presented highlight the importance of both 
constitutive and inducible NF-kB in CLL. In particular, it indicates that 
the specific NF-kB subunit, Rel A, is associated with survival and 
possibly proliferation of CLL cells. The regulation of this transcription 
factor is complex and requires further elucidation to understand the 
critical signaling events that control NF-kB activation in vivo. However, 
our data suggest that Rel A may contribute to fludarabine resistance; 
therefore, molecules designed to inhibit NF-kB, and Rel A in particular, 
may be clinically useful both as single agents and in combination with 
chemotherapeutic drugs.
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The Novel Nuclear Factor-K,B Inhibitor LC-1 Is Equipotent in Poor 
Prognostic Subsets of Chronic Lymphocytic Leukemia and 
Shows Strong Synergy with Fludarabine
Saman Hewamana,1'2 Thet Thet Lin,1 Chris Jenkins,3 Alan K. Burnett,1 Craig T. Jordan,4 Chris Fegan,3 
Paul Brennan,2 Clare Rowntree,3 and Chris Pepper1
Abstract Purpose: We have recently shown that the novel nuclear factor-KB (NF-kB) inhibitor LC-1 is 
effective in primary chronic lymphocytic leukemia (CLL) cells. Here we elucidated the mechanism 
of action of LC-1, evaluated its relative cytotoxicity in prognostic subsets, and investigated its 
potential synergistic interaction with fludarabine.
Experimental Design: Ninety-six fully characterized CLL cases were assessed for in vitro 
sensitivity to LC-1 and fludarabine. In selected cases, caspase activation, inhibition of Rel A DNA 
binding, and the transcription of CFLAR, B/RC5, and BCL2 were measured before and after 
exposure to LC-1. In addition, the efficacy of LC-1 was assessed in the presence of the survival 
factors CD154 and interleukin-4, and the potential synergistic interaction between LC-1 and 
fludarabine was evaluated.
Results: Cell death was associated with caspase-3 activation mediated via activation of both 
caspase-8 and caspase-9. Apoptosis was preceded by a reduction of nuclear Rel A DNA binding 
and inhibition of CFLAR, B/RC5, and BCL2 transcription. Importantly, LC-1 overcame the cytopro- 
tective effects by interleukin-4 and CD40 ligand and was equipotent in CLL cells derived from 
good and bad prognostic subsets. LC-1 exhibited strong synergy with fludarabine, and the 
combination produced a highly significant mean dose reduction index for fludarabine of >1,000. 
Conclusions: In view of imminent first-in-man study of LC-1 in Cardiff, these data show an 
important mechanistic rationale for the use of LC-1 in this disease. Furthermore, it validates the 
concept of targeting nuclear factor-KB in CLL and identifies the therapeutic potential of LC-1 in 
combination with fludarabine even in patients with fludarabine resistance.
B-cell chronic lymphocytic leukemia (CLL) is the most 
common form of leukemia in adults in the western world 
and is characterized by the accumulation o f CD5-, CD 19-, and 
CD23-positive lymphocytes in the peripheral blood, lymph 
nodes, bone marrow, liver, and spleen. Factors contributing to 
the pathogenesis and progression o f this disease are poorly 
understood, but decreased susceptibility to apoptosis ( 1) and 
altered control o f proliferation have been implicated (2 ). CLL 
manifests a heterogeneous clinical course, with some patients
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having normal age-adjusted survival whereas the median 
survival for those patients with advanced-stage disease is 
only 3 years (3). Clinical treatment o f CLL is limited by the 
development o f progressive drug resistance and the non­
selectivity o f most drugs toward malignant cells. Chemother­
apeutic drugs, such as fludarabine, chlorambucil, prednisolone, 
and certain monoclonal antibodies are able to induce CLL cell 
apoptosis in vivo, but complete remissions are rare and all 
patients eventually relapse (4). Therefore, new treatment 
options based on the biological characteristics o f CLL cells are 
required to improve the prognosis of this incurable leukemia.
The nuclear factor-KB (NF-kB) cell signaling pathway is an 
attractive therapeutic target as NF-kB proteins have been 
implicated in the regulation of genes controlling apoptosis, 
proliferation, angiogenesis, and metastasis in various cancers 
(5 -8 ). Consequently, numerous small molecular inhibitors of 
NF-kB have undergone preclinical investigation (9 -1 2 ) but 
none has yet reached clinical trials. In the context o f CLL, a 
number o f studies have suggested that CLL cells exhibit 
constitutive NF-kB activation (1 3 -1 5 ). More recently, however, 
we showed that there is considerable variation in the degree of 
activation of NF-kB in CLL patient samples (16). We and others 
have shown that parthenolide and its analogue LC-1 are able 
to induce apoptosis in vitro and this seemed to be mediated 
via the inhibition of NF-kB (16, 17). In view of an imminent 
phase 1 clinical trial of LC-1 in patients with CLL and other
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Translational Relevance
Our study contains important new evidence on the 
mechanism of action of the nuclear factor (NF) -kB inhibitor 
LC-1 and represents the most thorough investigation to 
date of the biological consequences of NF-kB inhibition in 
chronic lymphocytic leukemia. Our findings clearly show 
that LC-1 inhibits Rel A DNA binding and consequently 
down-regulates the transcription of NF-kB target genes. 
These events precede the induction of apoptosis. Impor­
tantly, LC-1 is able to overcome the prosurvival effects of 
CD40 ligand and interleukin-4; both thought to be impor­
tant in maintaining chronic lymphocytic leukemia cells 
in vivo. In addition, we showed that LC-1 is equipotent in 
good and poor prognostic subsets and showed profound 
synergy with fludarabine, suggesting that this therapeutic 
strategy may have clinical application particularly in drug 
resistant/poor prognostic disease. Given that LC-1 will 
undergo first-in-man studies in Cardiff later this year, our 
data are both timely and relevant.
hematologic malignancies, we set out to fully elucidate the 
mechanism(s) of action of LC-1, to assess its relative efficacy in 
poor prognostic subsets, and to examine the potential for 
synergy with fludarabine in CLL patient samples. We also 
assessed the ability of LC-1 to overcome survival signals 
thought to be critical for in vivo CLL cell survival.
Patients, Materials, and Methods
Peripheral blood samples from 96 patients with CLL were obtained 
with the patients' written informed consent (LREC 02/4806). CLL was 
defined by clinical criteria as well as cellular morphology and the 
coexpression of CD 19 and CD5 in lymphocytes simultaneously 
displaying restriction of light-chain rearrangement. Clinical informa­
tion including treatment histories was available for all patients, and 
none of the previously treated patients had received chemotherapy 
within 3 mo before sample collection. The novel compound LC-1 is a 
dimethylamino derivative of the naturally occurring small molecule 
parthenolide. LC-1 (also known as DMAPT) was prepared from the 
reaction of parthenolide with dimethylamine, and the resulting 
dimethylamino analogue was then converted to its water-soluble 
fumarate salt. The irreversible inhibitor of IkB kinase (IkK), BAY 11- 
7082, was purchased from Calbiochem. The Rel A inhibitory peptide set 
(Ser276) was purchased from Imgenex.
Isolation of mononuclear cells. Human peripheral blood was layered 
onto Histopaque 1077 (Sigma-Aldrich) and centrifuged at 300 x g for 
30 min. After centrifugation, the opaque interface containing mono­
nuclear cells was aspirated and transferred into a clean sterile centrifuge 
tube. The mononuclear cells were then washed with PBS (pH 7.2; 
Sigma-Aldrich) at 300 x g for 5 min. After washing, the supernatant 
was aspirated and discarded. The pellet containing mononuclear cells 
was then washed with 0.87 mol/L of ammonium chloride (Sigma- 
A ldrich ) so lution  to lyse co n tam in atiag  erythrocytes  
at 300 x g for 5 min. After centrifugation, the supernatant was 
aspirated and discarded, and the pellet was again washed with PBS (pH 
7.2; Sigma-Aldrich) at 300 x g for 5 min and repeated. After final wash, 
the mononuclear cells were resuspended in PBS (pH 7.2; Sigma- 
Aldrich) and counted using a Vi-cell XR cell counter (Beckman Coulter).
In vitro cytotoxicity assays. Peripheral blood lymphocytes from 96 
CLL patients were isolated from freshly collected blood samples by
density centrifugation. Mononuclear cells from CLL patients were 
cultured in RPMI 1640 supplemented with 10% heat-inactivated FCS 
(Invitrogen), 100 units/mL penicillin, and 100 pg/mL streptomycin in 
the presence of LC-1 (0.5-8 pmol/L) and fludarabine (0.25-16 pmol/L). 
Control cultures were also carried out to which no drug was added. 
Cells were subsequently harvested by centrifugation and were analyzed 
by flow cytometry for apoptosis or used for protein extraction. Similar 
experiments were also done using BAY 11-7082 and the Rel A inhibitory 
peptide.
Measurement o f apoptosis by Annexin V/propidium iodide dual 
labeling. Apoptosis was assessed by dual-color immunofluorescent 
flow cytometry as described previously (18). Briefly, 1 x 106 cells were 
washed in ice-cold PBS and were incubated for 15 min in the dark in 
196 pL of binding buffer and 4 pL of Annexin V-FITC. Propidium iodide 
(10 pg/mL; Invitrogen) was added and cells were immediately analyzed 
on a FACS Calibur flow cytometer (Becton Dickinson).
In vitro synergy assessment. Peripheral blood lymphocytes from 24 
CLL patients were isolated from freshly collected blood samples by 
density centrifugation. After the optimal molar ratio for the combina­
tion of LC-1 and fludarabine (2:1) was experimentally determined, CLL 
lymphocytes were cultured in the presence of LC-1 (0.5-8 pmol/L) and/ 
or fludarabine (0.25-4 pmol/L) for up to 48 h. Control cultures were 
also carried out in which no drug was added. Apoptosis was assessed by 
Annexin V/propidium iodide dual labeling.
Caspase-3 activation assay. CLL cells were incubated at 
37 °C in a humidified 5% carbon dioxide atmosphere in the presence 
of LC-1 (0.5-8 pmol/L) for up to 48 h. Cells were then harvested by 
centrifugation and labeled with CD19-APC antibody. Subsequently the 
cells were incubated for 1 h at 37 °C in the presence of the PhiPhiLux 
GjDs substrate (Calbiochem). Hie substrate contains two fluorophores 
separated by a quenching linker sequence that is cleaved 
by active caspase-3. Once cleaved, the resulting products fluoresce 
green and can be quantified using flow cytometry. Also cells were 
further analyzed using caspase inhibition with caspase-8 inhibitor 
(ZIETD.frnk; 50 pmol/L), caspase-9 inhibitor (ZLEHD.fmk; 50 pmol/L), 
or pan-caspase inhibitor (ZVAD.ftnk; 50 pmol/L).
Nuclear and cytosolic protein extraction. Nuclear extracts were 
prepared using a method previously described (19). Cells were first 
washed in 1 mL of hypotonic buffer [10 mmol/L HEPES (pH 7.9), 1.5 
mmol/L MgCl2, 10 mmol/L KCl] and centrifuged at 10,000 x g for 1 
min. Cells were then lysed in 100 pL hypotonic buffer supplemented 
with 1 mmol/L phenylmethosulfonylfluoride, 1:100 dilutions of 
phosphatase inhibitor cocktails I and II (Sigma P-2850 and P-5726), 
and 0.1% (v/v) NP40 detergent and placed on ice for 5 min. Following 
centrifugation (10,000 x g, 5 min, 4°C), the supernatant was retrieved 
and this represented a cytosolic extract. Before extraction, the nuclear 
extract was washed by the addition of 1 mL of hypotonic buffer 
followed by centrifugation. Nuclear extracts were prepared by incubat­
ing the remaining pellet for 15 min in 50 pL high salt buffer [20 mmol/ 
L HEPES (pH 7.9), 420 mmol/L NaCl, 1.5 mmol/L MgCl2, 25% (v/v) 
glycerol] supplemented with 1 mmol/L phenylmethosulfonylfluoride 
and 1:100 dilutions of phosphatase inhibitor cocktails I and U 
immediately before use. Following centrifugation (10,000 x g, 5 min, 
4°C), the supernatant was collected representing the nuclear extract. 
Quantification of protein was by Bradford-based assay (Bio-Rad).
ZAP-70 and CD38 expression. The VH gene mutational status, and 
ZAP-70 and CD38 expression were assessed as previously described 
(16). VH sequences with a germline homology of ^ 98% were regarded 
as unmutated. The cutoff point for ZAP-70 and CD38 positivity was 
;>20% expression.
Rel A detection by ELISA Nuclear proteins were assayed for Rel A 
DNA binding w ith a TransAM NF-kB k it according to 
the manufacturer's instructions (Active Motif). NF-kB binding assays 
in microwells are reported to be at least 10 times more sensitive than 
electrophoretic mobility shift assay (20). The consensus oligonucleotide 
used for NF-kB binding was 5'-GGGACillCC-3'. A wild-type and 
mutated consensus oligonucleotides were used to monitor the
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Fig. 1. LC-1 induces both the intrinsic and extrinsic apoptotic pathways. A  LC-1 induced a time- and dose-dependent increase in apoptosis in CLL cells. Here a composite 
graph of six representative patients is shown. B, the cytotoxic effects of LC-1 were consistent across the whole cohort (n = 96). C. CLL cells were treated with LC-1 
(0-8 pmol/L) for 24 h and 48 h and were then labeled with Annexin Vand propidium iodide. A concentration-dependent increase in Annexin V -  positive cells was observed. 
The percentage of apoptotic cells was calculated as the sum of the upper and lower right quadrants, i.e., Annexin V -  positive/propidium iodide -  positive and Annexin 
V -  positive/propidium iodide -  negative. D. under the same conditions, caspase-3 activity was determined by using a fluorogenic substrate molecule that once cleaved by 
active caspase-3, fluoresced green and was detected by flow cytometry. The increase in caspase-3 activation was concentration-dependent and was correlated with an 
increase in apoptotic cell death. E, cells were cultured with caspase-8 inhibitor (50 pmol/L), caspase-9 inhibitor (50 pmol/L), or pan caspase inhibitor (50 pmol/L) with or 
without LC-1.Caspase-3 activation was measured as in B.
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specificity of the assay. The absorbance reading at 450 nm (A450) was 
read on a microtiter plate reader (Bio-Rad). A450 values were converted 
into ng Rel A NF-kB per microgram of nuclear protein for each sample 
tested from a standard curve constructed using known quantities of 
recombinant Rel A.
Real-time reverse tratiscription-PCR. The amount of CFLAR, BIRC5, 
and BCL2 mRNA was assessed using real-time reverse transcription-PCR 
(RT-PCR) using the Light Cycler System (Roche Diagnostics). Total RNA 
was extracted, reverse-transcribed with random hexamers, and ampli­
fied using CFLAR-specific primers 5'-AGAGTGAGGCGAnTGACCTG-3' 
(forward) and 5'-AAGGTG-AGGGTTCCTGAGCA-3' (reverse); B1RC5- 
specific primers 5,-TGTTGGGAATCTGGAGATGA-3, (forward) and 
S'-CGGATGAACTCCTGTCCnT-S' (reverse); and BCL2 -specific primers 
5 -GGTCA TGT GTGT GGA GA GCG -3 '  ( f o rw a rd )  and 5'- 
GGTGCCGGTTCAGGTACTCA-3' (reverse) purchased from Eurogentec
S.A. In addition, the amount of RPS14 mRNA was quantified in all 
samples as an internal housekeeping control using 5'-GGCAGACCGA- 
GATGAACTCT-3' (forward) and 5'-CCAGGTCCAGGGGTCTTGGT-3' 
(reverse) and SYBRGreen as a detection method. The results of the 
real-time RT-PCR were expressed as normalized target gene values, e.g., 
the ratio between CFLAR and RPS14 transcripts calculated from the 
crossing points of each gene. All experiments were done in duplicate.
Statistical analysis. All statistical analyses were done using Graphpad 
Prism 4.0 software (Graphpad Software, Inc.). Drug sensitivity for each 
individual drug and drug combination was evaluated using nonlinear 
regression and line of best fit dose-response curves. Curves were then 
analyzed using the median effect method to determine the degree of 
synergy (21). Combination indices and dose reduction indices were 
assessed using Calcusyn software (Biosoft).
Results
LC-1 induces both the intrinsic and extrinsic apoptotic path­
ways. We have previously shown that LC-1 is able to induce 
apoptosis in primary CLL cells. Here we extend those studies to 
investigate the dynamics of LC-1 -  induced cell killing and the 
specific mechanism(s) o f apoptosis induction in a cohort o f 96 
CLL patient samples. CLL cells were incubated with a range of 
co ncen tra tio n s  o f LC -1 (0 .5 -8  p m o l/L ) fo r up 
to 48 hours and apoptosis was quantified using Annexin V  
and propidium iodide labeling. LC-1-induced apoptosis was 
dose- and time-dependent (Fig. 1A) with mean LD50 values 
(±SD) of 2.9 pmol/L ±  1.4 at 24 hours and 1.8 pmol/L ±  1.0 at 
48 hours (Fig. IB ). LC-1 -induced apoptosis was associated with 
caspase-3 activation (Fig. 1C and D ) that was inhibited 
by the pan-caspase inhibitor (zVAD.fmk), a caspase-9 inhibitor 
(zLEDH.fmk), and a caspase-8 inhibitor (zIETD.ftnk). These 
data indicate that LC-1 induces apoptosis through the induction 
of both the intrinsic and extrinsic apoptotic pathways (Fig. IE ).
LC-1 inhibits Rel A DNA binding. Our previous study showed 
that LC-1 inhibited NF-kB as evidenced by decreased DNA  
binding in electrophoretic m obility shift assays (16). Here we 
extend these observations by examining its effects on the 
specific NF-kB subunit Rel A. LC-1 induced a time-dependent 
(Fig. 2A) and dose-dependent (Fig. 2B) decrease in Rel A DNA  
binding. Importantly, these effects preceded the induction of 
apoptosis (Fig. 2C and D ). To show that the inhibition o f Rel A 
was important for the induction of CLL cell apoptosis, we used 
a previously described Rel A inhibitory peptide (22) to evaluate 
the consequences o f specific Rel A inhibition. The Rel A 
inhibitory peptide induced significantly more cell death in CLL 
cells than both the no-peptide controls and the control 
peptide-treated cells (Fig. 2E).
LC-1-induced suppression of NF-kB target gene transcription.
Rel A contains a transactivating domain that regulates the 
transcription of NF-kB target genes (22). Therefore, a down­
stream consequence of inhibiting Rel A DNA binding should be 
the inhibition of specific Rel A transactivated genes. Therefore, 
we next examined whether LC-1 -  mediated inhibition of Rel A 
had an effect on downstream gene transcription using real-time 
RT-PCR. We studied three NF-KB-regulated genes (CFLAR, 
BIRC5, and BCL2) selected for their importance in CLL cell 
survival (15, 23, 24). Gene transcription was compared in 
paired samples from individual patients (n = 6) with and 
without the addition of 2 pmol/L LC-1 for 4 hours. Figure 2F 
shows significant reductions in the transcription of all three 
NF-KB-regulated genes following exposure to LC-1 (CFLAR by 
2.7-fold, BIRC5 by 5.3-fold, and BCL2 by 3-fold). Furthermore, 
we showed similar reductions in gene transcription of CFLAR, 
BIRC5, and BCL2 following incubation with the IkK inhibitor 
BAY 11-7082 (25) with a 1.3-, 2.5-, and 2.5-fold reduction in 
expression, respectively (Fig. 2G).
LC-1 overcomes the cytoprotective effects of CD40 ligand and 
interleukin-4. There is growing evidence that microenviron­
mental factors play a major role in the in vivo survival of CLL 
cells (26). A number of these factors, including CD40 ligand 
(CD 154) and interleukin-4 (IL-4), cause their prosurvival 
effects, at least in part, via the induction of NF-kB (14, 27,
28). As these signals seem crucial to CLL cells in vivo, it was 
important to assess the cytotoxic effects o f LC-1 in the presence 
of these survival signals in vitro. We therefore added recombi­
nant CD 154 (1 pmol/L) or recombinant IL-4 (5 nmol/L) to 
our in vitro cytotoxicity assays. As expected, the addition of 
CD 154 and IL-4 significantly reduced spontaneous apoptosis 
in the untreated control cultures (P  = 0.0006 and P = 0.004, 
respectively). However, in the presence of LC-1 the prosurvival 
effect o f both CD154 (P = 0.49; Fig. 3B) and IL-4 (P = 0.33; F3 
Fig. 3D) was abrogated, suggesting that LC-1 has the potential 
to overcome in vivo survival signaling.
LC-1 is equipotent in poor prognostic subsets of CLL. Pleio- 
tropic drug resistance is a significant obstacle to the successful 
clinical management o f CLL whereby treatment with one 
agent causes resistance to others (29). To evaluate whether LC-1 
was subject to conventional drug resistance mechanisms, we 
compared the in vitro effects of fludarabine and LC-1 in samples 
derived from previously treated and untreated CLL patients. 
Previously treated patients were relatively more resistant to 
fludarabine than their untreated counterparts (P < 0.0001;
Fig. 4A). In contrast, both treated and untreated groups show F4 
equal sensitivity to LC-1 (P = 0.53; Fig. 4A). We next compared 
the LC-1 LD50 values within prognostic subsets to assess their 
relative sensitivity to LC-1. As shown in Fig. 4B, there was no 
significant difference in LC-1 LD50 values between prognostic 
subsets defined by VH gene mutation status (P = 0 .21) and 
in vitro response to fludarabine (P = 0.21). Prognostic groups 
defined by CD38 expression (P = 0.06) and ZAP-70 expression 
(P = 0.05) showed a trend toward increased sensitivity to LC-1 
in the poor prognostic subsets. In addition, patients with 17p 
and l lq  abnormalities also showed similar sensitivity to the 
apoptotic induction by LC-1. Taken together, these data show 
the potential value o f inhibiting NF-kB as a therapeutic strategy 
in CLL, particularly in resistant and relapsed disease.
LC-1 shows strong synergy with fludarabine in primary CLL 
cells. Having shown the cytotoxic profile of LC-1 in poor
Clin Cancer Res 2008:14(24) MONTH XX, 2008 4 www.aacrjournals.org
08-1673
__________________ Nuclear Factor-KB Inhibition by LC-1 in CLL Treatment
0.8->
f t
|  |  0.4-
< I
8. ^ °-2- c
0.0 0 2 4 6 8 10
[LC-1] pM
B
=5 2
C  Q .
CDJgOQ 3 
<
o£ o)
0.8-1
£  0 .6 -
® 0.4-
O)
0 .2 -
0.0
•k
\
\
s
3 4 5
Time (hours)
100-j
90-
80-
70-i/>
'55 __o 60-
_  50-
ro 40 -
^  30-
2 0 -
10 -
|
0 2 4 6 8 10
100 
90- 
80- 
m 70- 
o 60-
|  5°- 
to 40-
38 30-
20 -
10 -
0
[LC-1] pM
2 3 4 5
Time (hours)
P = 0.001
P = 0.005
u) 60
I I control (no peptide) 
k w w n  control peptide
Pel A inhibitory peptide
n = 6
] control (no LC-1) 
I2 .0 mMLC-1 *P<0.05
100-1
~  80-
o
'55
60-
5.x
® 40-
1
§
£  20 - 
cc
BCL2BIRC5CFLAR
n = 6
I I Control (no BAY 11-7082)
EZZ) 2pM BAY 11-7082 *P<0.05
100-1
90-
80-
70-
60-
50-
40-
30-
20 -
10 -
.1
i
I<D
I
a.
n = 6
CFLAR BIRC5 BCL2
Fig. 2. Effects of LC-1 on constitutive Rel A activity and antiapoptotic genes in primary CLL cells. A  CLL cells were treated with 2 pmol/L of LC-1 for 1, 2 ,4 , and 6 h before 
apoptosis assay and nuclear protein extraction. ELISA analysis revealed a time-dependent decrease in Rel A DNA binding. B. CLL cells were treated with LC-1 (0-8 pmol/L) 
for 4 h before apoptosis assay and nuclear protein extraction. ELISA analysis revealed a dose-dependent decrease in Rel A DNA binding. C and D, up to 4 h time point there 
was little evidence of apoptosis induction as measured by flow cytometry using the Annexin V/propidium iodide assay. Therefore, the loss of NF-kB activity preceded the 
induction of apoptosis and was not merely a consequence of the commitment to cell death. CLL cells showed a time- and dose-dependent reduction in Rel A DNA binding 
following exposure to LC-1. £, we confirmed the importance of Rel A for the maintenance of CLL cell survival by specifically inhibiting this transcription factor with a Rel A 
inhibitory peptide. The peptide (50 pmol/L) induced apoptosis in all of the samples tested (n = 6) following exposure for 24 h. F. we also examined the transcription of 
downstream NF-kB target genes by real-time RT-PCR. CLL cells were treated with or without 2 pmol/L of LC-1 for 4 h and (G) with or without 2 pmol/L of BAY 11-7082 
for 4 h.The expression of CFLAR. BIRC5, and BCL2 were quantified using real-time RT-PCR and were normalized to the housekeeping gene RPS14. Both LC-1 and 
BAY 11 -7082 induced similar reductions in these genes over the same time period, suggesting a common mechanism of action. All experiments were carried out in duplicate.
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prognostic subsets of CLL and its ability to overcome in vitro 
resistance to fludarabine, we next investigated potential synergy 
between LC-1 and fludarabine. We experimentally determined 
the optimal molar ratio (2:1, LC-1: fludarabine) for the 
combination of the two drugs by comparing the combination 
index derived from different molar combinations. Subsequent­
ly, we measured the cytotoxic effects of each drug and their 
combination over a 24-hour culture period. Figure 5A shows F5 
a representative dose-response curve for CLL cells derived 
from one patient treated with each drug and their combination.
The combination of the two drugs was significantly more 
cytotoxic than either single agent as shown by the median effect
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Fig. 3. LC-1 overcomes the cytoprotective effects of CD40 ligand and IL-4. A. mononuclear cells from seven patient samples were cultured with or without CD154 (1 pmol/L) 
for up to 48 h. There was a significant cytoprotective effect by CD154 when compared with control cultures (P = 0.0006). B. addition of LC-1 (2 pmol/L) overcomes the 
prosurvival effect of CD154 (P = 0.49). C. mononuclear cells from five patient samples were cultured with or without IL-4 (5 nmol/L) for 24 h. There was a significant 
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plots (Fig. 5B). Furthermore, the combination index plot 
(Fig. 5C) showed synergism across a wide range of cell killing 
(fractional effect). The combination index values revealed 
strong synergistic effects in the LC-l/fludarabine combination 
with a mean combination index of 0.26 (Fig. 5D). In addition, 
we showed undiminished synergy in samples from poor 
prognosis subsets (Fig. 5E). Our finding that the LC-1/ 
fludarabine combination exerts synergistic cytotoxicity in 
fludarabine-resistant cells raises the possibility that the combi­
nation of NF-kB inhibitors and conventional chemotherapy 
may be clinically useful in poor prognosis groups of CLL.
Combination of LC-1 with fludarabine would facilitate a 
significant dose reduction o f fludarabine. One of the major 
benefits of using combinations of drugs that have synergistic 
effects is that doses of individual drugs can be reduced to limit 
dose-dependent side effects, while maintaining efficacy. In this 
study we calculated the dose reduction index (DRI) for 
fludarabine in each patient sample tested (n = 24). Figure 5F 
shows a representative DRI for fludarabine (DRI/fractional 
effect curve) in CLL cells derived from one patient treated with 
the combination of LC-I and fludarabine. The DRI was highly 
favorable in all the samples tested with a mean DRI for 
fludarabine when combined with LC-1 of >1,000. This means 
that there could be a theoretical 3 log reduction in the dose of 
fludarabine.
Discussion
Molecular targeted therapies can alter the natural course of 
malignant disease because they have the potential to preferen­
tially target the cancer cells (30). Our previous studies have 
shown that the NF-kB subunit Rel A is a biomarker of disease 
progression in CLL (16). Furthermore, we showed that 
inhibition of NF-kB by the novel parthenolide analogue LC-1 
resulted in CLL cell-killing. Here we extend these observations 
by characterizing the cytotoxic effects of LC-1 in a cohort of 96 
CLL patient samples. All of the samples were sensitive to LC-1 
with a mean LD50 at 24 hours of 2.9 pmol/L. Furthermore, 
there was no significant difference in sensitivity to LC-1 within 
prognostic subsets. Indeed, LC-1 showed a trend toward 
increased efficacy in poor prognostic groups even in cells that 
showed marked in vitro resistance to fludarabine. Unusually, 
LC-1 -  mediated apoptosis resulted in the activation of both the 
intrinsic and extrinsic pathways, and this provides one possible 
explanation for the efficacy of this agent in samples with drug 
resistance to conventional therapy.
We went on to show that LC-1 specifically inhibited the DNA 
binding of Rel A in a dose- and time-dependent manner. This 
inhibition preceded the induction of apoptosis, indicating that 
it may be a critical regulator of LC-1 -  mediated cell-killing. We 
confirmed this by using a specific Rel A inhibitory peptide; the 
peptide induced significant cell death in primary CLL cells, 
showing that Rel A plays a key role in CLL survival and is 
therefore an important drug target in this condition. We next 
explored the downstream consequences of Rel A inhibition by 
quantifying the transcription of three NF-KB-regulated genes, 
CFLAR, BCL2, and BIRC5, which have been implicated in 
CLL cell survival and resistance to chemotherapy (15, 23, 24, 
31-34). Transcription of all three genes was significantly 
suppressed by LC-1, suggesting that NF-kB plays a role in 
preventing the activation of both the intrinsic and extrinsic
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Fig. 4. LC-1 is equipotent in poor prognostic subsets of CLL. A, fludarabine LDSo 
and LC-1 LD50 values were compared between treated and untreated patient 
groups. Previously treated patients showed significant ex vivo resistance to 
fludarabine {P < 0.0001), but treated and untreated patient groups were equally 
sensitive to LC-1 {P = 0.53). B, LC-1 LD50 values were compared between 
prognostic subsets of patients. CLL cells derived from patients with CD 38 
expression >20%  (n = 40) and <20% (n = 50), ZAP-70 expression >20%  {n = 37) 
and <20% (n =  53), unmutated VH genes (n =  23) and mutated VH genes (/? = 50), 
and ex vivo fludarabine resistance (n = 16) and fludarabine sensitivity (n = 44) 
showed no significant difference in sensitivity to LC-1 (P = 0.06, P = 0.05, P = 0.21, 
and P  =  0.21, respectively).
apoptotic pathways in CLL. This notion is substantiated by the 
fact that CFLAR is involved in the inhibition of the extrinsic 
pathway and BCL2 inhibits the intrinsic pathway (35). 
Importantly, we recapitulated the inhibition of these NF-kB 
target genes when we exposed CLL cells to the specific IkK 
inhibitor BAY 11-7082, thereby reinforcing the credentials of 
LC-1 as a NF-kB inhibitor.
Despite their prolonged survival in vivo, most CLL cells 
undergo spontaneous apoptosis when cultured in vitro (36), 
suggesting that humoral factors and cellular interactions 
provide critical survival signals in vivo. There is growing
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fludarabine were observed over a wide range of inhibition levels when combined with LC-1.
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evidence that the lymphoid organs are the sites o f delivery of 
many of these prosurvival signals as it is here that CLL cells 
come into direct contact with stromal cells, T cells, and 
follicular dendritic cells (3 7 -3 9 ). Two o f the key survival 
stimuli seem to be derived from CD40 ligation and IL-4, and 
both of these interactions have the ability to induce NF-kB in 
CLL cells (40, 41). We therefore included recombinant CD40 
ligand and IL-4 into our drug sensitivity assay to determine 
whether LC-1 could overcome their cytoprotective effects. In  
accordance with previously published data, CD40 ligation and 
IL-4 prevented CLL cells from apoptosis, but the addition of 
LC-1 abrogated this prosurvival effect. Taken together, our data 
clearly show that NF-kB inhibition can overcome the survival 
signals induced by microenvironmental factors, and this may 
be crucial in ensuring the clinical efficacy o f these agents.
The ability to induce apoptosis is an essential property of 
most chemotherapeutic drugs (42). Perversely this may result in 
the activation of survival pathways, including the NF-kB 
pathway, as an unwanted side effect (5, 4 3 -4 5 ). In  keeping 
with this notion, samples from previously treated patients 
showed relative resistance to fludarabine in our study together 
with elevated Rel A DNA binding. However, we clearly showed 
the equal potency of LC-1 in all samples tested irrespective o f 
their previous treatment or other prognostic parameters. This 
highlights the potential value o f NF-kB inhibitors for the 
treatment of CLL, particularly in the context o f resistant and 
relapsed disease.
One o f the major benefits of using combinations of drugs 
that have synergistic effects is that doses o f individual drugs can 
be reduced to lim it dose-dependent side effects, while main­
taining efficacy. The concept of the DRI was proposed by Chou 
(46). The DRI is a measure of how the dose of an individual 
drug in a synergistic combination can be reduced while 
retaining the same cytotoxic effect. A DRI >1 is beneficial, 
and the greater the DRI value the greater the dose reduction for 
a given therapeutic effect. Remarkably, the mean DRI for 
fludarabine was >1,000, indicating that the dose of fludarabine 
could theoretically be reduced by >3 logs thereby significantly 
reducing its immunosuppressive side effects while retaining the 
cytotoxic effects on CLL cells.
This study provides a number o f important new insights. We 
elucidated the mechanism o f action of the novel NF-kB 
inhibitor LC-1 and also went on to show its efficacy in poor 
prognostic subsets of CLL, including samples with fludarabine 
resistance. We also provide a compelling argument for the use 
of LC-1 in combination with fludarabine in the clinical setting. 
However, the ultimate efficacy and safety o f small molecular 
NF-kB inhibitors w ill come through their evaluation in clinical 
trials, and a first-in-man study of LC-1 w ill begin in Cardiff later 
this year.
Disclosure of Potential Conflicts of Interest
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ABSTRACT
PURPOSE
W e recently demonstrated the biological importance of the NF-kB subunit Rel A in chronic 
lymphocytic leukaemia (CLL) and hypothesized that Rel A DNA binding would have 
prognostic significance in this disease.
PATIENTS AND METHODS
Rel A DNA binding was quantified in nuclear extracts derived from 131 unselected CLL 
patient samples using a quantitative DNA binding ELISA-based method. W e then investigated 
the ability of Rel A to predict for the requirement for treatment and survival and compared our 
findings with other established prognostic markers.
RESULTS
Rel A DNA binding was strongly associated with advanced Binet stage (P<0.0001) but did not 
correlate with lgVH mutation status (P = 0.25), CD38 expression (P = 0.87) or ZAP-70 
expression (P = 0.55). It was predictive of time to first treatment (P = 0.02) and time to 
subsequent treatment (P = 0.0001). In addition, Rel A was the most predictive marker of 
survival both from date of diagnosis (hazard ratio 9.1, P = 0.01) and date of entry into the 
study (hazard ratio 3.9, P = 0.05) and retained prognostic significance in multi-variate analysis 
for both time to first treatment and overall survival in the presence of Binet stage, lgVH 
mutation status, CD38 and ZAP-70.
CONCLUSIONS
Rel A is an independent prognostic marker of survival in CLL and appears to have the unique 
capacity to predict the duration of response to therapy. Prospective assessment of Rel A as a 
marker of clinical outcome and as a therapeutic target are now warranted.
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INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is the commonest leukaemia in the Western world but it 
manifests a very heterogeneous clinical course.1’2 Some patients show rapid disease 
progression with a mean survival of less than 36 months, whereas others exhibit a more 
indolent disease profile with a significantly better prognosis.3 The biological factors that 
contribute to the progression of this disease are poorly understood but decreased 
susceptibility to apoptosis4-6 and dysregulated proliferation undoubtedly play important roles.7- 
9 This marked variability in clinical course has stimulated the search for prognostic markers 
that can predict patient outcome. The need for these biomarkers is particularly important now 
because of the introduction of more effective therapies that might be optimally employed in 
the early phase of the disease before the problems associated with high tumor burden and 
drug resistance are encountered. Clinical studies have consistently shown that unmutated 
lgVH genes, high ZAP-70 expression, high CD38 expression and cytogenetic abnormalities 
(especially deletions of 11q and 17p) are all associated with a poor prognosis.10-14 However, 
none of these markers are able to accurately predict the clinical course of individual patients 
or their likely response to therapy. This limits their use in clinical management particularly in 
deciding if and when to treat. Therefore, the search for better markers is both timely and 
relevant.
NF-kB proteins have long been known to be key regulators of cell survival, cell growth, 
immune response and inflammation and have been shown to be elevated in CLL cells.15-17 
This family of transcription factors transactivate more than 200 genes18 including a panel of 
anti-apoptotic gene products e.g. Survivin, Bcl-2 and FLICE inhibitory protein (FLIP) all of 
which have been implicated in the inhibition of cell death in CLL.19-21 We recently showed that 
the NF-kB subunit Rel A is associated with in vitro survival and clinical disease progression in 
CLL.15 These findings led us to hypothesize that Rel A might be a prognostic marker in this 
disease. W e therefore analysed Rel A DNA binding in 131 patients and correlated the results 
with the established markers of prognosis and clinical outcome.
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MATERIALS AND METHODS 
PATIENTS
Peripheral blood samples from 131 CLL patients were obtained following written informed 
consent (LREC # 02/4806). 32/131 (24.4%) were diagnostic samples and 112/131 (85.5%) 
were untreated at the start of the study. CLL was defined by clinical criteria as well as cellular 
morphology and the co-expression of CD19 and CD5 in lymphocytes simultaneously 
displaying restriction of light-chain rearrangement. Comprehensive clinical information 
including treatment histories was available for all patients either through their case notes or 
direct interviews with patients. None of the previously treated patients had received 
chemotherapy within 3 months prior to sample collection. Staging was based on the Binet 
classification system22 and the clinical characteristics of the CLL patient cohort are 
summarized in Table 1.
ZAP-70 AND CD38 EXPRESSION
Cytoplasmic ZAP-70 expression was determined by using a modification of a previously 
published flow cytometry method.15123 After appropriate lymphocyte gating, cytoplasmic ZAP- 
70 expression was determined in CD19+ CLL cells by gating on the CD3+ cells. Patients were 
considered to be ZAP-70 positive when £20% of the CD19+ CLL cells had equal or greater 
expression of ZAP-70 than the gated CD3+ cells. Cell surface expression of CD38 was 
examined by flow cytometry using a standard three-color flow cytometry approach utilizing 
CD5-fluorescein isothiocyanate (Dako), CD38-PE (Caltag) and CD19-APC (Caltag). The cut­
off point for CD38 positivity in CLL cells was £20%.
lgVH MUTATION STATUS
lgVH gene mutational status was determined for all patients using the method described 
previously.24 The resulting PCR products were sequenced and were considered unmutated if 
they showed 98% or greater homology with the closest germ line sequence.
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SUB-CELLULAR FRACTIONATION
All of the nuclear extracts were prepared in an identical fashion from freshly isolated CLL 
samples and the extraction method used showed remarkable inter-patient consistency in 
terms of the amount of nuclear and cytosolic proteins generated from a fixed number of CLL 
lymphocytes.25 Details of the methods employed have been described previously.15 Protein 
concentrations for each nuclear extract were determined by Nanodrop absorbance (Nanodrop 
Technologies).
REL A DNA BINDING DETECTION BY ENZYME LINKED IMMUNOSORBENT ASSAY 
(ELISA)
Nuclear extracts from CLL patients were assayed for Rel A activity with a TransAM NF-kB 
transcription factor assay kit according to the manufacturer’s instructions (Active Motif). The 
principle behind the assay involves the capture of NF-kB by an oligonucleotide containing an 
NF-kB consensus site which is immobilized in each well of a 96 well plate. The Rel A subunit 
was subsequently detected using a Rel A-specific antibody. The optical density reading at 
450nm (OD450) was read on a microtiter plate reader (Bio-Rad). OD450 values were converted 
into ng/pg of nuclear extract for each sample tested from a standard curve constructed using 
known quantities of recombinant Rel A NF-kB. In the range of Rel A proteins we were 
measuring there was a linear relationship between Rel A protein amount and OD450 (^=0.99). 
All the Rel A measurements were done using the same batch of ELISA kits and the same 
batch of recombinant Rel A protein was used for the purpose of generating standard curves. 
Intra- and inter-assay variability was assessed using standardised nuclear extracts derived 
from a Jurkat cell line. In addition, samples from the same patients were tested on different 
plates on different days. In every case, there was less than 10% variability between results 
suggesting that the method is reliable and reproducible.
STATISTICAL ANALYSIS
To assess the relationship between Rel A and known prognostic factors (CD38, ZAP-70, lgVH 
mutation status, treatment status and Binet stage) Rel A was examined as a continuous
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variable within each categorical group. To examine the relationship between Rel A and 
clinical outcome, the cohort was divided according to the median expression of Rel A. Overall 
survival and time to first treatment times were calculated from date of diagnosis. Time to 
subsequent treatment and survival over the course of the study were calculated from the date 
that Rel A was measured. Survival curves were constructed using the method of Kaplan and 
Meier and the Log-Rank test was used to assess any differences between patient and tumor 
characteristics. Cox regression analysis determined important independent prognostic factors 
for time to first treatment and overall survival. Statistical analysis was carried out using Prism 
3.0 (Graphpad) and SAS statistical software (SAS Institute).
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RESULTS
REL A DNA BINDING IS INDEPENDENT OF lgVH MUTATION STATUS, CD38 
EXPRESSION AND ZAP-70 EXPRESSION
W e measured Rel A in nuclear extracts derived from 131 serially collected CLL patient 
samples using a quantitative DNA binding ELISA-based method. Data from all 131 patients is 
shown in Figure 1A; Rel A DNA binding ranged from undetectable to 2.44 ng/pg of nuclear 
extract with a median value of 0.44ng/pg (95% Cl 0.48-0.66). Rel A was markedly elevated in 
patients with advanced disease (P<0.0001, Figure 1B) and those who had previously 
received treatment (P<0.0001, Figure 1C) but was not associated with CD38 expression (P = 
0.87, Figure 1D), lgVH mutation status (P = 0.25, Figure 1E) or ZAP-70 expression (P = 0.55, 
Figure 1F).
ASSOCIATION BETWEEN REL A DNA BINDING AND TIME TO INITIAL THERAPY
All patients who required therapy were treated in accordance with the published guidelines.26 
Of the 131 patients analysed, 19 (14.5%) had previously received treatment and a further 33 
(25.2%) required therapy during the course of the study. W e first examined the relationship 
between Rel A DNA binding and the time from diagnosis to first treatment (TTFT) using 
subsets defined by the median Rel A value. The median TTFT in the low Rel A subset was 
13.6 years versus 6.8 years in the high Rel A subset (P = 0.01, Figure 2A). Since Rel A DNA 
binding was independent of CD38, lgVH mutation status and ZAP-70 we examined the ability 
of these established prognostic parameters to define TTFT in our cohort (Table 2). In keeping 
with previous reports, unmutated IgVn genes, 2:20% CD38 expression and £20% ZAP-70 
expression were all associated with significantly shorter TTFT (P = 0.0005, P = 0.04 and P =
0.05 respectively) indicating that our study was carried out on a representative CLL cohort. In 
multi-variate analysis, the inclusion of Rel A in the model showed independent prognostic 
significance for TTFT (P = 0.01) and its inclusion diminished the prognostic value of CD38 (P 
= 0.25), lgVH gene mutation status (P = 0.05) and ZAP-70 (P = 0.28).
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REL A IS A PREDICTOR OF TIME TO SUBSEQUENT TREATMENT
W e wanted to more accurately assess the prognostic value of measuring Rel A in our cohort 
by controlling for previous treatment effects and to acknowledge that not all of the samples 
analysed for Rel A were taken at diagnosis. Therefore we assessed the time to subsequent 
treatment (TTST) using the date of entry into the study as a sensor date for each patient 
sample. Figure 2B shows the predictive value of Rel A in our CLL patient cohort. Patients with 
high Rel A DNA binding showed a median TTST of 22 months. In contrast, the median TTST  
of the low Rel A subset was not reached as only 5/68 patients with low Rel A DNA binding 
required treatment during the 24 month follow-up period (P = 0.0001). W e also evaluated the 
ability of lgVH mutation, CD38 and ZAP-70 to predict TTST during the study period (Table 2). 
Only lgVH mutation status had prognostic value in this context (P = 0.04); CD38 (P = 0.17) 
and ZAP-70 (P = 0.13) were not predictive.
REL A IS A PREDICTOR OF OVERALL SURVIVAL
We assessed the capacity of Rel A to predict patient survival from date of diagnosis. In 
addition, we assessed survival over the course of the 24 month study period using date of 
entry into the study as the sensor point. Rel A DNA binding was predictive of survival from 
date of diagnosis (P = 0.015, Figure 2C). Similarly, lgVH mutation status, CD38 and ZAP-70 
were all predictive of survival from date of diagnosis (Table 2). In multi-variate analysis, the 
inclusion of Rel A in the model showed independent prognostic significance for overall 
survival (P = 0.04) and its inclusion removed the prognostic value of CD38 (P = 0.38), lgVH 
gene mutation status (P = 0.22) and ZAP-70 (P = 0.14). Further, only Rel A (P = 0.01, Figure 
2D) was predictive of survival during the course of the 24 month follow-up period of this study.
REL A IS CONSTITUTIVELY HIGHER IN PATIENTS WHO REQUIRE TREATMENT
In order for Rel A to be considered a useful marker of TTFT in CLL it seemed important to 
demonstrate that Rel A was constitutively higher in untreated patients who went on to require 
therapy. W e therefore compared Rel A DNA binding in samples derived from patients who 
never required therapy (n = 79) with those who went on to receive their first treatment after 
we had measured their Rel A DNA binding (n = 33). Figure 3A shows that patients who
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require therapy have significantly higher Rel A DNA binding than those patients who do not 
(P<0.0001).
IS REL A MODULATED BY THERAPY?
Studies of other diseases have shown that Rel A DNA binding can increase in response to 
chemotherapeutic drugs.27'29 W e examined this question in two ways. Firstly, we compared 
Rel A DNA binding in samples derived from patients who received therapy after we had 
measured their Rel A with those who received therapy before we measured their Rel A 
(Figure 3B). Although there was no statistical difference in Rel A DNA binding between these 
two groups (P = 0.41) the median Rel A DNA binding was higher in the previously treated 
subset (median Rel A 0.81ng/pg versus 0.49ng/pg). Secondly, we evaluated intra-patient Rel 
A DNA binding in a longitudinal manner in patients before and after treatment and in selected 
patients that did not require therapy. Figure 3C shows a clear increase in Rel A DNA binding 
following treatment (P=0.04). In contrast serial samples from patients not requiring therapy 
showed no significant change in Rel A DNA binding (P=0.89). None of the samples tested 
were derived from patients within 3 months of completion of a cycle of therapy in order to 
avoid the possibility of a transient modulation in Rel A DNA binding induced by 
chemotherapeutic drugs. The median interval between measurements was similar for the 
treated and untreated patient groups (15 months vs 13 months respectively).
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DISCUSSION
A number of previous studies have shown that NF-kB is constitutively activated in CLL 
patients.15'17 Here we used an ELISA-based assay to demonstrate marked variation in Rel A 
DNA binding within a cohort of 131 unselected CLL patients. The Rel A DNA binding assay 
that we employed was both reliable and reproducible with less than 10% variation in biological 
replicates performed on different plates on different days. High Rel A DNA binding was 
strongly associated with advanced stage of disease but remarkably, was not associated with 
lgVH gene mutation status, CD38 expression or ZAP-70 expression; indicating that Rel A 
could contribute independent prognostic information in CLL. W e therefore assessed the ability 
of Rel A to predict for time to first treatment (TTFT), time to subsequent treatment (TTST) and 
overall survival in our patient cohort.
Elevated Rel A DNA binding was predictive of significantly shorter TTFT (P = 0.01, hazard 
ratio 1.9). As NF-kB has been implicated in the development of drug resistance in other tumor 
settings3* 31 we assessed whether Rel A could predict for the relative effectiveness of therapy 
in CLL patients. In order to do this we used TTST from the date of entry into the study as a 
measure of the depth of remission. Rel A was more predictive of TTST than any of the other 
prognostic markers assessed (P = 0.0001, hazard ratio 5.2) indicating that it is excellent 
biomarker of response in CLL patients. Although this result is encouraging, it will need to be 
tested more thoroughly in a prospective clinical trial in which all of the patients receive uniform 
therapy. Most strikingly, Rel A was the best predictor of overall survival from date of diagnosis 
in our study (P = 0.01, hazard ratio 9.1) adding to our hypothesis that Rel A is a key regulator 
of CLL survival both in vitro and in vivo.15 In keeping with this notion, Rel A was the only 
parameter tested that showed a significant difference in survival over the 24 month follow-up 
period of this study (P = 0.05, hazard ratio 3.9). Furthermore, the inclusion of Rel A in multi­
variate modelling showed the independent importance of Rel A in determining overall survival 
in our cohort (P = 0.05, hazard ratio 8.0); CD38 expression, lgVH mutation status and ZAP-70 
expression all failed to influence survival in the presence of Rel A.
10
NF-kB can be activated in response to chemotherapy and can promote drug resistance 
through the induction of anti-apoptotic proteins like Bcl-2, surviving and FLIP as well as the 
activation of the AKT survival pathway.19'21132 W e found that Rel A DNA binding was 
significantly higher in samples derived from previously treated patients (P<0.0001) and clearly 
increased in serial samples taken tested pre- and post-therapy. However, constitutive Rel A 
was significantly higher in patients who went on to require treatment when compared to those 
who did not. Furthermore, high Rel A was also associated with a shorter TTST in our cohort. 
Taken together, this data indicates that Rel A is constitutively elevated in patients with more 
aggressive disease but is also induced by conventional chemotherapy which in turn appears 
to contribute to the depth of response to subsequent treatment cycles.
In conclusion, this study identifies Rel A as a superior prognostic marker for survival in CLL 
and crucially demonstrates that Rel A has the potential to predict the duration of response to 
therapy.33 Although there are undoubtedly challenges involved in the routine measurement of 
Rel A DNA binding in clinical practice, our work shows that it is possible to generate robust 
and reliable results that have clinical importance using a widely available measurement 
platform. In addition, our findings strongly support the search for more accessible surrogate 
markers of NF-kB activation in this disease. The fact that Rel A DNA binding is independent 
of lgVH mutation status, CD38 expression and ZAP-70 expression offers the possibility that 
the prognostic information derived from some or all of these factors could be combined to 
provide even more accurate prediction of clinical outcome for CLL patients in the future.
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Table 1. Clinical characteristics of the 131 CLL patient cohort.
Factor Subset Number %
Median Age 67 years
Range 36 -  85 years
Stage at diagnosis A 100 77
B 16 12
C 15 11
Previous treatment Treated 52 40
Untreated 79 60
CD38 <20% 74 56
£20% 57 44
Genetics 11 q" /  17p' 9 7
N /O 87 66
Not Determined 35 27
lgVH gene status <98% 95 73
£98% 36 27
ZAP-70 <20% 73 56
£20% 58 44
11q' and 17p‘ = any FISH or karyotypic abnormality of 11q or 17p 
N = Normal (i.e. no abnormality detected by FISH)
O = Other cytogenetic abnormality (excluding 11q'or 17p )
Table 2. Comparison of prognostic factors in terms of time to treatment and overall survival
Time to treatment Survival
Time to first treatment Time to subsequent treatment From date of diagnosis From date of entry into study
P-value HR 95% Cl P-value HR 95% Cl P-value HR 95% Cl P-value HR 95% Cl
Rel A
(<medianfemedian) 0.01 1.9 1.15-3.41 0.0001 5.2 2.00-8.61 0.01 9.1 1.45-15.51 0.05 3.9 0.97-9.59
lgVH gene mutation 
(<98%te98%) 0.0005 2.7 1.84-9.01 0.04 2.1 1.04-4.73 0.01 3.9 1.66-40.29 0.71 1.2 0.38-4.05
CD38 expression 
(<20%A>20%) 0.05 1.6 1.00-2.80 0.17 1.6 0.79-3.46 0.05 2.8 0.96-9.82 0.66 1.3 0.25-2.42
ZAP-70 expression 
(<20%/>20%) 0.04 1.7 1.00-2.98 0.13 1.7 0.84-3.66 0.05 3.1 1.01-9.17 0.39 1.6 0.53-5.13
HR = Hazard ratio 
Cl = confidence interval
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FIGURE LEGENDS
Figure 1. Correlation of Rel A and other prognostic factors.
(A) Samples from all 131 patients were analysed for Rel A DNA binding using an ELISA- 
based assay. Rel A was then compared in categorical subsets of the CLL cohort based on (B) 
Binet stage (C) the requirement for treatment, (D) CD38 expression, (E) lgVH gene mutation 
status and (F) ZAP-70 expression. Elevated Rel A was strongly associated with advanced 
Binet stage and the need for treatment but did not correlate with CD38 expression, lgVH gene 
mutation status or ZAP-70 expression.
Figure 2. Rel A as a prognostic marker in our CLL cohort.
Time to first treatment was assessed from the date of diagnosis (A) Rel A DNA binding above 
the median value was able to define a population at increased risk of requiring treatment in 
unit time. Time to subsequent treatment was measured from the date of entry into the study to 
the time of next treatment intervention. (B) Rel A DNA binding above the median value was 
able to define a population at greater risk of requiring another cycle of treatment. Comparison 
of Kaplan Meier curves for survival demonstrated that (C) Rel A was prognostic for survival 
from date of diagnosis and (D) was also predictive of survival from date of entry into the 
study.
Figure 3. The effect of treatment on Rel A DNA binding.
(A) Rel A DNA binding was significantly higher in samples derived from previously treated 
patients (P<0.0001). (B) However, there was no statistical difference in Rel A DNA binding in 
samples analysed before treatment and those in whom Rel A was measured after treatment 
(P = 0.41). (C) Serial intra-patient analysis of Rel A in samples derived from patients who 
received treatment during the course of the study and those who did not revealed that there 
was a significant increase in Rel A DNA binding following therapy (P = 0.04). In contrast, 
samples from patients who did not require treatment remained stable (P = 0.89).
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